var title_f23_26_23968="ACR appropriateness criteria acute shoulder pain";
var content_f23_26_23968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Radiology (ACR) Appropriateness Criteria: Acute shoulder pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Radiologic procedure",
"           </td>",
"           <td class=\"subtitle1\">",
"            Rating",
"           </td>",
"           <td class=\"subtitle1\">",
"            Comments",
"           </td>",
"           <td class=\"subtitle1\">",
"            RRL*",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td colspan=\"4\">",
"            <br/>",
"            <strong>",
"             Variant 1:",
"            </strong>",
"            Any etiology; best initial study.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            X-ray shoulder",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT shoulder without contrast",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XXX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MRI shoulder without contrast",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MR arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            US shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td class=\"indent1\">",
"            X-ray arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td colspan=\"4\">",
"            <br/>",
"            <strong>",
"             Variant 2:",
"            </strong>",
"            Radiographs noncontributory. Persistent significant pain. Next study.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MRI shoulder without contrast",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT arthrography shoulder",
"           </td>",
"           <td>",
"            5",
"           </td>",
"           <td>",
"            If MRI contraindicated.",
"           </td>",
"           <td>",
"            XX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            US shoulder",
"           </td>",
"           <td>",
"            5",
"           </td>",
"           <td>",
"            If MRI contraindicated.",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MR arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT shoulder without contrast",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XXX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            X-ray arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td class=\"indent1\">",
"            X-ray arthrography shoulder with anesthetic and/or corticosteroid",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td colspan=\"4\">",
"            <br/>",
"            <strong>",
"             Variant 3:",
"            </strong>",
"            Radiographs noncontributory. Age less than 35 years, suspect labral tear with or without instability on physical examination.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MR arthrography shoulder",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            See footnote regarding anticipated exceptions.&bull;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MRI shoulder without contrast",
"           </td>",
"           <td>",
"            7",
"           </td>",
"           <td>",
"            With optimized imaging equipment.",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT arthrography shoulder",
"           </td>",
"           <td>",
"            5",
"           </td>",
"           <td>",
"            If MRI contraindicated.",
"           </td>",
"           <td>",
"            XX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT shoulder without contrast",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XXX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            US shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td class=\"indent1\">",
"            X-ray arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td colspan=\"4\">",
"            <br/>",
"            <strong>",
"             Variant 4:",
"            </strong>",
"            Radiographs noncontributory. Questionable bursitis or long head of biceps tenosynovitis based on clinical findings including physical examination.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MRI shoulder without contrast",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            MRI and US are equivalent in this evaluation.",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            US shoulder",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            MRI and US are equivalent in this evaluation. If local expertise available. Study may include injection of anesthetic and/or corticosteroid if clinically warranted.",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT shoulder without contrast",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XXX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MR arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            X-ray arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td class=\"indent1\">",
"            X-ray shoulder bursography/tenography with anesthetic and/or corticosteroid",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td colspan=\"4\">",
"            <br/>",
"            <strong>",
"             Variant 5:",
"            </strong>",
"            Normal radiographs or radiographs that demonstrate coracoacromial arch osteophytes/syndesmophytes. Suspect rotator cuff tear/impingement, over age 35 years.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MRI shoulder without contrast",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            US shoulder",
"           </td>",
"           <td>",
"            8",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MR arthrography shoulder",
"           </td>",
"           <td>",
"            7",
"           </td>",
"           <td>",
"            See footnote regarding anticipated exceptions.&bull;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT arthrography shoulder",
"           </td>",
"           <td>",
"            5",
"           </td>",
"           <td>",
"            If MR or US cannot be performed.",
"           </td>",
"           <td>",
"            XX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            X-ray arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td class=\"indent1\">",
"            CT shoulder without contrast",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XXX",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td colspan=\"4\">",
"            <br/>",
"            <strong>",
"             Variant 6:",
"            </strong>",
"            Radiographs noncontributory. Previous total shoulder arthroplasty. Suspect rotator cuff tear.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            US shoulder",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            X-ray arthrography shoulder",
"           </td>",
"           <td>",
"            8",
"           </td>",
"           <td>",
"            If US expertise not available.",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT arthrography shoulder",
"           </td>",
"           <td>",
"            7",
"           </td>",
"           <td>",
"            With optimized imaging equipment.",
"           </td>",
"           <td>",
"            XX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MR arthrography shoulder",
"           </td>",
"           <td>",
"            6",
"           </td>",
"           <td>",
"            See footnote regarding anticipated exceptions.&bull;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MRI shoulder without contrast",
"           </td>",
"           <td>",
"            5",
"           </td>",
"           <td>",
"            With dedicated metal suppression protocol.",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td class=\"indent1\">",
"            CT shoulder without contrast",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XXX",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td colspan=\"4\">",
"            <br/>",
"            <strong>",
"             Variant 7:",
"            </strong>",
"            Radiographs noncontributory. Status post prior rotator cuff repair. Suspect re-tear.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MRI shoulder without contrast",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            MRI, MR arthrography, and US are equivalent in this evaluation, depending on local expertise.",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MR arthrography shoulder",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            MRI, MR arthrography, and US are equivalent in this evaluation, depending on local expertise. See footnote regarding anticipated exceptions.&bull;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            US shoulder",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            MRI, MR arthrography, and US are equivalent in this evaluation, depending on local expertise.",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            X-ray arthrography shoulder",
"           </td>",
"           <td>",
"            5",
"           </td>",
"           <td>",
"            If MRI or US cannot be performed.",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT arthrography shoulder",
"           </td>",
"           <td>",
"            5",
"           </td>",
"           <td>",
"            If MRI or US cannot be performed.",
"           </td>",
"           <td>",
"            XX",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td class=\"indent1\">",
"            CT shoulder without contrast",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XXX",
"           </td>",
"          </tr>",
"          <tr class=\"divider_bottom\">",
"           <td colspan=\"4\">",
"            <br/>",
"            <strong>",
"             Variant 8:",
"            </strong>",
"            Radiographs noncontributory. Suspect septic arthritis.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            US arthrocentesis shoulder",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            US and x-ray guidance are equivalent.",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            X-ray arthrocentesis shoulder",
"           </td>",
"           <td>",
"            9",
"           </td>",
"           <td>",
"            US and x-ray guidance are equivalent.",
"           </td>",
"           <td>",
"            X",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MRI shoulder without and with contrast",
"           </td>",
"           <td>",
"            7",
"           </td>",
"           <td>",
"            Aspiration is the procedure of choice. May be appropriate if clinical concern warrants. See footnote regarding anticipated exceptions.&bull;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MRI shoulder without contrast",
"           </td>",
"           <td>",
"            6",
"           </td>",
"           <td>",
"            Aspiration is the procedure of choice. May be appropriate if clinical concern warrants.",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT shoulder without and with contrast",
"           </td>",
"           <td>",
"            5",
"           </td>",
"           <td>",
"            Aspiration is the procedure of choice. May be appropriate if clinical concern warrants.",
"           </td>",
"           <td>",
"            XXX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XX",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            MR arthrography shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            US shoulder",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CT shoulder without contrast",
"           </td>",
"           <td>",
"            1",
"           </td>",
"           <td>",
"            &nbsp;",
"           </td>",
"           <td>",
"            XXX",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"3\">",
"            Relative radiation level designations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2\">",
"            Relative radiation level",
"           </td>",
"           <td class=\"subtitle2\">",
"            Adult effective dose estimate range",
"           </td>",
"           <td class=\"subtitle2\">",
"            Pediatric effective dose estimate range",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            0",
"           </td>",
"           <td>",
"            0 mSv",
"           </td>",
"           <td>",
"            0 mSv",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            X",
"           </td>",
"           <td>",
"            &lt;0.1 mSv",
"           </td>",
"           <td>",
"            &lt;0.03 mSv",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            XX",
"           </td>",
"           <td>",
"            0.1-1 mSv",
"           </td>",
"           <td>",
"            0.03-0.3 mSv",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            XXX",
"           </td>",
"           <td>",
"            1-10 mSv",
"           </td>",
"           <td>",
"            0.3-3 mSv",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            XXXX",
"           </td>",
"           <td>",
"            10-30 mSv",
"           </td>",
"           <td>",
"            3-10 mSv",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            XXXXX",
"           </td>",
"           <td>",
"            30-100 mSv",
"           </td>",
"           <td>",
"            10-30 mSv",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as NS (not specified).",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Rating scale: 1, 2, 3: usually not appropriate; 4, 5, 6: may be appropriate; 7, 8, 9: usually appropriate.",
"    <div class=\"footnotes\">",
"     * RRL: relative radiation level. See \"Relative radiation level designations\" table on right for corresponding adult and pediatric ranges.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Anticipated exceptions: Nephrogenic systemic fibrosis (NSF) is a disorder with a scleroderma-like presentation and a spectrum of manifestations that can range from limited clinical sequelae to fatality. It appears to be related to both underlying severe renal dysfunction and the administration of gadolinium-based contrast agents. It has occurred primarily in patients on dialysis, rarely in patients with very limited glomerular filtration rate (GFR) (ie, &lt;30 mL/min/1.73m",
"      <sup>",
"       2",
"      </sup>",
"      ), and almost never in other patients. There is growing literature regarding NSF. Although some controversy and lack of clarity remain, there is a consensus that it is advisable to avoid all gadolinium-based contrast agents in dialysis-dependent patients unless the possible benefits clearly outweigh the risk, and to limit the type and amount in patients with estimated GFR rates &lt;30 mL/min/1.73m",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shoulder trauma. American College of Radiology. ACR Appropriateness Criteria. Copyright &copy; 2010 American College of Radiology. The complete version of the ACR Appropriateness Criteria&reg; Shoulder Trauma topic can be accessed on the ACR website at",
"     <a href=\"file://www.acr.org\">",
"      www.acr.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23968=[""].join("\n");
var outline_f23_26_23968=null;
var title_f23_26_23969="Talocrural joint line";
var content_f23_26_23969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Talocrural joint line",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The talocrural joint line is indicated by the transverse lines on the skin at the point of the pen. Effusion and pain on palpation of the talocrural joint line suggest an osteochondral talar dome fracture resulting from direct trauma between the talus and the fibula or tibia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Maughan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23969=[""].join("\n");
var outline_f23_26_23969=null;
var title_f23_26_23970="Polymorphic light eruptionB";
var content_f23_26_23970=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymorphic light eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clusters of pruritic papules and vesicles on the dorsal wrist and arm, and an erythematous plaque on the dorsum of the hand following first sun exposure of the season. The face and dorsal hand are typically spared.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick T, Johnson R, Wolff K, et al. Color atlas and synopsis of clinical dermatology: Common and Serious Diseases, Third Edition, McGraw Hill, New York, 1997. Copyright &copy; 1997 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23970=[""].join("\n");
var outline_f23_26_23970=null;
var title_f23_26_23971="Placement of retropubic midurethral sling";
var content_f23_26_23971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Retropubic midurethral sling: Placement in relation to blood vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Muir TW, Tulikangas PK, Fidela Paraiso M, Walters MD. The relationship of tension-free vaginal tape insertion and the vascular anatomy. Obstet Gynecol 2003; 101:933. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23971=[""].join("\n");
var outline_f23_26_23971=null;
var title_f23_26_23972="Methenamine: Patient drug information";
var content_f23_26_23972=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methenamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=see_link\">",
"     see \"Methenamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/54/41827?source=see_link\">",
"     see \"Methenamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hiprex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dehydral&reg;;",
"     </li>",
"     <li>",
"      Hiprex&reg;;",
"     </li>",
"     <li>",
"      Mandelamine&reg;;",
"     </li>",
"     <li>",
"      Urasal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691486",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat a bladder infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methenamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Kidney disease, very bad fluid loss, or very bad liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698573",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need to check the acid content (pH) of your urine using a dipstick test.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696851",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take aspirin, antacids, or drugs that raise the pH of the urine while on this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid citrus fruits, dairy products, and some veggies while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696713",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some types of water pills may lower the effects of this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bladder pain or pain when passing urine or change in how much urine is passed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12076 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-063D528ED5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23972=[""].join("\n");
var outline_f23_26_23972=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194204\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194205\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023692\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023694\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023693\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023698\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023699\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023701\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023696\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023697\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023702\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023703\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=related_link\">",
"      Methenamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/54/41827?source=related_link\">",
"      Methenamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_26_23973="Nephrolithiasis in renal tubular acidosis";
var content_f23_26_23973=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nephrolithiasis in renal tubular acidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/26/23973/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/26/23973/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/26/23973/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/26/23973/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/26/23973/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/26/23973/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/26/23973/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalciuria, hypocitraturia, nephrolithiasis (often composed of calcium phosphate), nephrocalcinosis, and skeletal abnormalities are frequently associated with untreated distal (type 1) renal tubular acidosis (RTA) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Stone disease is also seen with carbonic anhydrase inhibitors but typically not with proximal (type 2 RTA). Most of the studies on RTA and nephrolithiasis have been small, and there is variability in individual phenotype and the response to therapy. The following should be read with these cautions in mind.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Distal (type 1) RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors can contribute to the relationship between distal RTA and stone formation or nephrocalcinosis. In some families, for example, hypercalciuria appears to be the primary abnormality, with calcium-induced interstitial and tubular damage possibly responsible for the RTA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, however, RTA is the initial condition with subsequent acidemia promoting stone formation both by increased calcium phosphate release from bone during bone buffering of retained acid and by direct reduction in the tubular reabsorption of these ions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. The degree of hypercalciuria is roughly proportional to the severity of the acidemia.",
"   </p>",
"   <p>",
"    Two other factors also contribute importantly to stone formation in this disorder: the persistently high urine pH, which favors the precipitation of calcium phosphate (but not calcium oxalate, the solubility of which is relatively insensitive to pH); and reduced citrate excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/7\">",
"     7",
"    </a>",
"    ], since acidemia enhances proximal citrate reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/8\">",
"     8",
"    </a>",
"    ]. Urinary citrate is normally a potent inhibitor of calcium stone formation, both by forming a soluble complex with calcium and by inhibiting stone growth by agglomeration of calcium crystals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kidney histopathology of stone formers with distal RTA reveals calcium phosphate deposits plugging inner medullary collecting and Bellini ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/9\">",
"     9",
"    </a>",
"    ]. Significant interstitial fibrosis is also observed, even in areas without plugging. Although further study is needed to verify these results, some of the radiographic calcifications in these patients may represent surgically approachable stones rather than nephrocalcinosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Proximal (type 2) RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, stone formation does not appear to occur in proximal RTA in which the primary defect is a reduction in bicarbonate reabsorptive capacity in the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least three factors may protect against stone formation in this disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the plasma bicarbonate concentration has fallen to the level of reabsorptive capacity (usually between 12 and 20",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      all of the filtered bicarbonate can be reabsorbed. At this time, bicarbonaturia ceases (unless exogenous bicarbonate is given) and the urine can be normally acidified. The acid urine pH increases the solubility of calcium phosphate, thereby preventing its precipitation.",
"     </li>",
"     <li>",
"      Reabsorption of all of the filtered bicarbonate means that the daily acid load can be excreted as ammonium and titratable acids, as in normal individuals. Thus, in the steady state, untreated patients with proximal RTA are in acid-base balance, although at a lower plasma bicarbonate concentration and extracellular pH than normal. As a result, there is no continued increase in calcium phosphate release from bone due to buffering of unexcreted acid.",
"     </li>",
"     <li>",
"      Proximal tubular dysfunction can lead to increased excretion of organic anions (including citrate). These solutes can form soluble complexes with calcium, thereby limiting the amount of free calcium available for precipitation with phosphate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Carbonic anhydrase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbonic anhydrase is important for both proximal and distal acidification. Carbonic anhydrase inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , are thought to act primarily in the proximal tubule, where they inhibit bicarbonate reabsorption, producing a picture similar to proximal RTA. However, in contrast to the lack of nephrolithiasis in proximal RTA, calcium stones have been described with acetazolamide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] and with two antiepileptic drugs that have carbonic anhydrase inhibitory activity,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]. The stones have primarily been composed of calcium phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/11,16\">",
"     11,16",
"    </a>",
"    ], but calcium oxalate stones can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/10\">",
"     10",
"    </a>",
"    ]. A marked reduction in urinary citrate excretion had been documented in these patients and is a known risk factor for stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk factors for calcium stones in adults\", section on 'Hypocitraturia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data are limited on the risk of stone formation with carbonic anhydrase inhibitor therapy. In a study of 20 patients chronically treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    for neuromuscular disease, three (15 percent) developed renal calculi [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/10\">",
"     10",
"    </a>",
"    ]. The reported prevalence was much lower in a series of 167 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    (3.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/13\">",
"     13",
"    </a>",
"    ] and 1800 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    (1.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/17\">",
"     17",
"    </a>",
"    ], both of which appear to be a weaker carbonic anhydrase inhibitor than acetazolamide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RTA and nephrolithiasis should undergo a metabolic evaluation to design the optimal regimen to prevent growth of existing stones and new stone formation. A bone density examination should also be performed because of the frequent finding of skeletal abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=see_link\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of the above changes in distal RTA can be reversed by complete correction of the acidemia: less calcium phosphate release from bone, lower rates of urinary calcium and phosphate excretion, a rise in urinary citrate excretion (although not necessarily to normal), and prevention of new stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/1-3,19,20\">",
"     1-3,19,20",
"    </a>",
"    ]. The decrease in stone formation can occur even in patients with the incomplete form of distal RTA who have a persistently alkaline urine pH and hypocitraturia, but a normal or near normal extracellular pH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Incomplete distal RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potassium citrate (citrate is rapidly metabolized to bicarbonate) is the preferred therapy to correct the acidemia in stone formers with distal RTA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. Citrate is more palatable than bicarbonate solutions and use of the potassium salt will directly treat the hypokalemia. On the other hand, the increase in sodium excretion associated with sodium citrate administration can produce an undesirable increase in urinary calcium excretion, since calcium reabsorption passively follows that of sodium in the proximal tubule and loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential efficacy of potassium citrate therapy can be illustrated by the following observations in studies in which stone formation rates were compared before and after therapy; randomized trials have not been performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of nine patients with incomplete distal RTA and nephrolithiasis, treatment with potassium citrate (60 to 80",
"      <span class=\"nowrap\">",
"       meq/day)",
"      </span>",
"      for almost three years was associated with complete cessation of new stone formation compared to a mean of 39 stones per patient formed in the three years prior to potassium citrate therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of incomplete distal RTA and hypocitraturia associated with medullary sponge kidney, potassium citrate therapy in patients was given to patients with stone risk factors (eg, hypercalciuria and hypocitraturia) at an initial dose of 20",
"      <span class=\"nowrap\">",
"       meq/day",
"      </span>",
"      that was increased gradually until urinary citrate excretion exceeded 450",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or the urine pH reached 7.5 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/20\">",
"       20",
"      </a>",
"      ]. There were 65 patients who were treated for one year and ten patients who did not accept or comply with therapy. The stone event rate, defined as passage or surgical extraction or fragmentation of a stone was markedly reduced in the compliant patients (0.10 versus 0.58 stones per year per patient). The compliant patients had a substantial and significant reduction in urinary calcium excretion (378 to 178",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and a significant increase in citrate excretion (268 to 460",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      Neither of these changes were seen in the noncompliant patients, while the urine volume and sodium excretion were similar in the two groups. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"       \"Prevention of recurrent calcium stones in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=see_link&amp;anchor=H21853656#H21853656\">",
"       \"Medullary sponge kidney\", section on 'Kidney stones and nephrocalcinosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inverse relationship between urinary citrate and excretion and calcium-containing stone formation is continuous; thus, the higher the urine citrate concentration, the lower the stone risk. However, the administration of potassium citrate has the potential to increase the risk of stones by raising the urine pH, thereby increasing the likelihood of calcium phosphate crystal formation. Thus, alkali therapy must be undertaken with caution. We monitor the urine pH and citrate excretion with the following goals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with complete distal RTA, the goal of potassium citrate therapy is to increase the plasma bicarbonate concentration to the low end of the normal range, which should prevent a substantial increase in urine pH. We typically discontinue citrate therapy if the urine pH rises above 6.5 without a substantial increase in urinary citrate excretion or a reduction in urinary calcium excretion. Among such patients, we balance the need to administer alkali to maintain the serum bicarbonate level with the risk associated with a higher urine pH. Thus, if the serum bicarbonate level is acceptable, then the alkali dose is reduced or even discontinued and we administer a thiazide diuretic with the goal of lowering the urine calcium level. A thiazide diuretic may also be added in patients with low bone density, given the evidence that thiazides can help maintain bone density. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link&amp;anchor=H20#H20\">",
"       \"Prevention of recurrent calcium stones in adults\", section on 'Calcium phosphate stones'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H21#H21\">",
"       \"Drugs that affect bone metabolism\", section on 'Thiazide diuretics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with incomplete distal RTA, the goal is to increase urinary citrate concentration without exceeding a urine pH of 7.0. A thiazide diuretic can be added to reduce urinary calcium if stone formation persists, even if the urine calcium is in the traditional \"normal\" range [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/23\">",
"       23",
"      </a>",
"      ]. A thiazide diuretic may also be added in patients with low bone density, but this does not seem to be a common finding in incomplete distal RTA [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23973/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H10#H10\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Incomplete distal RTA'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with stone disease due to the administration of a carbonic anhydrase inhibitor, discontinuation of the medication will prevent new stone formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with distal (type 1) renal tubular acidosis may be at increased risk for nephrolithiasis due to higher urinary calcium excretion and urine pH and lower urinary citrate excretion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Distal (type 1) RTA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stone disease is also seen with carbonic anhydrase inhibitors but typically not with proximal (type 2) RTA. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Carbonic anhydrase inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Proximal (type 2) RTA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with an RTA and nephrolithiasis should undergo a metabolic evaluation to design the optimal regimen to prevent growth of existing stones and new stone formation. A bone density exam should also be performed because of the frequent finding of skeletal abnormalities. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In stone-forming patients with distal RTA, correction of the systemic acidosis with oral alkali (usually potassium citrate) may substantially reduce the risk of new stone formation. The urine pH should be followed carefully to be sure that it does not rise excessively. Some patients may also require a thiazide diuretic to reduce urine calcium excretion. Close follow-up is required to manage this life-long metabolic abnormality. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with stone disease due to the administration of a carbonic anhydrase inhibitor, discontinuation of the medication will prevent new stone formation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW.. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York City 2001. p.616.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/2\">",
"      Buckalew VM Jr. Nephrolithiasis in renal tubular acidosis. J Urol 1989; 141:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/3\">",
"      Brenner RJ, Spring DB, Sebastian A, et al. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med 1982; 307:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/4\">",
"      Gault MH, Chafe LL, Morgan JM, et al. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones. Medicine (Baltimore) 1991; 70:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/5\">",
"      Bleich HL, Moore MJ, Lemann J Jr, et al. Urinary calcium excretion in human beings. N Engl J Med 1979; 301:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/6\">",
"      Nijenhuis T, Renkema KY, Hoenderop JG, Bindels RJ. Acid-base status determines the renal expression of Ca2+ and Mg2+ transport proteins. J Am Soc Nephrol 2006; 17:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/7\">",
"      Norman ME, Feldman NI, Cohn RM, et al. Urinary citrate excretion in the diagnosis of distal renal tubular acidosis. J Pediatr 1978; 92:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/8\">",
"      Hamm LL. Renal handling of citrate. Kidney Int 1990; 38:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/9\">",
"      Evan AP, Lingeman J, Coe F, et al. Renal histopathology of stone-forming patients with distal renal tubular acidosis. Kidney Int 2007; 71:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/10\">",
"      Tawil R, Moxley RT 3rd, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 1993; 43:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/11\">",
"      Ahlstrand C, Tiselius HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987; 21:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/12\">",
"      Kuo RL, Moran ME, Kim DH, et al. Topiramate-induced nephrolithiasis. J Endourol 2002; 16:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/13\">",
"      Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993; 14:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/14\">",
"      Kubota M, Nishi-Nagase M, Sakakihara Y, et al. Zonisamide - induced urinary lithiasis in patients with intractable epilepsy. Brain Dev 2000; 22:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/15\">",
"      Sheth RD. Metabolic concerns associated with antiepileptic medications. Neurology 2004; 63:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/16\">",
"      Welch BJ, Graybeal D, Moe OW, et al. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis 2006; 48:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/17\">",
"      Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37 Suppl 2:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/18\">",
"      Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000; 41 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/19\">",
"      Preminger GM, Sakhaee K, Skurla C, Pak CY. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 1985; 134:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/20\">",
"      Fabris A, Lupo A, Bernich P, et al. Long-term treatment with potassium citrate and renal stones in medullary sponge kidney. Clin J Am Soc Nephrol 2010; 5:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/21\">",
"      Sakhaee K, Nicar M, Hill K, Pak CY. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 1983; 24:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/22\">",
"      Lemann J Jr, Gray RW, Pleuss JA. Potassium bicarbonate, but not sodium bicarbonate, reduces urinary calcium excretion and improves calcium balance in healthy men. Kidney Int 1989; 35:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/23\">",
"      Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23973/abstract/24\">",
"      Pongchaiyakul C, Domrongkitchaiporn S, Stitchantrakul W, et al. Incomplete renal tubular acidosis and bone mineral density: a population survey in an area of endemic renal tubular acidosis. Nephrol Dial Transplant 2004; 19:3029.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2369 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-90821EDB07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23973=[""].join("\n");
var outline_f23_26_23973=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Distal (type 1) RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Proximal (type 2) RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Carbonic anhydrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=related_link\">",
"      Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=related_link\">",
"      Medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_26_23974="Left upper lobe atelectasis A";
var content_f23_26_23974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51657%7EPEDS%2F63366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51657%7EPEDS%2F63366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Left upper lobe atelectasis in a child with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 332px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFMAj0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDhbjwjBLkpGv8AKs2fwYVOQs6j/ZIIr00RYOMqfxpwQD1H40AeRS+FJAcJcMD/ALaf4VVk8M36/cMUg9jg/rXs7RKx+ZQc+oqM2tux+aJM/TFAHi50C8T/AFsZWp4dF6FyTXsX9k279E2/Q019Ct2HUE+6g0AeX2+lIhGI8/UVpRWGAOMV27eH0DfIoOfQ4qP+w2B6OB/u5oA5iOzAxgVet7Xnp9a3Ro7joQfqMVag0mbOBEzfQZoAx4rTpgVo29q2OFOPXFbNvpbIeYyW9xV37EYwPMwvsaAMiC1YkcVpRQgAZFTAQqceYB+FXEWOQfKQ/wDunmgCvBEFdWBII5B9K7bw9qxO1JdpkHHJ6j1rlY7bcuUbP1q5bQSK6sG2kdDQB6xp2oK6hXIx2PpWmHU9CK890y8A2rMxMmOCOhHtXTWN4CNvJ/HmgDcLAdSKaHGetUJbhAo+fH40wXCjH7xQPrQBq1BcXCQoWYjiqxugsW4NkHtXP6tqB7twOwoAh1y/aVi3Qdua828QXzXMhjQ/uweT/e/+tW1rWoSXO6OLOzoSP5Vz80JK/N19KAMKZKy7yLlhiujkgyaoXdowyVwcUAcTqNplicdawru03cEGu6vLbKkYrFubPBPH4YoA4m407PQE81QmsHVjgdO1drNaDjAxVSW16hhQBxTxshIYUyupuLBWBAGDVF9JJBxgfSgDEorZXQLh+ikD3qQ+HZuMyY9guaAMKit9fDcp6GQn2SpF8L3B7P8AjxQBzlFdSvhGf+JlUe7U0eGVS+SGW4QK0LSZAJyQwGP1zQBwV9fXEN08ccrKq4wAfYVZ0/xJfWx2vKzL2yelQ+KrZLPXrqCMllTZgkYz8gNZNAHoul+LbtHRklYMvIOa9Q8J/EC7lQJJIdw96+drGYowFdVpF80MiMrdKAPqfSvFEkhjM+fLbjd6V0dzrhgUfMCp6GvJvB2qx3GmJuILDit651CJ4WiVsHtzQB1K+MZLeV0kIAP3TVDU/F8txC6K/wAw9689vrkqzI5yR1qmbzyVLuxLdhQB2F14quoIyiP87dBnpWPdeLbi2T/WbpT71x17qwjLMzbpD056VhT35dizNk0Adfc+KbyRizTHP1qhP4jumUgSnJ965OW95PNVXvDnrQBb1PUr13IDsRnrmq8F9dCIgyMD6mop7pWjAGPrVJ7zLYz7UATXGqTswBkOfrW74X1O5RtolYEc9a4+chpNy9D1+tb3htmF1HxkE4xQB7l4Qv7yV13O+wdTXtPhe6kZVDMTkV5b4Hs1ECbeeOa9R0K3MUqYoA68HIBpabHnYM06gAooooAKKKKACiiigBsi7lIrifEtkw3gE7TyK7is7VbPz4TgAkUAfNXxDsHGydQTtO0keleYapbvgkZwa+ofEvhV9QgljCgFgcZ9a8W1Tw/JBK8U0W1gcEHqKAPAvEVi1tdeaAfLkP5GsivW/EOhho5YJVyrDg46H1rym6ge2uHhkGGU4NAEVFFFAH1zJZg54GKgksz2rp/sLMcYxV+PSoAg3oTkdc80AcFLBInQmqxaYN1NdlqOkmL7uWT1xyKyjYc8qaAMeOaYEZA+tX4LmVsAxIfcircWnEnO39Kvw6azAcY/CgCnA0bN+8iI+hrVs7eKbAQ/99DFW7HRi5yQcDsOpq7d/Z9OjwQJJMcIPuj/ABoAIdLiKFpY1YevQD8aefsFumARnuI+lcxe6jcTOS0rBeyg4A/CoBqLgbXwcfyoA29Ru0WJvJYqcdWQGuYuIjKxLSM2e+TVk6lG+VccEVWkkifmI8/3c0ANiswTwST9asR27ocxuVb0quszDO0nj9Ku2WoqCFuYxIp6E9RQBrafIzoAzEuOoI5/OuhtIQ6BQ2QfUcisqxiglAaHkH3rbswFdQ4bHQEHFACPavGcnpV6ynmjDAfMMd+tTzIhUHcee/pUD2e9DtcH2zQA681MJCNwcMD0xVKPWUDdTn3BqvfWLeUSX71n29qfMUbnLegFAHTrq+6LgEgZ61g6heSzvyQq+lWI0wrDlj+lUbr5QeBk0AUJvmBJY8d+grPuLuCMklg3sBU12uc+a5x/dHU1lXKgnCIV9zzQBZW6t2PKDHqMineVbT5COyk9M9KxHdwx5YfhUazSxuCkjCgDTvNM3ZDEZ7NiuevtPeI4deD0PUGuo07U5mXZNCJ16fODn863La3s7xCoCW8v91sMCfrQB5S9k7YCoW+gqNtHnk6R/nXrUmiwgDjB7dlNU57QQZVUC49BQB5ivhxycuP6VZj0aKEc7QfYZNdhdiNB87AVlzzRKPljLUAYv2KBefLLH3Jp7W6rFwqLz6VPNdyKD5carWdPNNKDlsD2oAH2L1YD8ah8yEd8n2FRmMnrk/WnpFk4oARpkPSMn6mkEhP/ACyX8qupaNIPlUn6Cg2zIcMpB9xQB4f4/OfFt+cAf6vgf9c1rnq6X4jrs8Z6gpGMeX/6LWuaoAch2nNa9hccDnmsapYZChFAHqfhLXGtYipOV9K6k6sr7ZFfO415Do9+qSbXbCtxn0rrLOcmUeY+2Ick54oA7W8u/MuFZyNqrXN6rrADkIcntWDrPiMO7pA3yDgGudl1LcSS2TQBvTXxZizNyaqSXw9a5qW/cng1A1y7d6AOhk1AZ61VfUR0LVhl2PU03NAG6mpIRtcn61X+2Ak7TWVTo8lwB1oA6GxZpnVRzmu+8OWIRVOMse9cp4ds8BT1J6mvUvDlmSq4WgD0zwDIRBGD1HBzXrmjjIQ45ryTwnBIl0gCkKepr2LRkCInOTQBsjpS0UUAFFFFABRRRQAUUUUAFBGRRRQBiajCMn1rzrxtpayt54Xlup969Rv4wc1ymsW4mhkjYfjQB4F4k0/5CcdK8W8daZ5UxuEXjvX0f4mtPLaWORcYrx/xdaB4po2Gcg0AeP0U6RSkjKeqnFNoA+/jabSMjnNWo4kKbJFYY6EDpXQ3OmfxxkFe4zyKrLpx2k5AX1oAwLq2BiOQD2rNFipPQV1E9qDwTwDUa2sa5BoAwo7EdSKtRWWSBjAPFbCwov3RU6W3y+Y52qOfrQBQmRLSHd2xxXB6zO73Dk5Pf611muagrsUjAVBx7muM1KVXJLNj8aAMe4kYE46/WqM0jEEq4z9KmvJFUk5474qg9wgBIyT60AOEhPO4ZxzxSxsSclqrNOvYHmiO5TO00AXmaRR8r5z61LazkECUYz3xxVTz4y+AcfWrUW0tgEEelAHS6RcNbzAg7kOK7mzfJVlIK15zp67duBj09q7DTpyFCk4OPwoA397BmGeAelTQkY3EfQCqqbpBkqfXNTRyqONufxoAlukWWGqUFssZLAc4wOK0C4KRnHU9M054TtwEwTz1oAypQB8i4C85461lX6iOMseXbpW1JGom45P8qydTh3SZx8o7UAYEkRYZBYknOR3qnLbMxOS35Ct5ogY8HHtiqcqKMg8e+aAMlrRQOY2Yn3pv2HnMcYB9MZIrRkeKJSS43dgDzVf7UeSpC/jQBAIxEcEtnvkUC4EbZz+VNlcvksx5qJVwpJwR7igDVsdfaMeXINyZ79Pxq/OovICyMWTrtHUe49RXKlFY4A2k+lXrC4ktZFCEsv6igBlzp5VsvyD0PrWfc2h5Kjp2rvBHHc24fA+YZI6c+orHubPY7KR/9egDip7fjkc1SktiD0612c9irdcc1Rm00EcGgDlvs/tVi0td74xx1JrZ/suTGAuRVizsjETuU5oAjt4AEACgYFTy2KmEbxudjuAPatK1t2Uhgin0Lcj8qufZgWzJksRz70AfKHxaj8r4g6qmMY8r/wBFJXIV3HxrAX4m6yFGB+5/9Ex1w9ABRRRQA5WK9Kn+2z7NnmNt9M1WooAe0jN1Jpu40lFABRRRQAUUUUAFWbK3klmUoDwal07TpbuQAKcV3uhaEsSruXmgDQ8J2PmqhIx617H4Y0xEVeM159o1v9kmQY+Q8GvWvC0JcL2HrQB0Vrb+SFKLx7V3GhO0kSHBrBsYQMALuNdRo8XlZB78gelAGtRRRQAUUUUAFFFFABRRRQAUUUUAQXSblFYt9bCRG45xXQMNykVRliIJoA8j8b2Z+ymbHzL8p+leFeLUwWI6V9O+MLHdZ3AA4dDj2NfNvi6DHmj3NAHiOtRiLUpgOhO4fjVGtnxNHtukfHUbTWNQB+mkDOOWOAO9NluFm4+4e3pUcshK47VCPegBHtie/P1qv5DBvmB/KrYPGDgj0p6DjCZ57UAMtLQud7DKg4A9T6Vm+JtSjtVa3jYPJ/Hjp9K6OVxa2pIOCqkA+5715bq0zNK3GWyc/WgDE1i7klkPO3vxXPz3BJIcnPrWnflmzxgj3rDuFZgSMfnQBDNIc/KetUnZGz2z1pkyyDPIxVeYH7xb8hQA5iynk/0ppbLbhxUQbsTkehFOiVdxHOD60ASmXqcnnjNTQ3LKRlvpiqxhAj6nHrRHG2Dg5/SgDp9N1JlYLIMp655rsbK6QRRFScdDXnEG4RBjgEd/atzSr50Ty2bKjkH0oA9WsbnbHgsCWww21chVXOSOT+FcXp2oMgXBwAOa6rS7tZWTdgZ70AbWxVjTaAPwp8wHlHLYJA5psv8ADjBA4pbrhB9KAMp8CdyOeKy9Sm2yEDB9avy7vMYjHNZV0hZ2J5oAzZnbcwLHB6VQupcKQoy2evpV2YKZdhOCB61XngC43JyeetAGRIcDJzk1BnGc9a0bmJOgHIqg8a5IANAEZ4IxkfSovMfnGTUyRZbJzimSpgBVINAEf2hlblakgukMgydpqrKrDBK8VBGhZ8CgD0HQLlZIfLkPBPB9KtanCVC5HPqO4rjLC7ltmXa3AI4Nd1p13Dqliccun+sTuPRh7UAYLx7ieOajNsSfQVuyQGJyCFx1DY6j1qtKXH3TQBQitnA+7x7irSxxJgucuOcL1oYsR856etQMoycGgDXjkheIMI03AYPHWo8IzZcYPtVa0bYcNVnjkg8DoKAPkr48qF+K+uBen7j/ANER1wFd58czn4qa4T/0x/8AREdcHQAUUUUAFFFFABRRRQAUUUUAFbGj6S926s4IWn6JpL3EivIvy+leg6TpyxooC0AQ6RpaQKoCiur06zBI44ptpZ4A4re0+1OAApJ7UALbWiDBK8+9d14QmyBH1YcVkWOh3Vzj92VHqa9E8GeFBYr51ySZG5A9KAN3S4jwcZb+VdHZRFSC3XFRW8UUK8ACrkUqscLQBLRRRQAUUUUAFFFFABRRRQAUUUUAFIyhhzS0UAYPiCz820kAHIGRXzF48szBeXEbDuSPpX1leLuiYH0r58+LWnBbh5VHQ88djQB8weKoSC3H3TmuZrvfGFtjecda4KgD9KGbJFKtV1fJ4qZT2oAcB71PCjMwCjmo1HNaltEI4RnAJG5iey0AZmuyqluFJy3U15zrRLElTz3HrW94s1xRO4gBKA4yeprg9QvnkJJfjtQBRvJQrHkg+lZUsqjdu5B4Jp9yyyHqay5gy9OaAGXTrk46GqLSr0zj8KsqWJIIGMcg1VuIwHygwPSgCu8iljwQ3sKI7heQwNRSgf8AAqiLBl6c0Aa63KNHkg5HDCpNyjJBBHvWRFkNznB6VKsrRt0O09jQB0EartQK2QQO9acChIwCmfXPaudin2IhQ89j6Vo2d80haOTk9QaAOt0t4pIyGLL3rrNIcjy1ySMg7vWuF0y4XYVVAGPB712nhp/k3fwqPzoA6gSs9xhDn3z0rSkClMkZIAH1rFglBlU5OfYVrowZgrAkcGgCm8eF6dT0rGvTsZsnC571vztgsSO/Sua1MNKzE8+lAHOalcLHKSuSM54qBL8lkymRgcE0/UYSMsV9qoohBA/IUAWpp9zj92MHkYNVsHcxKYA77qsuQiBRywHJqnO5Kcngn86AFMsSICxYn0FVnki6b+fcVG+c81CxGOn1oAtiJWx84xntQEVei59OKp7iFYg+nNRtdSIeGzQBdIAJ2n5vQ1paHdy2V4kwJHY+9YcFyjt+84Pc1s2jISAQCtAHodxGlzaq8Y4Yb0A7eorFlTjgVr6Lk6ZHzkIevtVa7ixM+MYJzQBkFcjmmlOKtPHjOB+lRYoAZGAGFWifkGAfpVVqkDMQQSaAPk345cfFLWx/1x/9ER1wld38cf8AkqOt/wDbD/0RHXCUAFFFFABRRRQAUUUUAFbWh6W1zKrOvy+lRaRpz3MgLD5a9C0XTQiqAtAEulacEVQFrrdL04uQAKk0fS3mdVVfxrvtL022skUzEFvSgDO0rw602CwwK7LR9GgtQuI13epGTTILtBhYlx9K2LOTGCRk0Ab2nWkUSqzqpbsMVqKx7sAPasSCdiBk1ZjmJPWgDYV1HuauWrZI4AFc8t382I+vrWlZSEsNx5xQBtbh60ZFU3lA+tPifJFAFqikHSgsAeaAFooBzRQAUUUUAFFFFABRRRQBHOPkNeP/ABStd5kGOqHH4V7DKMoa85+I9sXginA4GVagD5T8W2m5H4ryi7Qx3DqfWvePFtmFklQjvkV49r1kRekqOtAH33FMGYYOauRN3rlrG93OFJ5roLSXcuaANW2XfIoPQnFXdWm2afOFIBdSAapWbYKkA5zSa64SIBiM4JxQB5drchaZlwc56elcvfLIGOOCex712utKHYkfKc9uAa4/UZB91u350AY8nuQp/PNVpR0yT744q3O0ZHU/jWdNOVyoXK4oAZKiMCVB3Drmog/PzqCAOuKR5GA3KOhxkCq8jSHPzNg9sUASTxI5yjYwOOO1VzbqATwcGnK7xk7mc+1BZnBA4PbigCPZjHynGatJCrkEhsd6iV5E/hV/TtVq3dTtIBDZxjtQA+3iSTdtJBPQYqzHbSR5k27QvynjpUCgRiUAEKehrY06XzrdoM5JGMmgC3pMDyBTGpY9OBXe6NavaWqLKcSNyw64rkfDVuY55FOSVA79OetdraSs8mPvADANAGtp8JeUcHtW7FB+8JHoKr6PCW+bbxjrjpW1HDsjdgOT3oAwbtCZT6d6zp7Xc2MYFbs4wx+tUZhlMn86AOR1WzBONpHY1QisYxIuQSR05rob4oZcMeKqqiA5Azg4oAw57ZMng+gGaz7mAKx44HvW/eSBXYhDyM5zWJcyZ58sgfWgDPlQc8Emqs0YAGDz6YzV1yCN2wgHuahZ1RehJ6n2oApPESAnXHJxVZ4zuIIIPvV5mUjI4B7VE4x90478UAVQQOPzq5Y3EsTqIzkHjB6VCkYcnPX1FWIIWQ5AyP1oA9Q8GXcdxE0adVT5kPWrmpQbZgV+6Rwf6VxHhm8a01KKVSRtbn/CvR7tBNEWTo481B6HuKAObmQc+tVWFX7kYNU3xQBWcc0A4X2Jok60yRgq0AfKfxxIPxS1vHT9x/6IjrhK7j41nd8TdZP/AFx/9EpXD0AFFFFABRRRQAVp6PYNcyBiDjtUGm2bXU4GPkB5r0XQdLCKvy0ALoulhFXC13OiaWXK4X86j0vT8AFgAo6mt6OVY4zHDwO7dzQBpxTRWMflWwDS93x0qxbGSVwXYnPrWTAVJ61pRTiPpQB0unqiAFiK1o7hAcA1ylvcMcY+7WlbS7jknrQB1Fvc7sY6VZacldq9e9YtvLgdcCr0Uy98k0AaducYOea17I85NYcMnPStW0kIA7UAapxuGatwY61lecWOQatxOeBQBqZGKoXU+CSDipGlwp+lc9qd3tYoDQBt292rY5q9HIGHFclYyksATiuhtmwg5oA0KKjjcHjvUlABRRRQAUUUUAI/3TXL+KLQXVjLEw6jOa6hulZOpR7kYeooA+X/ABvalJmDDDDKmvI9Ztg11yK+g/itYGG7EmMLIM/iK8R1eH/SaAPoqGUpIpBxXX6TMJIlbPWuJb7+e1dL4flzHtJ6HigDudMQFd57EKPrWF4u1CO2uGiyHdRg+i10GmSKsEWexLV5x4skY385J+8xYGgDC1O9ed2+bp7VzF4pd92Tu9a0bqYoDgsx9euKzpvNwQwJJ7Z/WgDMmjCkgsAarSc8BQcetXJgcjcMD361QnyWyetAEMrKjkBwp9OtMBDL97P9KUxddxHPQVC0OWI3GgAdXBOCMUpO3HzbSOCMZBpFidDlXOakEbtksxx9KAEBAwMBl9qmDnOO3bIpoiUg/MAeuaswMzRbHAcKcDtQA+GXa4K4IYYI7VfsxGg8xQVY91/lVmx02MxZ37sDsKdDa4iPbH8J60AaulyMchDzwD6muq0mTZJuORkjgiuZ02L5N+MY5rpdJDO6ptO31oA9H0c77JZBxnggVob9oGeh61neHc/Z3jIwOMVqSxnZyOlAGLeNtdj1znHvWXISAxatO8OHIP3elZV06kFAeDxxQBj3A3yF/f8ASpEt2ZVVRk9am8gM3ytWlbxojAbwSvbH6UAc/dWL4beCMDnNc9eLsBXaCv0rub3e5fIGOmK5a+siMsWG3PT2oA5yUHBbAOKoTuVyQAcj0rWvE+Y7QQp461kXSsdxGQAKAKkr8fP+GKiVpOSjkKOuafKoXGWBqJhtHXP0oAlhuVDDdkD1FX1mU8q2R2UdawZZNoIUdfU0xZeAVY5+tAHZ6Y3nTqSTweo/rXqWmuTpttu6hcV414evv9IRZuRnlx2Hv617FopWXT1UEFeqkUAZmoKFYgdiRWXcHHatXUs7nz1DVz+oTrFGzMcADJoArz3CJkuwA65NYuoa/CgIiDSEenA/OsHUNQkvJ2JYiIdF7VnSv0oA8X+Klwbrx7qkxABbyuB/1yQVyddJ8RTnxlqH/bP/ANFrXN0AFFFFABUtvC08gRR1qNFLsAoyTXV6Bpm3azDLGgDV8OaWEVfl5r0LSrARxh3GAKz/AA/p4JXI4FdBcuqoEXgDvQA8TLjHTHYU5CT1OB6VlifYxP8AOmyX+DtXOaAN1LhYxxUiXIJzk1z1uXlbLMSPatizgcgY54oA27SdsDbnnuTWtazMxwx/Ksq1gO3sD6Vq20LcYFAG1afMgwc81rxDZtPU4rKsoXVBnitu0QMMPzQBbt2yeetacZ2oByTVO2gwRxxWgUyRg4oAmt8nnHFXoSSaq2+1R8x4p8l0kKEkgGgCa/uEgt3Zj9B61yjy+ZIxJPJzXNfEjxTe6ZDBe2QSa2jl2TxN/ED0IPYgjH/AulV/D3i/Ttaj/wBHl8u4x80EnDD6eo+lZe2hz+zb1O/+zMQ8KsZGN6eqbWtmu/b8js7eRUk3E1vWlx5idenWuMF6r4CnJHGK3NNucoVHGa1OA6q1ccnvVsOMCsi0k2oPerSzEigC8DThVPzcd6nil3cUAS0UUUABqjeLkGrrdKq3OCKAPJvi5YeboxnUfNE2T9DXzfqw/wBJr658X2i3elXULDIdCK+StYRo72RH4ZWKkfSgD3Vvv1taA2JAPWsU8sp9q2NG/wBcMewFAHd2bE2chBwFBOa43xBGjFsDLdcn+VdrOvk6ZKq4JUYP1rznV9Sh+YBhI2eQOmfrQBy+pORleV56VjSyMpI7flV3VLh5JCVwDWHcFm5LAHvQBLKdwJyv51SmfacHP9KjbKnhgR6CmyMrDnd7CgBrsoye1MeUYyvNNdQeAfwppgYjPB/GgAEq7wSrCh7g+jY9PSoiCB83XNMADtjIHrQBeWRduMnB9qsW6bmHltkZ61RgZVnBZWYdK3rKM7RGqbQ2DnqQKALsI/dIVJ+YZJB6Vo2yL5RUEgkdT2pJIIysYjGMDBzSIvlrt3dDyKANjR4TJbOuASCMN6V0el28iFcSEN0wWrH0Yh7fCDBJycHrXTWCh3QHkdsUAdToO9Xwz9ffNdC6kwsCc5rE0qMIFIGK3jyn4UAYGoQ9Tjt1rm7kEzkE9BXU3m7c3OKwHjUzOcc+tAFCMruJBOR7VPYy77kbiTg9cd6sLAnO7PrioZCtuwCnHcCgCW8wgYlicdciuZ1B1KvuZeeRmupvlEtu02AMjkVwupsZJZRuxgcCgDNu8MSVYHmqEu5OQdueDimXbFDx0HpWXLK6jhjn2oAmlZSxyAfwrPnIPG3H07USTFuWI5qvJcx54BGKAI5owSdrHn1pihxjPOfQZpxYOcK350+BcSfNkN7UAamlHa4JxmvV/AN4zwz2rnPyb4/YjtXllkFZh/Mda7nwW7RapAf4M4zQB1GsLlVkA++Dn6iuA8WzmOydR1dgtehatj7Mw9GzXmPi9vliX0cn9KAOV7VWlbrU78LVC6fbGx9sUAeNePm3eLb8+pT/ANAWufrc8bHPie9P+5/6AtYdABRRVmwgM86rjjvQBq6Fp5ciRx16V3+j2PK4XrWVoVn93jgV6Fo9mtvF5sg4xxQBYjVLKzx0Yjk1kzXRkY4qXUrg3ExUfcH61m3EgiQjuaAC4uMNjqxqS0j39TVC3jeSTce9b9hCFCigC5ZW5wMDiujsbBwoYfnVbToMKM4A9TW7bvGoA6n2oAsWlqP4sGtC2jXf0qvDIp24GKsqpOCKANeAKMAgAVpW2B05rGtWOAAD+Natq54BHSgDZgfoKkVmLHPFSoBNCrrgEUwKASW6UAJLJtTOcAVz2pXjyO2CcEY+lamoOSvolZrwiQDCnaaAOW1yzGqaVdWeABKhXJ/vdQT9CBXK+FfCM2kalDc3ginYqeUb/Utj3+9np7frXolxZFA3lnGeoqkbdwygBgPesZ4eE5qo90elhs2xOFw08JTfuT3Xyt/Xe2ul0T2sbAkggH37VtaXJjIJ5z07msYSLv2ocEdav6Ko83LA4JzWx5p2McpCjGFGKcZwT97NUPOwmBgLQsufr60AaaPgdTVmKccc1kxOwODirCScUAbcUobHNTVk20nzD0rUjbK0AK3Sqk5+U+tW26VSnPWgDB1pd1vJ9DXyb4/g+zeJrsDgM28fjX1lqp/dP9DXzB8UoA2vhsc4I/WgD1BeUQ/rW94eAN5Bu6bwfyrBg5ird0clCjjqDmgDpfFFwV8NXAjYhnlDOQeoryPUJijMedp6ivTvEErNbpEBuV1J9sV5jq9rJG7KzADt34oAx5n3jJP41mXWN3U1dkjCOcuxU+gqCRIyOhJ+vWgDNc8gbTio9jsRjfn6datvgE7Bj681VkmbPU+1ADWGDyOR6nNKVdgCPxApu/Dc4Ptip42QplkIz6GgCIhgT8jEdcdaTbvH3cDtxVpW2phELVNbxmTKsAM0AJZwEjMgyp4HHWujsLI+TnIBPTPesmzjVmAHAU4BJrekZURY1BLAdfWgCGeUxoyliMdCaisJ2nJJ7HrSz2okkCbxz2PWrcNvHYwjGC27cO9AHTaYDHaqwALP2HYe9djpFnIkas6EEjpjoK5rwta/bysrHCqckHv7V3ltblTksMGgDQsY2XqOPpWun3RkVnWsZHR81ooCFAJyaAMbUV/eMBWK0QYnGc5ror2Ml24rIaLFAFN8qp4ye2KzrsMwBxz06VtOg6AcVXmjUIQxwDQBVXdJpuGyc8GuF1lZElcDIB9K72DaoeJlAXkHPaub1y1Zctj1wc0AcFc7ssBnFZ9wADhuvrW9d2xZWIb5qwLmKUE8huefagChOoB3KchapSbc8nJ9KuzAxrtYHaepB5qjIwBACgCgBuBt4GO4NOjuHi6HeD61XkdhliQBnFV2nLnKvg9/egDqdPu45GUZ2N79K9D8IcTqxHQ8CvJbH5gAevSvQPCmoG0MaSktEDjPdfcUAei66DHEwH3W6V5d4ny0uPTmvUtdxJauAckIJVI7jH+FeW+IPmmNAHKz8cVkag+MLz61r3nU1z185ZnNAHk/jI58SXh/3P8A0Baxa2PFxz4huz/uf+gCsegAAycCun8P2JADFeTWPpNqZ5gSPlFegaLZZKACgDoPDenl3TjgVvapcbcQx/dXjjvU+n24srHP8ZHFZc7gMzv07UAVZW2A54rMkYySc5NS3c4fOTgdveo4Mk4AwT360AX7ZAANxwa3rDHACceprKsbbcQDg10tlbKMetAGnZxgqPyrWt4Bjsar2NuMYPeta3hAGADmgCSKBSoAU+9XbaAhh1I9KWJCAMfjVyH5cdM0ATQWxJHGBWlb2hXjOc96rW8oGM4+lXhdrHhmOKANezjEaYY+9Z2q3oVgqcgU1tRMmAo2isbUZzuOG5oAupfedG0W0Fj0NI2RwXC+1Y9m5jlkkJ5xTJrlt2SSf0FAGzOhiXex5rJupkZj+8AJGM01tQaRBGzHb3qAxCQ5UjB9aAK7Kqsdsu4mtjSMRpkt+tc5clxKwxx7Vsae5SFAeuM80AdKJuOCBTxMgx8wrIE4YdM+/anLOBwoHNAGzHdJ6k+lSpcEmsiGQhh2/CrscgDUAbdq5yM1s2zZAFc3byEkHOK3rA5AyRQBcc4WqNyeDVyQ/LzWddNwaAMTVW+R/oa+aPiXIP7bHPY19G6zMFjbntXy98SLr/ieNzwC39KAPYrP5o/c10ejQmWVEHGeTjsK5zTeQM12Ph1cGZ+4QAfif/rUATeIQsUMQ6BVOK871yRX3DIX611fxK1GS2NvbWxwyxK7v1OT2FeWXl28jMxck+5oAjvJBkhj9cVlvcLGxyRinXbMwyCc+9Zs0hxyePpQBbecMOAAcc81Tkkz3qEz7WAK59x2p4KH5sA0AOVmPOAD2xTAHduSx/HpTjvkGT17dhQzFDtCkL60ATB9ufmJx2FOEhaLcuRzxVYbjkgYPTpVq3jOPnJoA0dOjJlVmGABV6Vykp5ZR/Cc/rUKELHwfkXGfU00SmWZsc46D0oAt2bMjhmdiewz1q7Hc+Y+044OOKxDM5fahBxxk961tPiM91EuCrFgDigD13wJbhNPjLD5nGTXXxwbeQCQa5/wvF5VpFn0rq4VPHP1oAlt0xj0q1TIxxT6AKl5gA+9YsjFME/hW3ej5c+1c3cSZfB6e1ADGnOW2k4/lVS6lcjG7+tKTtfDEfN+lV712jwygEE4PFAFgtugdnwT0ziudu50d5FbP07it9CssLqGGOuK53VYCkwKEA96AOYv4lVmyTkHIANYd2xJ4IUY65rb1WP5jlhgehziuX1CMoxJOGHagCKVl2kSEHjis+d0jXAXPv1qK4mYjnnFVDdFQdwB+tADJ0EhbacZ7ZqGKE55P4U9pYywK9R1BqWNSGBH3DzQBoadCwbJ69hXTWMu0DP4Vh2B5HT6Vv2iLKV4yB3oA9MsrgzaTpzsxOVaNvfFefa0pErA9iRXbaejRaRbo2flz+Z5rkNcHzyN6sT+tAHGamdqtXL3zYBFdLq3Qj3rlNSbAPtk0AeYeKjnX7o/7v8A6CKylG4gDqa0PELbtYuT7r/6CKi0yHzblfQUAdLoNntRBjmvTPCmnb2V2HHauR0G0MkiKB1r1G0iWysBjAJGBQBFqcqoCB0UcVx2pXmWKJzWprl/8pVT8xrmSGd80APiQyPk9a3bGzPBI61W0u0MjLtFdhptiRtyBQAzTdPdtpAAFdNZ2KoFLgE0y1hCqPU1p2oxwAWoAsW0aAZ2mrqSRqOarCNmwAePQVLHb47GgC0s6ZyFqZX3kADiqyxHIwKiuLhoxthHzetAFttQtYb9LQzqbtl3rETgkc8j16dBVsSbnJckntXmfxE06dtLivwCsls+SQcEK3GfzxWl8LdX1bVlnjvws9pCAouGPz7uyn1471y/WbVvYyXoe9/YvtMtWY0Zqy0knunfp3vdO2/qegxFs+w6Vl6w7JISTgda2lVQ2Ac1keIlDxjrkdhXUeCZ1pdiQbUfJ7805JNzYJwe9YAYwXKsmck5q7Hds3DJg+tAGkoQHrz71O3zKAGwM9u9UFZyM8AeuOTTwTkZyTQA11d7pUXoTzxWisLO+QdoHYVNBBEFMkpCsR0FKoUN8rDb6k0AAUj5easxQk9j+dCXIkbBA4qZbgJgOAaAJUhGQCxzVsIF5b0qiL1CwAWpvPVmwpwaAL8J2nIat3TpDgZNc9aAFsE10FjtGMUAar52Gsm9kwDWrK4CA+lYGoyfKaAOY16b5G5r5V+Jl3t1zr1LfzFfTmvy4jcn0NfI3xLut2vH2B/nQB9OaTyBzXY6KcLIM9cVx+j/AMNddphIkXHfigDmfiG5ln830XYfw6V5jdPtYkcg16l4nt/OWRXz/hXmeoW6o7DnIoAzZGyPmOPes+4GGzyRmrciopI6/Wo32gfd5I4oApgqRjb+NIr4bJzgDgAVPjawwvAp2VABI5NADopDJGVxgk5oZSrYCn8TTo03N8vzex7VcsoWJ/eH5RQBDawyMwY8KOhq20BQcgDPQVLMwjwqsCT6DOKZIfMlUfNtX26UAXYIU8gocluuegpI7dombj5cYB96a7bYmxkn64q69whSIqoXjrmgCuLMBwBwcjhhjNdBpcHlahHu2569c1kCcFA/339M1d0SVjdopyQDnp0oA9o0XcLWPb90CuitmZlBzyK5jQiTYqAflwBmt22Y5wCeKANiPNPqvbse5qxQBDdjMZ+hrmrhOe1dNc48o56Vz9wwB6H8qAMqeMdTUUqmS3zngdjVmZ1GS4IHaoFlRlcFsc8cdKAM2Jnjl3DJB4NZurKzHdHyT1B61qzyKSoRlwOMD1rP1GVlwzZIzzQBx93nDg/eHBrnr0blKt1FdlqUCyDzYuD05HWubv4hIhVeHHtQByd6oQEge1ZEvryAOSfSuhvYnWRl/vViXcToCdvNAGbkncO1XbWUqPvZHpVZpPlyw7/nSCQZCjI9aANy3u2V8cEDrXXaDdRyTopIB9D3rhbfoASa39NIULQB7XZL5ulPg85x+OOK4rW0O1geveug8GXrXWi3MbkmWEh8nqV/+tWV4oj2XUuB8rDePxFAHnWrjrXIaudqMfauy1Qda4vXTiF/900AeWayd2pzn3H8hWnoFtyGI61n3UZl1VwPUfyFdj4fsi7xoB1NAHaeD7AlhIw+lb+s3WBtTgAYH+NS6fEtlYjHBxgViapNl2546UAYd25lmPep7K08xgT0psCb34A5NblpHgDGCeg9KAL+nW2wqBgCuitR0Cqc+prO02Ekrxk101ha9OMfWgCS2t92C2TWva2x28dKdZwKO2T61pQwE9BmgCvHa981ajt1XO5sCrSw7RlsACql7cIgI3YA/WgCC8mRUKgcdMisogM42sc5p1zcqFJKk/Ws2S+Ktwqovr1NAGxcJDdbobsJJCy4ZGGQR9Kuacum29wJoo4oZTGIcoNo2ZyBgccdvTmubhvI3yXLb+xqWWeMgABiw9KXKm7lqrOMeVSdux1V1qEcCkKckdKxLi+MjMWwAe3WkSMzW4dieOoFZ53ZOB/9amQU7uZXZSnBB5z3qxDIu5VYZz1NUZE2vhyMZqvPfJDOQpyc4oA6u3tlnbCsNvaoW2W8uH4x2zWRp2oyOoCgjnrV47LhsZy3pQBoNdDywRxnnFQfaSBt7nv6VE4KEqFx2zUWSzYyPSgDTimbH3g1TxzkjAJrPiRxyF49qsKzqg2rz3oAuea4OCRVyN8YJ61QiLEfvB9DQ5wcZOKAN+C6GBjg/Wt/SZDK6jORXC282H4Heut0OfJTn5vSgDo7ohYjXO6jJ8prXu590XXpXNanN8poA5LxTOEtZTnop/lXx945uDN4gnIP3eK+p/G11ssLhs9ENfImtzefqtzJ6uaAPsrRx0rttDh3sW9CAK4jRjwvNd7pDiDTmmboqySH8BgfrQByHiicG4m+YY3GvONaYFiwwc9cVua/dyy3UjyNkknjPA/CuWvssrYP4ZoAzJZFzhj+FQiZAcHp0qtcBwxwTgdzVd3bICZI6Z9aANE/MMg5A7GmsW5649Kr2xMWCx6dBVpWZ8Z4HYCgBYizEZYKv0q+ZPLCoScDv3NR7VijBIy55yKgldmcF+h6AUAXRMIgQB261C1633FbgGoXnPklUwQeGz2qK3QGYbs4B4oA14JGVWaQA+xp0jHcEHCkYyO1MYGO2LsMkngUyAtI+CCRjJ56GgC7CuFVgwyOBitfSSftq5HI6VjeVuVWweOtbOlsfOgyOj4z7UAe06DzZRocDvxXQQR/mKwdCUm1iwOwrorYEZxxzQBcgUrirFQxZznqKmoAiuRmI4rnbrgnnHNdM/3DXPXiYkb60AZN22SxxVJMYk7jGau3Azn17Z9KoTERk8EZ/lQBlyk/MTk4PNZ15IdrDcVGK0bwlATnj9Kyrtgq5xkHg5oAymndNythlIzxWVf7NwdTg+/ark2d7HJAxzWVcyAko5PXg0AVrmH7RFuVRuGTWJf2wWPLsd2ckDtWhNcvE7bTx0+orG1CZmLEDg9cUAZtwkcjf5H5VFHCMDYdv49qSWUSE4yWz0HWnW7ndlj06A0AXrSBxyTntzWxbAquccZrNgkwQeR75rWs2Vmycj2oA774eykPcoTw8LA+54qx4oO4xEddmKr+DVAbKjluKk8QEFgPTNAHAasMFq4TxKcW8n0rvdY/irzvxU2IXHrQBxVrBv1GVsdx/IV6X4NsQSJWHsK4XSod9ycDkkCvWtGg+y2HH8K4/GgCxfzhSQD8qCuZvZN341pahKRlSeT1rIx5shHagCzYR5xXSWFrnBNUNLt1wO5rq9Mt8EE49qANDTbMBAVXk10VladCar6dAMBm4Fa8O1vlXjHWgCeFEjXsTVqNzjjgVDFETyTgCo7m4C4SL6ZoAL24AXBOMVi3F1nO1Qfc1JclnJ3MTiqMoJBKjFAFO4d5sh+B2qm8BLBmOT6VdkXGeg4qocK4x8zH1oAcEAA9+1TKwUDgCmsCXw2BU8QRScrnFAHQ6H88fI+Q8HNUNQMSXMiqRtGe1XNMfZDg8cZxXKajcMbxgr9T3oAlnhkZvOUfIBk1g6iI4gWz+9f5jmusMy22nlGTc5GcngZriNRlZ9rPjeSePagDW0hsxLjr61vWgw+7jNctYTOiYxg4rorC4IQcdfagDZ/dyqVkwrdjUBgAI9uA3rWdc3JVxtepYNQOwByGX+VAGzbhlHDcU8l1/hDViyXLptKsCp6c05L9xncpORxz0oA1vtIDHcuKRZg2RzzWRHesSQ5yv8qeuooowCPyoA3LVCZBk11WiRgzIMZFcPZaiHIGMmuy0Gdm2vjFAG3qYVYXxxt4rjdUn4PNdBq10SNp49cd64zVp8BhQB558Sr3yNGu2z/Ca+W5mLyux7nNe8/GS/8AL0aRAeXOK8DoA+0dGfpXaSThPD8qg/ei2/ma4XRz8q10OoXBj0RuehA/nQBwGruGc5PNc3cyZJBNaeqXOZnAHGc1h3G52JGAaAKl2dygA9PaqSMYyztknoAa0DEW5Y/pUc1n5jKTnp+dAFFSZHxk7s1q2yrbjzJgWbHAqONY7f5UUb/WnblZwrE5PU+lADzK78kYz0B6UOr5Y8Fxj8KD/rAD0HPJpwIBJzkE96AHQ2eVK7sluTj+GrMNurSqijp61CsyBdsY3Z6k1q2UV0UQW8TFvXGB+ZoAW+ZfLjijGVXjOO5qC1iAlG4Hg4PtWg2g6hK6+Y6g5zkn/CtK08LSS48ydjyMhR1/OgDOtsByCykdOTWrp8RkI7/MCCOtb+n+CbYgiRpjz0BFdvofhixswvlwBM9ycmgDY8JpusRvX5io/A9634o/bBo060it4QI1xmrmKAGKMDFPoooADWNfAB35HWtmsXVBiRuM4oAyZlBBYjPsKzJV3eZk5GKmu2IJI6+tVGmMaktgsQeooAp3sQaPr8vBrG1JD5QKL8p9K0HuwdwdefY1n3UysdoYHAxt6cUAczeMdrZ4OcVkXQBB5+btXR3yhgQ2Cp55rBuoRycEAc0AYV4T2HIrLuV3DK8gcVr3UbK3PORnFZV1mM5UfKetAGFOu2TOMPTFuGjbBI45GR2qxdMrOQcDHSqMuD8pBOOeKANK3vDuG7itmwvA0gBz9a5eIdxnnnrmtjTRjBOdx9aAPXfBMwa5iUEENwKt+JI8TluzD9e9cV4Z1BrDUIJVOQGBZfUV6B4mCvbmRDlQyup9VYUAeaa0Mbq828WH92R716RrjctXmXixvuj1agBvhK1868RiOAc16PcOLezUVy3gK13WiS45Yn+Zra1ubdOYx91ePxoAyrqVpHJJqXTYi75IpscRLA9a2dPj+cMAAAc0Aaumwj5R39q6ewEcagsM1h2mCMKMZ9K6PToCdvfHNAGta/OFyMD0Fa0EQC9MVWs4QijufetOJeKAKt/dw2No891II4lxuc9Fycc/nVcFZVEkbBkYZVlOQfpU+q20d7Y3NrNykyNGfYEYrxPw3qetaPrP9l2h81vOMTW0h+TcDg49PqK5a+J9hOKktH+Z72VZL/aeHqzpTSnT1s9nH16Ws/LbY9cmVQcZzVSVcjrj6VakOcZGD7VVlLBSO1dR4JSuAo+tUiV38jr3q5LGSNzEgHvUOwDhcc8UARLkvhOnqauWcKGTbK+B1yazru7it3+ZhwO1UTqczlm24jHQdKAOkkugshiibJ79uK5zVwUvEkUZUGo9Lvy7O0py3tVPV7otGQjbSe9AGheawEhjRjv9c9axdQlWWSPYp2dQaz4jJI4V8ketXEVolwQOT6UAaFmJD1GRite3lIjCjKgHOTzVDTmYEbc++a1ooAEJbqTnFAFWQh7hAOM+tXBCQPlxx6GqcsTmU5+57dauwoFXa5IJ6GgBmG6N07Ypru0YyTxT5gYjmPDd+P8ACqbSb2IdR07UALLeERk4GT+tUJb9gBs4/WiWXdyoOBwATVPnzAcH24oA3tFuZZp1G7BPrXrnhlQNPO85c968o0O2ZZkdhg9q9P01mhslOP4RQBHrE4Mj49a4vWZ8K3NdBqs/LknrzXEa7cYjfmgDxH4zX2+SC3B6ksa8urrPiVefafEUig5EY21ydAH2RojZRa2NZH/Ekkz0LqP51zPh6feI0zySBXSeKZVi0iJB0Jz+A4oA871NQOfTjGKyJWAHp7VqX8ynO7n2PpWBLLhz/OgCVc5GeF706SZAo25JFUWuOSMDFMMnmADOMHnFAE5cZLY5PpTXkVDkDHt6mtLTdHuLkB9pCngZ6/8A1q6Kx8MorDIDHuetAHJ21tcXOPlKj/a61uab4becqJGc98AYFdnpvh5VYHaN3XmuosNNFuAAoJPXjk0AcdpnheGBldowWByK6W30kF03pjjjjqK3LfTyZckcZ6VpLaclcHAGMelAGG+mgbSEz/IVcs9NywJXGMVuwWmYwMAcYqzHBj/6woAr28CxoDsG7POK1LVNxHtUcUGMYFXYY9vagC/ECI1Bp9Iv3RS0AFFFFABWNrgKncvpWzVHU0DqB3xQBxlw2d2RgHuaybyfdIQucAdK6m5slOd65GM1my6PG3IBAoA4+aYCX5uAazbq4zKxOGxxXayeHoHHzA+ncYqlceErfecZ+ocigDi5ZlXKsdwxkH0+lZF1cD5sV39z4TiWJsgYJ4+c5FYlzoVkgwqDeDxuJoA4a5YyIXRe/WsadyFdWHHXPYV3d7poxgKB6CuevdJIY4yARg0AcdcqJFOeq9D3qo6Oq5jPTk59K6C80SYEmJuT0BrMlsriDBkiO0dSORQBRWM5yoIzzgd61bE7VUkketVYU5DLVpiG4x78UAbemzZmQ54Br06abz/DkTE/N9nA/I5rx+zkMbDByP1r0nT59+hqv91MfpQByOstuya8y8Vn98g9ya9L1UfKa8z8V/8AHzH+NAHa+BQsPhmGZuuHx/30ajmy7ljySc0nhNifClovYB//AENqsGPkZGaAHQxHbknArRsot5AHSqyQs4AAOK6HSbQYBIOaANPSLMfKXHA/Wums4xnao4rOsozjjgVt2iBevf8AWgC9AnSrZO1MVXiOAKJHZ84oAZK47dayJtJsphPus4czsHkYLhmYdDkc5HrWo5wBkiqzP/tD8KTinui6dWdN3hJr0I3CjGcZqtMQeAPxqUgF89u/vVW644WmQV5Wj5DmsLUL8JJlW2qtal2VggkeXrjg56VyN7MruWHzDrQAtxKsoMnO4nAHrVe+1DZaCIY4zwBVKW4ZjwwA9KquxuJfLIxxn8KAL2kTt56kZIYfNUerysXzkhc02Ob7IuduG6DNF60LwqwlUsTyCO9AEdhMQQpBOO9dHEY3iAfp2yK5m22xSOG5C962YrzdB8q8UAbWnbd6ouOTgVpXA8skNjd7Vxn26WM5QgEdOa0YdQmuIv3pNAG5DKgkyxp1xNhcqQQTxiubluRuIJb6jtSiZ/KJLbgOmKANe+uwFBz838qqQ325irkPnisu5vcxc8n1qkt5wd2RnigDZV49+MVesRHuBHNc1HdAcscfTvWxo93vYbQp9fWgDvdDgV2jyRg1386rb2iJgYC5Ncd4QQXagL/A2T7Cug1qciFFU4HIoA5bWJeTivP/ABNdCOCRiegJrrtYmwW56V5b8QL/AOz6XcNnsaAPDNcuDc6tcyk5y5qjSsSzFj1JzSUAfVPheTF3Cey5Y/gCa0/GeoFWS2U/MkS7vbIz/WsDwvKGmx6oR+eBTvFkpfWbh/4WII/LFAGFM5JwTx6mqV0v5Crj4PFRRxvPJ5ca5Yn8KAM2GOSWULEpJPpXWeH9BAYSz8sOenSrWkaQsAHyZPcnqa62xs1QKqgD1oALGwCqNi4PcVuWFgBjiprGzLsvTPfNbtra7MYHPtQBHa2hRBgVoQWhLDg5H6Vct4cAccir8EXqKAKtvZqmD3+lWRCqnhee9Wo1Qtx1FNZSzE5NAEcaKBkk/hQDg/KmT71MkfHT8aXYCCR1oARNzYyeParMQINRxrxz/KrMS5PsDQBMvQUtFFABRRRQAVWvl3KtWaZKoZDmgDEdWUnHftSKoLcjHH4VfeLn3pvlfhQBU+yh06ZHtVW8i8thtGR3rU8tgMpnHpVe6RnTBXB/pQByepOzEkfpXN6jEZgSc5PFdteWLuTlSPoKxZ9NnDH92SD3AoA4t7Rw2GYkfWqGoQSDIUbh24rsJ9LuRkeS4/CsyfS7kMCYzk8HigDkEh88hCMMO/aluLAiIZTPr2rp4tH2uDIAvOR71ZmsR5DAjPpxQB5ZqmkoSXjyj/SsCaOS3fDjp0PrXqd9p4IOR146dK5HV9PILKy5B68daAMKycNKvoTzXoOkNnQ3ZexIP+fxrzuCJ7a42ydD90+1dz4ZmDafcRE9w36UAZOqng15f4rbN4g9jXpWvOIi4J4HI+leV69L5uoE9gMUAeieCYt/haz99/8A6G1dBbaf5kg+Xis/4cwGbwvp4C5+/wD+jGr0fS9JyAcUAYljo+9lG3jNddpegDAJXtWrpmlruDEV0UMAQAADFAGPb6LEo6ZNTDTADwordjj9BxUyw5xxQBzj6eyj5Tgmqc9hcBfkK8117QBiOKY9oCcmgDgprK6/iQn8eKrmBwcN1rvZbLjgVn3GnDGSKAOUSMhSzHAqpPHtyxPvW9fQeWCSOB2rkdev/LjZc4GMcUAc54lviZBEp+X+dc7e3McFvhj8x4NVNa1hVnfGGccA9hXPzXTzyFnJoA05LkE5BOD6UyKbCs2cZPWqUAYnrn1pJ5gz7FGEWgC1e30l0+5n4AC1GJTtBzkA5xVTdukzjg1ZVMsqKeTzQBp27edGWzjNaEDbQFb/APXVWziMduSwGauQKZuWGT2oARjH5g6/StCznZDgp978xVTy1WYcfN3FW4woTJHPWgCG7k3XB3ICp7jg1SIcMzWzkt2GeRU95lsv3qgzfMOcH0oAsGZzCvmqGPPI4qswL4O3AP6VaX54sOMntU1pHFhgwPPbNAGclu7yDYf0rrfD2lssiu5+YjkVFp1muflGWrsNAsy08YxzQB2PhqCO1sZggAYjk1U1i439+AMVpNEbWzUdOOfrXL6jPhTQBzutz43V4j8Vr/FqIAeXOK9X164xu54r59+IN99q1bYDlVyaAOWooooA+hfCl1nymzwRitrxEm+UPjqAa4XwLd+ZEEJ+ZDg16Lep52mpIOsfyt9DQByoBY7V+8eK6jQtNEeGK5Y9TWTp1mz3ZYDge1d3pdruCjHPtQBLZWYwCRwB0rbs7Ilh8vHrV2ztBsQEDgc1sW0AXBxQAlhaJHHnBLn+VacMQAxjpTIV55FXI1A560ASQoMH0FTqCzD0pIkJU5FWY0I96ABExxin+WN3FSImOTUirzigCEphaEXDdqsFMmnBAKAIxGc+3rmnqgBzT6KACiiigAooooAKKKKAGNGDSiNR2p1FADWTIqN4hnNTUUAVXj9QMfyqFrdD/CKvkZqJkoAy5rSPJ4/Ws66sgOQK33GetVpY+PXNAHJz2YDE471QubbCn5a6y4gB7YrHu7chelAHH3tsMdOKwLuyV2IYYPrXZ3UWM4FZk9tnnHP8qAPOtb0UPC7x/wCsXlazPDN2Yrjy3ON3yj/Cu51OLJ244PWuJ1mzNvcG4h45yQOx9aAM3xc5Qn2JU/zry+7bfcOT1zXp/jVt0crgYzsf6ZWvLJDl2PvQB9BfCC083wbpr46+Z/6NavVtOtAByK4X4IxBvh7pLY/57f8Ao569QtIQKAJ7eEIuQOauRpmmxrmrkMVABHHU4TAqREwKRue1AEe2jaOpp+G+lMZCfU0ARSOoHHNULtwV6VpfZmY8g0psA3UUAcfqIMgIVTivPvFmjXEschgBye1e3PpEbdRiqV14djmQqW/MUAfHGs2cltdlJgVbuDVUKeuMccV9GePvhj/alq0tsFFwgypHU+1eJat4a1HRywu4WwOAQOKAMm3JhtpXP3jwB6VBg8/Ly1TuxA2hMD3qE71Ix3oAWJUEvUkA1eg5m9yap2W0zANyK0Y+JSR0HegDTCkW5GclamsmkUjZkZ61FBIQgLDjPPerUAYb8g47fSgCadAzEr9/qeajFwFlCyfgw6j/ABpjFiAwO0ioGlVnKyj6MOooAvXKb4SyYcdSV5xWQy5YjpVweZATJG+5TxkVWmu2fhkG4fxUACt8wAPAq5Ap3Aoc5rMjdpHIX860tOjkLHIIHrQB0ekozSKHBX3r07wpZ7bnzZAGUdK4fRLYu8fPGOTXp+mILa2Y/wAJxigCHXJtsbDuTnHtXB6rNgMc10/iC4zK3PQVwmtXG1WwaAOM8W34htpm3Y4IFfPupTm5vppSc7mOPpXpnxK1XZE8SNyePxryqgAooooA9H8GXPkausZPyyD9a9q03E9m8fBDJjHvXgGmyGHULdwcENXunhi4EsKN/eGaALukQB5MqvIrtdJtlQA461z+jQbGPqzZ+ldbZYRR/KgDWtFGASK0EIyABwOtULVmbHp6ZrUgTkZzQBYt1OfSrkSZ5qOJeAB1q5EtAEsSYB9anUd6SNetTIvOaAFC9KcBilooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACgiiigCKRKrSrjrV4jIqCRaAM6dck5qhcR5FakycHFU5xigDAvLUE52isi8tyiHgV1EwGDWRfxgrQBw+pR8k1y+rQhiB613Gq2+QxFcnfp95zQBwPjB8wSepwPyry09SfevS/Fx3RyAdFBrzSgD6q+BaZ+G+jn/rt/6OevUbeP5RXm/wABo93wz0Y4/wCe3/o6SvVLWOgCW3izV9Ex1pIUwKsBfagBgXNL5YqUClxzQBEI/anrGBUgFFACBQKXFFFABimtgDmnUySgCtMwweK4rxbp0M8b+bErIwPbvXbOuazNVtPtFs6kc44oA+cNd0W2gnbMOVOeR2rmb3QixBhY8817Lr2k+YzgR5JBBGK45NJktrwqykoehoA8/Gky24BcZJ6EVHIhj+ua9KudNHAKZNY1/occudiEMO9AHNQTOsSn1rWgkCqGPzA8+xpt1okyIDGpwKS2iliDKUJUDJzQAyeZZZWK5XA4A6VmvMQxyAc+laSJHPJ8jhWJ+63BqCS2McuGXDdKAJLeRlXjg/xVEikyt8owT6VZijIfLd+tSCH95kEYPNAD7SzdmyEA+ldBYaWZCQxIPQVU08SxlcAH6iu/8PWi3YR1XaerCgCTQtL8sIXXBzXS3cgjiRc4CinyRrEkbDACisXVrnKkA4FAGPrFzkuxPWvPvEt8IopGJ4UZrptXucKxzXj/AMSNbFraMgb536CgDzbxbqBvdTcZyqH9aw6VmLMWY5YnJNJQAUUUUAdXGdsiH0YV7L4KmysK+4rxg16t4HmBeDn/ADigD1Ox2xj5uMVv2B3/ADGuaDbpkx0wCa6XTD8o9aAOhslG0e9a9ulZlkPlBHFa9uBgUAWYVq5GvTFQQDmrsagdaAJI0456VLSCloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKaw9cU6g0AVJRVGdB6VpSrVOcdc0AY10D2rJuzjOTW3dgc1h6h0NAGJfDdkDgVx3iMCNCVHHpXVX8wTOelctrLCaN84x2oA8v8Sj9xJnnivNRXpHiZtsMozyAa83oA+vfgAmfhboh/wCu/wD6Pkr1S3TGK80/Z7TPwn0I/wDXf/0fJXqUKdKALEY4qYCmIKkFAC4ooooAKKKKACiiigAoIBoooATYvpSNGrA5FOooAx7vS4WZm2L+VYGpaHDJG4EYBPfFdsy5FVJbcGgDyS70t4ZjGy59DUH9lZ5YCvS9T01ZYyQo3DoawJbXaBgcd6AOLn0vdGy4+X2FZD6cIXZAodcYrvbi2+VvlIrHuLT580AeS6rp7W16yoCcHOO9V47x4WYModTwA3aux8U2DuwkjXDqc5rl+JiBIgZu1AFcSFmOBjH6VLASeCCfQ1dtrNGLfLkkYrUs9M2svy/KTQBY0GCSVAjLlu1epaFZfY7WPI+dxiub8M2AD7ivvz6V2VqcbmPRRkUAV9VkCR7R24rkNWuODzW3rE4DEHtXFa1d7UYk9KAOe8QXwjR9zYAGT7V87eLdWbVtWlcHMKHCf413/wAUtfMFqbOFsTXHDYP3UryWgAooooAKKKKAOprvPA93tWEk/dIzXB10HhK48udoye+RQB7vp8u/ymzn5Qp/Dj+VddphyFI6V5x4fut0aqTyK73R5flXmgDr7N+BWxbnOMVgWRzyK3rMYA9aANO3HSrinFUoWxVhGyRQBbU5606mR0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqN2x3oAWTpVG4HBNWGk9ahmOc0AZN10rD1AcNW9dD0rn9RPBFAHJ6wx2sK5O5lJ8xD6ZH0rp9ZbrmuMvnCPI5POxgPxFAHn3jKTas3uM15+Oldj41nzvA9QtcdQB9n/s7pn4RaCf+vj/0okr1CNa80/Z0XPwf0D/t4/8ASiSvUEGBQA5RTqBRQAUUUUAFFFFABRRRQAUUUUAFFFFABSEZpaKAIZY9wrndUt2hl3rkITXUHmqd5CsiMrDINAHJyCNojuUA+tZlxaHzAcZHbFbt1Z7SVXt2qjIjw4G04x0NAHHa1YFtxbqa8+vtPa1v2IHyNyD2r1jUwXOAMVwnii0OwvydhzQBS06PYwDjAJ9OK62zs1lt8oMMO1c1oEU00saMpKN0Jr0/SNMEVmskv5etAEWj2xjiPGGYAVoXDrBFj05PvVnCxR56HFYGq3OQcHgUAYms3GWck8mvOPFeqpb28skjYSMEn39q6nX70IrnPNeB/FPXi7jT4X/2pCP5UAcLr2oyapqc1zIc7j8vsKz6KKACiiigAooooA6mrmkzeTfRt68VTpVYqwYdVORQB7F4euMhOa9G0afhM968f8K3QZE57Zr0/RpvkQ+hFAHo2lNnBro7dgRzXK6U+2JT7c1vQS8DmgDYRsng8Vci7VmW79K0Im4oAvRdKkqGFu1TUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIxwKryt/kVO/SqkpoAid+f61BLLjIP50rtyapXD+9ACXEnyn3rndVbqR+IrRmnIBBrG1CXKnNAHJ6xJnOOtcRrUwRH55rr9cbYzehrgNelwG/GgDzfxVNvuUTOeprCq/rcvmag/txVCgD7Y/ZzH/FnvD//AG8f+lElenKK8y/Zx/5I74f/AO3j/wBKJK9OHSgBaKKKACiiigAooooAKKKKACiiigAooooAKKKKACmsM06igDJ1CDPzDqKyrpS3GM8da6WeMMprElQLKQRQBz11ZCQg96xNT0qN0fcN2eOa7OWPOcVmXUBO4kcCgDnvDelh7tOP9WMV2TkbhEvCgYqlo1uLWN2bAZsn6VY+7Gzt1bp9KAKGqXG0lemBiuP1e8wG5ra1e44Y5rgfEF9sRueaAOT8a62llZzzuwwg4Gepr52v7p7y8lnlJLuxJrsfiXrhvL37HE+Yoz82O7Vw1ABRRRQAUUUUAFFFFAHU0UUoGaAOt8Gznaq+hIr1zQJCwUc15J4JjUpk9fMP8hXtHhqFMR8elAHaabITEmeorcs3ZiDg1R02FNpGOK6KygTA4oAltt2BxWjDuOOKfbQpxxV+KJRzigBkKk9RxVigcdKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAAjIqB4A3ep6KAKD2nJOKpXFn14rcpCoPUCgDjruxJzxWTc2LcgivQnt426is27tItp4NAHlGt6aXVuOgrzTxJYsivketfQl9ZQlZCV9q848XadbiJiFOeaAPmHWojDqMinjPNUq7rXtMtpdUlLqSRgDmqP9i2ew/K350AfVX7ORx8INAH/Xx/6USV6iOlebfAiFLb4YaLFFnYvn4z/13kNekJ0FADqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBkv3a5/U2ZJgQe1dBJ0rD1ZRuQ0AQQN5o96nNovl7mGaSyQZz3zV644TA6UAc8il5D2XOTUGpzhYyF47CtG4UIuFGBXMatI2W5oA5/W7oKrc15B8QNdWyspnDfOQQv1r0DxHM6o+DXzz8T7qV7xIy3ydcUAcRcytPO8jnLMcmoqKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiographs of an eight-year-old girl with cystic fibrosis, recent wheezing, increased cough and secretions, and diminished breath sounds in left upper lobe. Upright frontal radiograph reveals relatively increased opacity of the left lung and indistinctness of the left mediastinal border. The lateral view shows anterior displacement of the major fissure caused by left upper lobe atelectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Resolving left upper lobe atelectasis in a child with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Follow-up radiographs obtained four days later demonstrate partial reexpansion of the left upper lobe, with residual posterior segment and ligular atelectasis. The opacity on the lateral film represents \"plate-like\" atelectasis of the posterior left upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23974=[""].join("\n");
var outline_f23_26_23974=null;
var title_f23_26_23975="Acetaminophen and tramadol: Drug information";
var content_f23_26_23975=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen and tramadol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/57/31637?source=see_link\">",
"    see \"Acetaminophen and tramadol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13114310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ultracet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F1582162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tramadol/Acet&reg;;",
"     </li>",
"     <li>",
"      CO Tramadol/Acet;",
"     </li>",
"     <li>",
"      JAMP-ACET-Tramadol;",
"     </li>",
"     <li>",
"      Mar-Tramadol/Acet;",
"     </li>",
"     <li>",
"      Pat-Tramadol/Acet;",
"     </li>",
"     <li>",
"      TEVA-Tramadol/Acetaminophen;",
"     </li>",
"     <li>",
"      Tramacet;",
"     </li>",
"     <li>",
"      Tramaphen-Odan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F229734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic Combination (Opioid);",
"     </li>",
"     <li>",
"      Analgesic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F229719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute pain: Oral: Two tablets every 4-6 hours as needed for pain relief (maximum: 8 tablets/day); treatment should not exceed 5 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F229720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F229721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Maximum of 2 tablets every 12 hours. Treatment should not exceed 5 days.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F229722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Acetaminophen 325 mg and tramadol hydrochloride 37.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ultracet&reg;: Acetaminophen 325 mg and tramadol hydrochloride 37.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9378372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F229703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (&le;5 days) management of acute pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5118567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ultracet&reg; may be confused with Ultane&reg;, Ultram&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F229732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (6%), dizziness (3%), insomnia (2%), anxiety, confusion, euphoria, fatigue, headache, nervousness, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (2%), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (6%), anorexia (3%), diarrhea (3%), nausea (3%), dry mouth (2%), abdominal pain, dyspepsia, flatulence, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Prostatic disorder (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, amnesia, anaphylactoid reactions, anaphylaxis, arrhythmia, coma, depersonalization, drug abuse, dysphagia, dyspnea, emotional lability, hallucination, hepatitis, hypertonia, impotence, liver failure, migraine, muscle contractions (involuntary), oliguria, paresthesia, paroniria, pulmonary edema, rigors, seizure, serotonin syndrome, shivering, Stevens-Johnson syndrome, suicidal tendency, stupor, syncope, tinnitus, tongue edema, toxic epidermal necrolysis, urinary retention, urticaria, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     A withdrawal syndrome may occur with abrupt discontinuation; includes anxiety, diarrhea, hallucinations (rare), nausea, pain, piloerection, rigors, sweating, and tremor. Uncommon discontinuation symptoms may include severe anxiety, panic attacks, or paresthesia.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F229706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen, tramadol, opioids, or any component of the formulation; opioid-dependent patients; acute intoxication with ethanol, hypnotics, narcotics, centrally-acting analgesics, opioids, or psychotropic drugs; hepatic dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Note",
"     </b>",
"     : Based on Canadian product labeling: Tramadol is contraindicated during or within 14 days following MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F229691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Rare but serious anaphylactoid reactions (including fatalities) often following initial dosing have been reported. Pruritus, hives, bronchospasm, angioedema, toxic epidermal necrolysis (TEN), and Stevens-Johnson syndrome also have been reported with use. Previous anaphylactoid reactions to opioids may increase risks for similar reactions to tramadol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Acetaminophen may cause severe hepatotoxicity, potentially requiring liver transplant or resulting in death; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day).",
"     </b>",
"     Risk is increased with alcohol use, pre-existing liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Even when taken within the recommended dosage seizures may occur; risk is increased in patients receiving serotonin reuptake inhibitors (SSRIs or anorectics), other opioids, tricyclic antidepressants or other cyclic compounds (including cyclobenzaprine, promethazine), neuroleptics, MAO inhibitors, drugs which may lower seizure threshold, or drugs which impair metabolism of tramadol (ie, CYP2D6 and 3A4 inhibitors). Patients with a history of seizures, or with a risk of seizures (head trauma, metabolic disorders, CNS infection, malignancy, or during alcohol/drug withdrawal) are also at increased risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use tramadol with caution and reduce dosage in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Patients with chronic respiratory disorders may be at greater risk of adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicide risk: Avoid use in patients who are suicidal; use with caution in patients taking tranquilizers and/or antidepressants, or those with an emotional disturbance including depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Use with caution and reduce dosage when administering to patients receiving other CNS depressants; may cause CNS depression and/or respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Avoid use, if possible, with serotonergic agents such as TCAs, MAO inhibitors (use with extreme caution; contraindicated in Canadian product labeling), triptans, venlafaxine, trazodone, lithium, sibutramine, meperidine, dextromethorphan, St John&rsquo;s wort, SNRIs, and SSRIs; use caution with drugs which impair metabolism of tramadol (ie, CYP2D6 and 3A4 inhibitors); concomitant use may increase the risk of serotonin syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion: Healthcare provider should be alert to problems of abuse, misuse, and diversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Tolerance or drug dependence may result from extended use (withdrawal symptoms have been reported); abrupt discontinuation should be avoided. Tapering of dose at the time of discontinuation limits the risk of withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F229728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiemetics (5HT3 Antagonists): May diminish the analgesic effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: TraMADol may enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. Cyclobenzaprine may enhance the serotonergic effect of TraMADol. This could result in serotonin syndrome. Management: Seek alternatives.  If these agents are given in combination, monitor for seizure activity and signs and symptoms of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: TraMADol may enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors.  Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): TraMADol may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F229714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (increased liver toxicity with concomitant use).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: May delay time to peak plasma levels, however, the extent of absorption is not affected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acetaminophen: Avoid St John's wort (may decrease acetaminophen levels).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tramadol: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F229709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies using this combination. Acetaminophen and tramadol cross the placenta. Refer to individual monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F229723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F229710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acetaminophen and tramadol can be detected in breast milk. The manufacturer does not recommend this combination for use as a preoperative medication or for postdelivery analgesia in nursing mothers. Refer to individual monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F229711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F229708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tramadol-Acetaminophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5-325 mg (100): $102.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ultracet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5-325 mg (100): $216.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F229700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory rate, blood pressure, and pulse; signs of tolerance, abuse, or suicidal ideation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1582163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acetram (ID);",
"     </li>",
"     <li>",
"      Acetram-Semi (KP);",
"     </li>",
"     <li>",
"      Analgan Tram (EC);",
"     </li>",
"     <li>",
"      Analtram (ID);",
"     </li>",
"     <li>",
"      Beartra (KP);",
"     </li>",
"     <li>",
"      Calmex (PY);",
"     </li>",
"     <li>",
"      Cetamadole (KP);",
"     </li>",
"     <li>",
"      Cetodol (PH);",
"     </li>",
"     <li>",
"      Cetra (PH);",
"     </li>",
"     <li>",
"      Dolantag (EC, PE);",
"     </li>",
"     <li>",
"      Dolcet (PH);",
"     </li>",
"     <li>",
"      Doltramcet (KP);",
"     </li>",
"     <li>",
"      Dotramol (ID);",
"     </li>",
"     <li>",
"      Duodyne (KP);",
"     </li>",
"     <li>",
"      Fastfen (CO);",
"     </li>",
"     <li>",
"      Ixprim (FR);",
"     </li>",
"     <li>",
"      Metagesic (EC);",
"     </li>",
"     <li>",
"      Neutracet (KP);",
"     </li>",
"     <li>",
"      Rapicet (KP);",
"     </li>",
"     <li>",
"      Supercet (PE);",
"     </li>",
"     <li>",
"      Suprafen (KP);",
"     </li>",
"     <li>",
"      Tracan (KP);",
"     </li>",
"     <li>",
"      Traldiar (GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Tramacet (BB, BM, BS, BZ, CO, DO, GB, GY, IE, JM, MX, PR, SR, TT);",
"     </li>",
"     <li>",
"      Tramiphen (KP);",
"     </li>",
"     <li>",
"      Ultracet (BR, CL, HK, ID, KP, MY, SG, TH, TW, VE);",
"     </li>",
"     <li>",
"      Ultramac Semi (KP);",
"     </li>",
"     <li>",
"      Zafin (EC);",
"     </li>",
"     <li>",
"      Zaldiar (AT, BE, CH, CN, CO, CR, CZ, DE, DO, EE, ES, FR, GT, HN, ID, IL, MX, NI, NL, PA, PE, PL, RU, SV, VE);",
"     </li>",
"     <li>",
"      Zultracet (PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F229690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Based on",
"     <b>",
"      acetaminophen",
"     </b>",
"     component: Inhibits the synthesis of prostaglandins in the central nervous system and peripherally blocks pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Based on",
"     <b>",
"      tramadol",
"     </b>",
"     component: Binds to &mu;-opiate receptors in the CNS causing inhibition of ascending pain pathways, altering the perception of and response to pain; also inhibits the reuptake of norepinephrine and serotonin, which also modifies the ascending pain pathway",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F229705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/26/23975/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/26/23975/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/26/23975/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/26/23975/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/26/23975/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/26/23975/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/26/23975/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/26/23975/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, \"Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),\"",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, \"The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,\"",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/26/23975/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9166 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23975=[""].join("\n");
var outline_f23_26_23975=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13114310\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229717\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1582162\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229734\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229719\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229720\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229721\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229722\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229702\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229687\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9378372\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229703\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5118567\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229732\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229706\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229691\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229728\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229695\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229714\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229697\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229709\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229723\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229710\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229711\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229708\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229700\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1582163\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229690\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229705\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9166\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9166|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/57/31637?source=related_link\">",
"      Acetaminophen and tramadol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_26_23976="Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure";
var content_f23_26_23976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, diagnosis, and treatment of autoimmune ovarian failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/26/23976/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/26/23976/contributors\">",
"     Lawrence M Nelson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/26/23976/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/26/23976/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/26/23976/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/26/23976/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/26/23976/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/26/23976/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune ovarian failure due to autoimmune oophoritis is one of the known causes of primary ovarian insufficiency (commonly referred to as premature ovarian failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/1\">",
"     1",
"    </a>",
"    ]. It is found in about 4 percent of women who present with spontaneous primary ovarian insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/2\">",
"     2",
"    </a>",
"    ]. Autoimmune oophoritis was first confirmed histologically in a woman with coexisting autoimmune adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/1\">",
"     1",
"    </a>",
"    ] and subsequently in additional series of women with similar presentations. There is strong histologic evidence that primary ovarian insufficiency, when it occurs in association with adrenal autoimmunity, is autoimmune-mediated ovarian failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/3\">",
"     3",
"    </a>",
"    ]. However, there is only circumstantial evidence to suggest that autoimmune premature ovarian failure occurs in the absence of steroid cell autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmune oophoritis may occur as part of type I and type II syndromes of polyglandular autoimmune failure, which are associated with autoantibodies to multiple endocrine and other organs (",
"    <a class=\"graphic graphic_table graphicRef67520 \" href=\"UTD.htm?9/25/9629\">",
"     table 1",
"    </a>",
"    ). Primary ovarian insufficiency has also been described in women with systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] and myasthenia gravis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the pathogenesis, diagnosis, and treatment of autoimmune ovarian failure. The evaluation and treatment of spontaneous primary ovarian insufficiency and autoimmune adrenal insufficiency are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Autoimmune adrenalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which ovarian autoimmunity is initiated is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. It could be by exposure to a virus or other substance similar in structure to some component of ovarian tissue. Due to such \"molecular mimicry,\" activated lymphocytes or antibodies might react with ovarian tissue. It is also possible that a virus or other agent could damage ovarian tissue in such a way that it becomes antigenic. Alternatively, a basic failure in immune regulation might develop, leading to loss of specific tolerance to some ovarian component, and ultimately, ovarian autoimmunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymectomy in mice at three days of life appears to impair development of suppressor T cells and induces loss of self-tolerance. In specific strains of mice this leads to the development of organ-specific autoimmunity, such as autoimmune thyroiditis, gastritis, or oophoritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Autoimmune oophoritis in this model is characterized by an ovarian lymphocytic infiltration that begins around the time of the first estrous and becomes florid in the ensuing weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/10\">",
"     10",
"    </a>",
"    ]. Thereafter, the ovaries become atrophic and fibrotic. These changes are accompanied by the development of antibodies against an oocyte cytoplasmic protein that has been identified as MATER&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Studies in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, ovarian biopsy of women with primary ovarian insufficiency (premature ovarian failure) shows autoimmune oophoritis, characterized by lymphocytic infiltration involving secondary and antral follicles but sparing primordial follicles (",
"    <a class=\"graphic graphic_picture graphicRef74476 \" href=\"UTD.htm?23/15/23801\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/13\">",
"     13",
"    </a>",
"    ]. The lymphocytic infiltration is most intense in the theca of developing follicles and is associated with intense luteinization of follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/1,2,14,15\">",
"     1,2,14,15",
"    </a>",
"    ]. These findings are found almost exclusively in women who have circulating antibodies against adrenal antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The fact that the inflammatory reaction is confined to growing follicles that have a theca suggests that the antigens are fully expressed only in these follicles, consistent with the hypothesis that steroid-hormone-producing cells express the antigens that stimulate the immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmune oophoritis may also be associated with the development of large luteinized follicle cysts, resulting in enlarged cystic ovaries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. These findings suggest that an increase in gonadotropin secretion in response to the reduced negative feedback provided by impaired follicle function may be the cause of ovarian stimulation and large cyst formation, similar to what may be seen in 17-20 desmolase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report of three women with presumptive autoimmune oophoritis and multiple follicles, the following biochemical findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum LH concentrations were in the postmenopausal range while FSH concentrations were at the upper limit of normal for premenopausal women.",
"     </li>",
"     <li>",
"      Serum estradiol and androstenedione concentrations were extremely low, but inhibin B concentrations were high.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This observation of normal inhibin B production in the absence of estradiol precursors (or estradiol) suggests that theca cells are selectively affected while granulosa cells are spared in patients with autoimmune oophoritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cellular immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies have demonstrated that major histocompatibility complex (MHC) class II molecules are aberrantly expressed in the granulosa cells of women with autoimmune oophoritis, a phenomenon that can be induced in normal ovaries with gamma interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/22\">",
"     22",
"    </a>",
"    ]. Because FSH has a synergistic effect with gamma interferon in inducing class II expression on granulosa cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/23\">",
"     23",
"    </a>",
"    ], it is theoretically possible that ovarian stimulation with gonadotropins in patients with autoimmune-mediated ovarian failure might worsen the disorder, although this has never been demonstrated. Studies seeking to define particular MHC class II types that increase susceptibility to primary ovarian insufficiency have been inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with primary ovarian insufficiency have increased numbers of activated T cells in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Nonetheless, patients with primary ovarian insufficiency have an impaired immune response to candida antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/29\">",
"     29",
"    </a>",
"    ]. Other reported abnormalities include a decrease in circulating natural killer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/4,29\">",
"     4,29",
"    </a>",
"    ], a decrease in macrophage migration inhibition factor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/30\">",
"     30",
"    </a>",
"    ], and an increase in leukocyte migration inhibition factor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/27\">",
"     27",
"    </a>",
"    ]. Similar abnormalities are found in patients with insulin-dependent diabetes mellitus, chronic autoimmune thyroiditis, and autoimmune adrenalitis, suggesting a common autoimmune pathophysiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Humoral immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with histologically confirmed autoimmune oophoritis have circulating antibodies against the steroidogenic enzymes such as 21 hydroxylase, 17 hydroxylase, and side chain cleavage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/2\">",
"     2",
"    </a>",
"    ]. Specific antibodies to other ovarian antigens have been difficult to define in women with primary ovarian insufficiency who do not have steroidogenic cell autoimmunity, probably due to several factors, including the difficulty in obtaining human ovarian tissue. Many assays for anti-ovarian antibodies have used animal tissue, in which the putative antigens may differ from those in human ovarian tissue. Indirect immunofluorescence using various sources of ovarian tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] and enzyme-linked immunosorbent assay (ELISA) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/33-35\">",
"     33-35",
"    </a>",
"    ] to identify ovarian antibodies give inconclusive results, as does immunoblotting using patient serum [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Steroidogenic cell autoantibodies are better detected by using adrenal tissue rather than ovarian tissue when using the indirect immunofluorescence method [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     FSH-receptor antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies against membrane-bound receptors are known to cause diseases such as myasthenia gravis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/37\">",
"     37",
"    </a>",
"    ]. Anti-FSH receptor antibodies, detected using animal systems, have been reported in a few patients with primary ovarian insufficiency. However, a study using a recombinant system expressing human FSH and LH receptors did not confirm these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/38\">",
"     38",
"    </a>",
"    ], which suggests that antibodies against the FSH-receptor or the LH-receptor interaction are a rare cause of primary ovarian insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Co-existing autoimmune adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, steroid cell autoantibodies detected by indirect immunofluorescence have been identified in patients with primary ovarian insufficiency associated with Addison's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. These antibodies may also be present in patients with isolated primary ovarian insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/2,42-44\">",
"     2,42-44",
"    </a>",
"    ]. One study has demonstrated that steroid cell autoantibodies as detected by indirect immunofluorescence (using adrenal tissue substrate) are significantly associated with the presence of histologically confirmed autoimmune oophoritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Autoimmune endocrinopathies'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present the only validated marker to detect autoimmune oophoritis is the presence of steroidogenic cell autoantibodies as measured by indirect immunofluorescence using adrenal tissue as substrate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/2\">",
"     2",
"    </a>",
"    ]. There is no validated serum marker to identify women who have other potential autoimmune mechanisms for their primary ovarian insufficiency (premature ovarian failure). The predictive value of a commercially available serum anti-ovarian antibody test (an indirect immunofluorescence assay using cynomolgus monkey ovary) to identify these women is poor. As an example, in a study of 26 women with 46,XX spontaneous primary ovarian insufficiency and 26 normal cycling women, 50 percent (13 of 26) of women with ovarian failure and 31 percent (8 of 26) of normal women had ovarian antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, this test has an unacceptably high false-positive rate.",
"   </p>",
"   <p>",
"    Ovarian biopsy to detect autoimmune oophoritis is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/46\">",
"     46",
"    </a>",
"    ]. Testing for the presence of adrenal autoantibodies is sufficient to make the diagnosis of autoimmune oophoritis in a woman with proven spontaneous primary ovarian insufficiency. The presence of another autoimmune disorder does not necessarily indicate that the primary ovarian insufficiency is also autoimmune.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Autoimmune endocrinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young women with spontaneous primary ovarian insufficiency are at increased risk of developing autoimmune adrenal insufficiency, a potentially fatal disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/5\">",
"     5",
"    </a>",
"    ]. Generally, the development of disordered menses associated with primary ovarian insufficiency precedes the development of symptomatic adrenal insufficiency by several years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If proper screening is performed, approximately 3 percent of women with spontaneous primary ovarian insufficiency will be found to have asymptomatic autoimmune adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/7\">",
"     7",
"    </a>",
"    ]. As a screen for the presence of asymptomatic autoimmune adrenal insufficiency, serum anti-adrenal and anti-21 hydroxylase antibodies should be measured at the time of diagnosis of spontaneous primary ovarian insufficiency in all women. Those with positive antibodies should be carefully evaluated for the presence of adrenal insufficiency. This topic, as well as the treatment of adrenal insufficiency, is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Young women with spontaneous primary ovarian insufficiency are also at increased risk of autoimmune hypothyroidism and should be screened for this condition. Testing should therefore include TSH, free T4, anti-thyroid-peroxidase and anti-thyroglobulin antibodies. Other disorders associated with autoimmune polyglandular syndrome are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Autoimmune adrenalitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of autoimmune ovarian failure includes any non-autoimmune cause of primary ovarian insufficiency. This would include chromosomal abnormalities (Turner syndrome) and premutations in the FMR1 gene, the gene responsible for fragile X syndrome. The non-autoimmune causes of primary ovarian insufficiency are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prevention of osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen and progestin should be replaced for prevention of bone loss, as it should be for any woman of premenopausal age who is hypogonadal. Although there are no clinical trial data specific to women with primary ovarian insufficiency (premature ovarian failure), indirect evidence from estrogen therapy for postmenopausal women demonstrates that it is effective for prevention of bone loss and reduction of fracture risk. In addition, indirect evidence from the WHI and HERS trial suggest that the excess cardiovascular risk that was observed was primarily in older, not younger postmenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Estrogen deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with autoimmune oophoritis who desire contraception, we suggest the use of barrier contraception, as there is still a small chance of conception. The oral contraceptive may theoretically not be as effective in women with spontaneous primary ovarian insufficiency due to the elevated gonadotropin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those with autoimmune oophoritis who are interested in fertility, a potential ovulation induction strategy is immunosuppression with glucocorticoids. Although there are no clinical trial data, there are reports of women with autoimmune premature ovarian failure who have responded to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in doses of 20 to 40 mg daily for one to six months with resumption of menstrual cycles; a smaller number have had successful pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/27,33,49-53\">",
"     27,33,49-53",
"    </a>",
"    ]. However, both iatrogenic Cushing's syndrome and osteonecrosis have been reported (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58808 \" href=\"UTD.htm?31/55/32639\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/49\">",
"     49",
"    </a>",
"    ]. Therefore, at present, glucocorticoid therapy should be reserved for the clinical trial setting.",
"   </p>",
"   <p>",
"    Estradiol replacement also appears to be ineffective for ovulation induction and fertility. This was illustrated in a trial of 37 women with primary ovarian insufficiency who were randomly assigned to receive 17-B estradiol (2",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for 12 weeks with weekly ultrasound monitoring. Overall, 78 percent of subjects had evidence of follicular activity, but estradiol treatment appeared to be no better than placebo for follicular development and ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/54\">",
"     54",
"    </a>",
"    ]. There were, however, some women who ovulated and conceived, but this was independent of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/54\">",
"     54",
"    </a>",
"    ]. Other ovulation induction strategies have been largely unsuccessful in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For couples who choose to pursue assisted reproduction, in vitro fertilization with donor oocytes is a highly successful technology. This therapy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/5/19538?source=see_link\">",
"       \"Patient information: Early menopause (primary ovarian insufficiency) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/63/12276?source=see_link\">",
"       \"Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Autoimmune oophoritis is one of the known causes of primary ovarian insufficiency (commonly referred to as premature ovarian failure), and is found in about 4 percent of women who present with spontaneous primary ovarian insufficiency. It may occur as part of type I and type II syndromes of polyglandular autoimmune failure, which are associated with autoantibodies to multiple endocrine and other organs (",
"    <a class=\"graphic graphic_table graphicRef67520 \" href=\"UTD.htm?9/25/9629\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Autoimmune adrenalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for adrenal antibodies by indirect immunofluorescence can identify those women who have autoimmune oophoritis as the mechanism for their primary ovarian insufficiency. The predictive value of a commercially available serum anti-ovarian antibody test (an indirect immunofluorescence assay using cynomolgus monkey ovary), has an unacceptably high false-positive rate. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that all women who present with spontaneous primary ovarian insufficiency be tested for anti-adrenal antibodies by indirect immunofluorescence to identify those women who have autoimmune oophoritis.",
"     </li>",
"     <li>",
"      Referral to centers conducting randomized trials on the management of autoimmune oophoritis should be considered for those women who test positive. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend against ovarian biopsy for diagnosis of autoimmune oophoritis.",
"     </li>",
"     <li>",
"      As a screen for the presence of asymptomatic autoimmune adrenal insufficiency, serum anti-adrenal and anti-21 hydroxylase antibodies should be measured at the time of diagnosis of spontaneous primary ovarian insufficiency in all women. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Autoimmune endocrinopathies'",
"      </a>",
"      above.) Testing for anti-21 hydroxylase antibodies may serve the dual purpose of screening for autoimmune adrenal insufficiency and making the diagnosis of autoimmune oophoritis. However, in rare cases, 21-hydroxlase antibodies may be negative despite a positive anti-adrenal antibody test determined by indirect immunofluorescence (due to the presence of antibodies to other steroidogenic enzymes such as 17-hyroxylase or side chain cleavage).",
"     </li>",
"     <li>",
"      Women should be also be screened for autoimmune thyroid disease with anti-thyroid peroxidase and anti-thyroglobulin antibodies. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Autoimmune endocrinopathies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of women with autoimmune ovarian failure is similar to that of women with other causes of primary ovarian insufficiency. Some form of estrogen replacement is necessary to prevent bone loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Estrogen deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Maintaining bone health",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with primary ovarian insufficiency, we suggest hormone therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically start with replacement doses of transdermal estradiol and cyclic progestin therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prevention of osteoporosis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Options for estrogen and progestin doses and routes of administration are reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link&amp;anchor=H5#H5\">",
"       \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Estrogen deficiency'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"       \"Preparations for postmenopausal hormone therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Contraception",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with autoimmune oophoritis who desire contraception, we suggest the use of barrier contraception, as there is still a small chance of conception (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In theory, the oral contraceptive may not be as effective in women with spontaneous primary ovarian insufficiency due to the elevated gonadotropin levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Fertility",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with primary ovarian insufficiency have a low chance of conception that appears be independent of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23976/abstract/54\">",
"       54",
"      </a>",
"      ]. Unfortunately, there are no ovulation induction agents for these women with proven efficacy. Gonadotropin therapy and estradiol replacement have been tried without success. However, in vitro fertilization with donor oocytes is a highly effective intervention. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Fertility'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"       \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"       \"Oocyte donation for assisted reproduction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other options include donor cryopreserved embryos (embryo adoption) and traditional adoption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dr. Nelson's work was supported by the Intramural Research Program on Reproductive and Adult Endocrinology, National Institute of Child Health and Human Development, National Institutes of Health. The editorial staff at UpToDate, Inc. would also like to acknowledge Dr. Vladimir K Bakalov, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/1\">",
"      Irvine WJ, Chan MM, Scarth L, et al. Immunological aspects of premature ovarian failure associated with idiopathic Addison's disease. Lancet 1968; 2:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/2\">",
"      Bakalov VK, Anasti JN, Calis KA, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil Steril 2005; 84:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/3\">",
"      Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997; 18:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/4\">",
"      Pekonen F, Siegberg R, M&auml;kinen T, et al. Immunological disturbances in patients with premature ovarian failure. Clin Endocrinol (Oxf) 1986; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/5\">",
"      LaBarbera AR, Miller MM, Ober C, Rebar RW. Autoimmune etiology in premature ovarian failure. Am J Reprod Immunol Microbiol 1988; 16:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/6\">",
"      Escobar ME, Cigorraga SB, Chiauzzi VA, et al. Development of the gonadotrophic resistant ovary syndrome in myasthenia gravis: suggestion of similar autoimmune mechanisms. Acta Endocrinol (Copenh) 1982; 99:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/7\">",
"      Nelson LM. Autoimmune ovarian failure: comparing the mouse model and the human disease. J Soc Gynecol Investig 2001; 8:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/8\">",
"      Kojima A, Prehn RT. Genetic susceptibility to post-thymectomy autoimmune diseases in mice. Immunogenetics 1981; 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/9\">",
"      Kalantaridou SN, Nelson LM. Autoimmune premature ovarian failure: of mice and women. J Am Med Womens Assoc 1998; 53:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/10\">",
"      Taguchi O, Nishizuka Y, Sakakura T, Kojima A. Autoimmune oophoritis in thymectomized mice: detection of circulating antibodies against oocytes. Clin Exp Immunol 1980; 40:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/11\">",
"      Tong ZB, Nelson LM. A mouse gene encoding an oocyte antigen associated with autoimmune premature ovarian failure. Endocrinology 1999; 140:3720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/12\">",
"      Tong ZB, Gold L, Pfeifer KE, et al. Mater, a maternal effect gene required for early embryonic development in mice. Nat Genet 2000; 26:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/13\">",
"      Sedmak DD, Hart WR, Tubbs RR. Autoimmune oophoritis: a histopathologic study of involved ovaries with immunologic characterization of the mononuclear cell infiltrate. Int J Gynecol Pathol 1987; 6:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/14\">",
"      Bannatyne P, Russell P, Shearman RP. Autoimmune oophoritis: a clinicopathologic assessment of 12 cases. Int J Gynecol Pathol 1990; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/15\">",
"      Gloor E, Hurlimann J. Autoimmune oophoritis. Am J Clin Pathol 1984; 81:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/16\">",
"      Biscotti CV, Hart WR, Lucas JG. Cystic ovarian enlargement resulting from autoimmune oophoritis. Obstet Gynecol 1989; 74:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/17\">",
"      Burrell LM, Murdoch A, Angus B, White MC. Autoimmune ovarian failure with elevated serum levels of luteinizing hormone and enlarged ovaries. Case report. Br J Obstet Gynaecol 1990; 97:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/18\">",
"      Lonsdale RN, Roberts PF, Trowell JE. Autoimmune oophoritis associated with polycystic ovaries. Histopathology 1991; 19:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/19\">",
"      Welt CK, Hall JE, Adams JM, Taylor AE. Relationship of estradiol and inhibin to the follicle-stimulating hormone variability in hypergonadotropic hypogonadism or premature ovarian failure. J Clin Endocrinol Metab 2005; 90:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/20\">",
"      Welt CK, Falorni A, Taylor AE, et al. Selective theca cell dysfunction in autoimmune oophoritis results in multifollicular development, decreased estradiol, and elevated inhibin B levels. J Clin Endocrinol Metab 2005; 90:3069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/21\">",
"      Larrea F, Lisker R, Ba&ntilde;uelos R, et al. Hypergonadotrophic hypogonadism in an XX female subject due to 17,20 steroid desmolase deficiency. Acta Endocrinol (Copenh) 1983; 103:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/22\">",
"      Hill JA, Welch WR, Faris HM, Anderson DJ. Induction of class II major histocompatibility complex antigen expression in human granulosa cells by interferon gamma: a potential mechanism contributing to autoimmune ovarian failure. Am J Obstet Gynecol 1990; 162:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/23\">",
"      Tidey GF, Nelson LM, Phillips TM, Stillman RJ. Gonadotropins enhance HLA-DR antigen expression in human granulosa cells. Am J Obstet Gynecol 1992; 167:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/24\">",
"      Walfish PG, Gottesman IS, Shewchuk AB, et al. Association of premature ovarian failure with HLA antigens. Tissue Antigens 1983; 21:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/25\">",
"      Anasti JN, Adams S, Kimzey LM, et al. Karyotypically normal spontaneous premature ovarian failure: evaluation of association with the class II major histocompatibility complex. J Clin Endocrinol Metab 1994; 78:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/26\">",
"      Arif S, Underhill JA, Donaldson P, et al. Human leukocyte antigen-DQB1* genotypes encoding aspartate at position 57 are associated with 3beta-hydroxysteroid dehydrogenase autoimmunity in premature ovarian failure. J Clin Endocrinol Metab 1999; 84:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/27\">",
"      Rabinowe SL, Berger MJ, Welch WR, Dluhy RG. Lymphocyte dysfunction in autoimmune oophoritis. Resumption of menses with corticosteroids. Am J Med 1986; 81:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/28\">",
"      Nelson LM, Kimzey LM, Merriam GR, Fleisher TA. Increased peripheral T lymphocyte activation in patients with karyotypically normal spontaneous premature ovarian failure. Fertil Steril 1991; 55:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/29\">",
"      Hoek A, van Kasteren Y, de Haan-Meulman M, et al. Analysis of peripheral blood lymphocyte subsets, NK cells, and delayed type hypersensitivity skin test in patients with premature ovarian failure. Am J Reprod Immunol 1995; 33:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/30\">",
"      Mignot MH, Drexhage HA, Kleingeld M, et al. Premature ovarian failure. II: Considerations of cellular immunity defects. Eur J Obstet Gynecol Reprod Biol 1989; 30:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/31\">",
"      Damewood MD, Zacur HA, Hoffman GJ, Rock JA. Circulating antiovarian antibodies in premature ovarian failure. Obstet Gynecol 1986; 68:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/32\">",
"      Ho PC, Tang GW, Fu KH, et al. Immunologic studies in patients with premature ovarian failure. Obstet Gynecol 1988; 71:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/33\">",
"      Luborsky JL, Visintin I, Boyers S, et al. Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failure. J Clin Endocrinol Metab 1990; 70:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/34\">",
"      F&eacute;nichel P, Sosset C, Barbarino-Monnier P, et al. Prevalence, specificity and significance of ovarian antibodies during spontaneous premature ovarian failure. Hum Reprod 1997; 12:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/35\">",
"      Wheatcroft NJ, Salt C, Milford-Ward A, et al. Identification of ovarian antibodies by immunofluorescence, enzyme-linked immunosorbent assay or immunoblotting in premature ovarian failure. Hum Reprod 1997; 12:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/36\">",
"      Wheatcroft NJ, Toogood AA, Li TC, et al. Detection of antibodies to ovarian antigens in women with premature ovarian failure. Clin Exp Immunol 1994; 96:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/37\">",
"      Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973; 180:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/38\">",
"      Anasti JN, Flack MR, Froehlich J, Nelson LM. The use of human recombinant gonadotropin receptors to search for immunoglobulin G-mediated premature ovarian failure. J Clin Endocrinol Metab 1995; 80:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/39\">",
"      Elder M, Maclaren N, Riley W. Gonadal autoantibodies in patients with hypogonadism and/or Addison's disease. J Clin Endocrinol Metab 1981; 52:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/40\">",
"      Uibo R, Aavik E, Peterson P, et al. Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease. J Clin Endocrinol Metab 1994; 78:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/41\">",
"      Winqvist O, Gebre-Medhin G, Gustafsson J, et al. Identification of the main gonadal autoantigens in patients with adrenal insufficiency and associated ovarian failure. J Clin Endocrinol Metab 1995; 80:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/42\">",
"      Betterle C, Rossi A, Dalla Pria S, et al. Premature ovarian failure: autoimmunity and natural history. Clin Endocrinol (Oxf) 1993; 39:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/43\">",
"      Chen S, Sawicka J, Betterle C, et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinol Metab 1996; 81:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/44\">",
"      Weetman AP. Autoimmunity to steroid-producing cells and familial polyendocrine autoimmunity. Baillieres Clin Endocrinol Metab 1995; 9:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/45\">",
"      Novosad JA, Kalantaridou SN, Tong ZB, Nelson LM. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. BMC Womens Health 2003; 3:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/46\">",
"      Khastgir G, Abdalla H, Studd JW. The case against ovarian biopsy for the diagnosis of premature menopause. Br J Obstet Gynaecol 1994; 101:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/47\">",
"      Check JH, Chase JS, Spence M. Pregnancy in premature ovarian failure after therapy with oral contraceptives despite resistance to previous human menopausal gonadotropin therapy. Am J Obstet Gynecol 1989; 160:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/48\">",
"      Alper MM, Jolly EE, Garner PR. Pregnancies after premature ovarian failure. Obstet Gynecol 1986; 67:59S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/49\">",
"      Kalantaridou SN, Braddock DT, Patronas NJ, Nelson LM. Treatment of autoimmune premature ovarian failure. Hum Reprod 1999; 14:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/50\">",
"      Coulam CB, Kempers RD, Randall RV. Premature ovarian failure: evidence for the autoimmune mechanism. Fertil Steril 1981; 36:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/51\">",
"      Taylor R, Smith NM, Angus B, et al. Return of fertility after twelve years of autoimmune ovarian failure. Clin Endocrinol (Oxf) 1989; 31:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/52\">",
"      Blumenfeld Z, Halachmi S, Peretz BA, et al. Premature ovarian failure--the prognostic application of autoimmunity on conception after ovulation induction. Fertil Steril 1993; 59:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/53\">",
"      Corenblum B, Rowe T, Taylor PJ. High-dose, short-term glucocorticoids for the treatment of infertility resulting from premature ovarian failure. Fertil Steril 1993; 59:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23976/abstract/54\">",
"      Taylor AE, Adams JM, Mulder JE, et al. A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. J Clin Endocrinol Metab 1996; 81:3615.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7414 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-714CE7359B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23976=[""].join("\n");
var outline_f23_26_23976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Studies in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cellular immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Humoral immunity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - FSH-receptor antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Co-existing autoimmune adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Autoimmune endocrinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Maintaining bone health",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Contraception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ACKNOWLEDGMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7414\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7414|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/55/32639\" title=\"diagnostic image 1\">",
"      MRI osteonecrosis glucocorticoids POF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7414|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/15/23801\" title=\"picture 1\">",
"      Lymphocytic infiltrate autoimmune ovarian failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7414|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/25/9629\" title=\"table 1\">",
"      Polyglandular autoimmune syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=related_link\">",
"      Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/63/12276?source=related_link\">",
"      Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/5/19538?source=related_link\">",
"      Patient information: Early menopause (primary ovarian insufficiency) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=related_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_26_23977="Management principles for burns resulting from mass disasters and war casualties";
var content_f23_26_23977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management principles for burns resulting from mass disasters and war casualties",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/26/23977/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/26/23977/contributors\">",
"     Steven E Wolf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/26/23977/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/26/23977/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/26/23977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/26/23977/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/26/23977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8992446\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude and impact of burns associated with wars, bombings, and mass disasters can be devastating as they can affect large numbers of individuals simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/1-10\">",
"     1-10",
"    </a>",
"    ]. In contrast, civilian fires and the resultant burns are generally due to structure and vehicular fires, impacting small numbers of individuals.",
"   </p>",
"   <p>",
"    The management principles of war casualties and mass disasters are discussed here. The global epidemiology of burns is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=see_link\">",
"     \"Epidemiology of burn injuries globally\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8992525\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe burn injuries occur in approximately 5 to 20 percent of survivors of conventional casualties of war and casualties from civilian mass disasters or terrorist events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. Burns are more common during wars at sea and during wars that involve armored vehicles; 80 percent of burns in survivors involve less than 20 percent total body surface area (TBSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/17\">",
"     17",
"    </a>",
"    ]. Most civilian disasters produce fewer than 25 to 50 patients requiring inpatient burn care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/3\">",
"     3",
"    </a>",
"    ]. The vast majority of severe burn patients die at the scene or within the first 24 hours following the burn [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/1,3,5\">",
"     1,3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following contemporary civilian mass disasters and wars illustrate the frequency of burns in survivors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were 39 survivors with severe burns requiring hospital admission following the World Trade Center bombing in New York City on September 11, 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/5-7,18,19\">",
"       5-7,18,19",
"      </a>",
"      ]. The burn patients comprised 19 percent of all hospitalized patients and 4 percent of all patients (survivors and rescue workers) treated during the initial 48 hours following the attack [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There were eight burn and one smoke inhalation survivors of 106 people medically treated following the Pentagon terrorist crash of September 11, 2011 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The exact number of survivors from the 2002 terrorist attack on a nightclub in Bali is uncertain. However, estimates indicate that over 200 were killed, more than 300 survived with injuries, and at least 66 suffered severe burns ranging from 15 to 85 percent total body surface area (TBSA) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/21-25\">",
"       21-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Station Nightclub fire in West Warwick, RI in 2003 was associated with 100 deaths following an indoor pyrotechnic display [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/9,26\">",
"       9,26",
"      </a>",
"      ]. Two hundred and fifteen survivors were injured, 47 burn patients were admitted to a hospital and 18 discharged. The extent of the TBSA burn of those reaching medical care was less than 20 percent in 33 patients, 21 to 40 percent in 12 patients, and greater than 40 percent in 2 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For the three months (January 25 to April 24) after the 2010 Haiti earthquake, a national surveillance of post-earthquake conditions revealed a total of 149 patients treated for burns (0.4 percent of total injuries) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Between March 2003 and May 2004, the US Army Burn Center treated 109 burn patients that occurred during the wars in Iraq and Afghanistan, and approximately 20 percent were greater than 20 percent TBSA [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/17\">",
"       17",
"      </a>",
"      ]. Fifty-one patients (47 percent) were severely burned. Burns were judged preventable rather than due to hostile fire in 56 percent. At the in-theater treatment center for war casualties established by the USNS Comfort Hospital Ship in Iraq, burns comprised 5 percent of civilian and military admissions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the direct flame injury resulting in severe burns from mass disaster events, patients may also suffer neurologic injuries, inhalation injures, blast overpressure injuries, penetrating injuries, chemical burns, radiation contamination, amputations, and fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. A retrospective review of 29 civilian terrorist bombings producing 8364 casualties found the frequency of burns in survivors was related to structural location of the bomb [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/28\">",
"     28",
"    </a>",
"    ]. Bombs in confined spaces resulted in the highest median rate of survivors with burns in contrast to bombs occurring in open spaces or associated with structural collapse (22 versus 2 percent).",
"   </p>",
"   <p>",
"    The priorities at the scene of a mass disaster include scene crowd control, scene safety, triage at the scene, triage at the hospital, management of hospital resources, integration with law enforcement for civilian casualties, and identification and release of information regarding victims [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8992453\">",
"    <span class=\"h1\">",
"     MANAGEMENT PRINCIPLES OF THE BURN DISASTER PLAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Burn Association (ABA) has defined a mass burn casualty disaster as any catastrophic event in which the number of burn victims exceeds the capacity of the local burn center to provide optimal burn care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/7\">",
"     7",
"    </a>",
"    ]. Capacity includes availability of beds, surgeons, nurses, support staff, operating rooms, equipment, and supplies specific to burn care.",
"   </p>",
"   <p>",
"    Surge capacity is the capacity to handle up to 50 percent more patients from a disaster than the normal maximum number of burn patients. Model burn disaster plans have been developed in multiple countries, including the United States (US), Switzerland, Australia, Britain, and Denmark, that can serve as a basis for the development of such plans in other local and regional areas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/1,7,13,33-36\">",
"     1,7,13,33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Burn disaster plans focus on mass casualty incidences in general and more specifically on hospital and community planning including preparation, training, pre-staging equipment, supplies, personnel, and triage plans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/5,37\">",
"     5,37",
"    </a>",
"    ]. Much of the planning is based upon the expected outcomes associated with various mechanisms of burns and the environment (eg, indoors versus outdoors) in which the disaster or explosion occurs, including the possibility of chemical or radiological contamination of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/12,13,28,38,39\">",
"     12,13,28,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disaster plans need to ensure that the impact of burn patient care includes not only immediate triage and patient stabilization but also prolonged care associated with burns [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/8\">",
"     8",
"    </a>",
"    ]. For example, a patient with a 50 percent TBSA burn has an average length of stay in the intensive care unit of 50 days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/7,28\">",
"     7,28",
"    </a>",
"    ]. An increase in healthcare facility capacity (eg, space and equipment) and personnel are required at the time of the disaster and during the rehabilitation phase of patient care. The costs to provide medical care even for a small number of burn patients are in the millions of dollars [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The care of severely burned patients is generally best rendered in dedicated burn centers, and the ABA can assist with planning transfer of burned patients to regional burn facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/7\">",
"     7",
"    </a>",
"    ]. Most of the disaster plans in the US are designed for a surge capacity of a maximum of 50 burn casualties that need to be distributed to regional burn centers. This is typically about a 50 percent increase in pre-event capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. The impact of casualty flow may be more relevant in a disaster scenario than the actual number of beds required [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disaster plan should include preparations for an influx of assistance from outside of the locale. In the US, the local and state governments take the leading role in disaster planning and relief efforts, followed by the national government with a minimal role of the US military. In other countries, the military might play a much greater role [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/13\">",
"     13",
"    </a>",
"    ]. Pertinent issues that should be addressed in the disaster plan to ensure a coordinated response include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Documentation of licensure of medical and other healthcare personnel, required versus waived",
"     </li>",
"     <li>",
"      Permission for outside agencies, regional and state governments, and foreign governments to assist in disaster relief efforts",
"     </li>",
"     <li>",
"      Appropriateness of the type of support being offered",
"     </li>",
"     <li>",
"      Compatibility of equipment and supplies with power supplies",
"     </li>",
"     <li>",
"      Language needs",
"     </li>",
"     <li>",
"      Country approved medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The key components of a disaster plan for war and civilian mass casualties include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Command, control, and communication",
"     </li>",
"     <li>",
"      Triage",
"     </li>",
"     <li>",
"      Treatment strategies in the field",
"     </li>",
"     <li>",
"      Transportation of injured to local hospitals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8992468\">",
"    <span class=\"h2\">",
"     Command, control, and communication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Command, control, and communication components of a disaster burn plan must be reviewed, communicated, tested, and updated regularly. There needs to be adequate and redundant personnel and processes in place to assist in delivery of adequate burn care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3609531\">",
"    <span class=\"h3\">",
"     Command",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scene command and control is typically defined by regional disaster plans that should also be followed in the case of a burn disaster. These command cells need to have defined contact information with burn experts to optimize patient care and movement of patients, but surgeons or healthcare providers do not perform the role of scene command. The command post should be established in a safe environment with good flow of communication but not necessarily at the location of patient care as they are also directing other services including police, ambulance movement, media interaction, etc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3609538\">",
"    <span class=\"h3\">",
"     Control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlling the disaster scene or receiving hospital is vital to maintain order, safety, and maximize patient outcomes. This includes control of patient flow to and within the healthcare system, civilian traffic flow, media access, family member notification, onlooker movement, and good Samaritans among others. &nbsp;A system should be developed in advance of a disaster that involves the local emergency response personnel and police for safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6524715\">",
"    <span class=\"h3\">",
"     Communication",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clear line of communication is one of the key lessons learned repeatedly in disasters with burn patients, especially communication with regional burn centers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/8,9,41,42\">",
"     8,9,41,42",
"    </a>",
"    ]. Communication and point of contacts with local, regional, national and international collaborators or governments should be defined in advance of a disaster, as a component of a disaster preparedness plan [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/23,26,40,43,44\">",
"     23,26,40,43,44",
"    </a>",
"    ]. A simple process should be planned that does not require extensive training, power sources, or special computerized programs. Emergency code numbers and identifiers should be uniform and shared by all personnel involved in disaster relief.",
"   </p>",
"   <p>",
"    Communication is vital for adequate patient tracking. An example of maintaining optimal communication is to link a single healthcare provider with a single patient throughout the evacuation process until the patient reaches definitive burn care.",
"   </p>",
"   <p>",
"    Major medical centers, healthcare facilities, and burn centers may be overwhelmed or destroyed, and healthcare providers may not be able to access the facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/45\">",
"     45",
"    </a>",
"    ]. As occurred during the Haiti earthquake of 2010, the only burn center in the country was destroyed, relegating to other facilities the burden of burn care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In disasters, land and cellular telephone communication systems can be destroyed or overwhelmed. Alternative methods of communication that have been used in disasters include texting messages and handheld walkie-talkies within a triage site or medical facility. Telecommunication has been developed for remote visualization of patients or communication with other healthcare experts if electricity is available to support computers and internet sites such as Skype, a software application that allows free voice calls over the internet [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to natural disasters (eg, earthquakes, floods), the site of a mass disaster (eg, terrorist attack, explosion) is secured as a crime scene.",
"   </p>",
"   <p>",
"    Clear communication and interaction with crime scene personnel is required. All patients and debrided materials (eg, fragment or bomb pieces, suicide bomber body parts), gathered from the patients are included as evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/27,49\">",
"     27,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Communication is also important for crowd control. Disaster plans should include scene safety, which involves removing untrained people, well-intentioned volunteers, and unruly mobs from the scene where they can contribute to excessive injury and death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/32,50\">",
"     32,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8992475\">",
"    <span class=\"h2\">",
"     Triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key components of triage of a burn disaster preparedness plan include the primary and possibly secondary and tertiary surveys of the survivors, location of the surveys, triage officers, and the triage system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/7\">",
"     7",
"    </a>",
"    ]. Regardless if the burn injury is civilian or combat, the severity of the burn is determined by the intensity and duration of exposure, and the percent of body area burned [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30679900\">",
"    <span class=\"h3\">",
"     Triage surveys and location",
"    </span>",
"    &nbsp;&mdash;&nbsp;During triage, it is vital that the entire body is visualized to ensure that other injuries are identified and addressed. The triage sites should be safe, a short distance away from the immediate scene, and protected from the elements to prevent additional complications including unnecessary injuries, hypothermia or hyperthermia, or deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/5,27,41\">",
"     5,27,41",
"    </a>",
"    ]. Numerous first responders died in New York on September 11, 2001 after the building collapsed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The types of triage and the location where triage is performed include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary triage &mdash; Occurs at the disaster scene or at the emergency room of the first receiving hospital.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abides by local and state mass casualty plans.",
"     </li>",
"     <li>",
"      Burn centers are included in state disaster plans as per federal bioterrorism legislation and implementation actions of the Health Resources and Services Agency of the Department of Health and Human Services.",
"     </li>",
"     <li>",
"      The disaster site incident commander should call the nearest verified burn center regarding available capacity and alternate site burn center information, if needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ABA policy states that burn patients should be triaged to a burn center within 24 hours of an incident. (See",
"      <a class=\"local\" href=\"#H30679978\">",
"       'Triage guidelines'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the combat zone, we continually triage patients for evacuation to receiving facilities in Germany and the US. This continuous triage is designed to maximize burn outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary triage &mdash; Occurs at the first burn center, once the center reaches surge capacity. This involves transfer of burn patients from the first burn center to a second burn center.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Should be a component of all burn centers.",
"     </li>",
"     <li>",
"      Requires written agreements to formalize the process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tertiary triage &mdash; Tertiary triage is performed by critical care physicians in medical facilities. This triage is beyond the initial life stabilizing management of airway, breathing, and circulation stabilization and includes more definitive intensive care and burn wound management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Awareness of terrorist strategies can minimize casualties and deaths. Terrorists typically explode an initial bomb and then time a second explosion to coincide with maximum number of first responders and curious onlookers associated with the first explosion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. Determining if a burn team will be sent to a scene for triage or remain at the burn centers for patient care should be defined in the disaster plan [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If triage cannot occur at the scene or if a &ldquo;scoop and run&rdquo; process is used for patient movement, triage must be done prior to entering the Emergency Department [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/31\">",
"     31",
"    </a>",
"    ]. Preprinted order sets and burn size determinates, and triage tags in an easy to use format that will not be destroyed by the elements will facilitate triage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30679907\">",
"    <span class=\"h3\">",
"     Triage officers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triage officers are physicians or other healthcare professionals trained to triage victims in a disaster. The challenges in a disaster associated with burns are that the percent TBSA burned is frequently inaccurately determined except when performed by adequately experienced surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/5\">",
"     5",
"    </a>",
"    ]. However, burn surgeons are generally attending to severely burned patients in hospitals and are not available for ongoing triage in the field. Utilizing a burn surgeon at the scene from a burn center or hospital expected to receive the fewest patients is an option that is possible in regions with numerous burn centers. Specialized burn teams can assist with primary and secondary triage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30679914\">",
"    <span class=\"h3\">",
"     Over-triage or under-triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate triage management limits misutilization of hospital and personnel resources. Over-triage occurs when noncritical patients are evacuated or hospitalized when they do not need specialized medical care. In a mass casualty disaster, over-triage can be as life threatening as under-triage because of the inundation of overwhelmed medical facilities with large numbers of noncritical casualties all at once, which may jeopardize the survival of critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/27,31\">",
"     27,31",
"    </a>",
"    ]. Some authors consider under-triage unavoidable during initial hospital evaluation in these chaotic situations, stressing the importance of repeated surveys [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/54\">",
"     54",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30679978\">",
"    <span class=\"h3\">",
"     Triage guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current triage system guidelines for mass disasters associated with burn victims is that victims with a greater than 20 percent TBSA burn, adults and children, should be transferred to a burn center [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/1,7,13\">",
"     1,7,13",
"    </a>",
"    ]. In contrast, the standard criteria for burn center referral (outside of a mass disaster or combat) are more inclusive of small burns or specific anatomical sites of burns. For example, referrals to a burn center are recommended for 10 percent TBSA for young children and elder patients, 5 percent TBSA full thickness burns, or burns of the face and hands during non-disaster periods (",
"    <a class=\"graphic graphic_table graphicRef74855 \" href=\"UTD.htm?2/13/2268\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Burns less than 20 percent can be managed at hospitals without a dedicated burn care center. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    .) Most patients typically have a very good outcome with standard burn care. Consultation with burn experts for details of grafting, reconstruction, and rehabilitation, should be established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Criteria were established to maximize patient care without overwhelming the medical system as shown in the ABA triage decision table (",
"    <a class=\"graphic graphic_table graphicRef70760 \" href=\"UTD.htm?7/40/7818\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to percent TBSA burned, patient age, presence of inhalation injury,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other severe injuries should be incorporated into patient dispositions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Transfer of burn patients should occur between 24 and 72 hours after initial fluid resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/5\">",
"     5",
"    </a>",
"    ]. In remote areas without dedicated burn centers that can provide surgical grafting support, ICU care, and rehabilitative care, the survival rate for TBSA burns greater than 50 percent is extremely low and might greatly influence triage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/7\">",
"     7",
"    </a>",
"    ]. For example, patients with burns in the US are not placed in the expectant category (not expected to survive) with a 50 percent or greater TBSA burn unless they are older than 70 years of age. Other patients placed in the expectant category in the US are children less than 2 years of age with a greater than 91 percent TBSA burn, or patients between the ages of 50 and 70 years with greater than 81 percent TBSA.",
"   </p>",
"   <p>",
"    The American Burn Association (ABA) categories and expected outcomes for patients based upon age and percent TBSA burn include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outpatient &mdash; Survival (100 percent) and good outcome expected without requiring initial admission.",
"     </li>",
"     <li>",
"      High benefit-resource &mdash; Survival (greater than 90 percent) and good outcome expected with limited or short-term initial admission and resource allocation including length of stay, &lt;14 days, and one to two surgical procedures.",
"     </li>",
"     <li>",
"      Medium benefit-resource &mdash; Survival (greater than 50 percent) and good outcome likely with aggressive care and comprehensive resource allocation, including initial admission and resuscitation, expected length of stay &gt;14 days, and multiple surgeries.",
"     </li>",
"     <li>",
"      Low benefit-resource &mdash; Survival (less than 50 percent) and expected good outcome, including long-term, aggressive treatment, and resource allocation.",
"     </li>",
"     <li>",
"      Expectant &mdash; Survival less than 10 percent even with unlimited, aggressive treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These categories should match similar triaging strategies developed within the disaster system for other injury patterns. Color patterns describe the categories as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Green &mdash; Outpatient",
"     </li>",
"     <li>",
"      Yellow &mdash; High benefit-resource",
"     </li>",
"     <li>",
"      Red &mdash; Medium benefit-resource",
"     </li>",
"     <li>",
"      Blue &mdash; Low benefit-resource",
"     </li>",
"     <li>",
"      Black &mdash; Expectant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although difficult, placing patients in the expectant category is required to save the greatest numbers of lives. This involves not abandoning the patient by ensuring personnel are present with liberal use of pain control medications as necessary. It might also be necessary to redirect or have a second redistribution of patients once the initial event has been managed, as occurred during September 11, 2001 in New York City with 66 percent of burn patients being redirected to a burn unit after initial hospitalization and stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8992482\">",
"    <span class=\"h2\">",
"     Treatment strategies in the field",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of burns in a combat or disaster area is complicated by the presence of multiple wounds in a dirty environment and massive hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Burn management strategies in the field follow the guidelines of the American College of Surgeons Advanced Trauma Life Support [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/55\">",
"     55",
"    </a>",
"    ] and the ABA Advanced Burn Life Support [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/56\">",
"     56",
"    </a>",
"    ]. Management of combat and mass casualties with severe burns and associated traumatic injuries, as learned during the wars in Iraq and Afghanistan, requires a coordinated interaction of surgical, critical care, and evacuation assets [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/51,57\">",
"     51,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial burn care in the field, as in any trauma situation, focuses on airway, breathing, and circulation. Immediate and simultaneous control of bleeding is a key strategy as exsanguination is the primary cause of reversible death during combat operations and mass disasters. Additional maneuvers that can be performed in the field include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary assessment for associated injuries",
"     </li>",
"     <li>",
"      Evaluation for inhalation injury (eg, facial burns or singed nasal hairs)",
"     </li>",
"     <li>",
"      Calculation of percent of total body surface area burned",
"     </li>",
"     <li>",
"      Evaluation of carbon monoxide poisoning through simple questions including the presence of a headache, vertigo, flu-like symptoms, central nervous system complaints, and cardiac complaints. These later are positive in the presence of a high level of exposure to carbon monoxide. A CO-oximeter is unlikely to be available at the disaster scene but should be available at the receiving medical facility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"       \"Carbon monoxide poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aggressive thermoregulation to prevent excess mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pain control (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      ) can be provided by oral, intramuscular, or intravenous routes.",
"     </li>",
"     <li>",
"      Intravenous fluid resuscitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Life saving maneuvers that might be applicable at the scene include early airway control through a definitive airway. However, even patients with severe burns are often conscious, and unless sedation is possible, patients do not tolerate placement of definitive airways. There are no indications for antimicrobials or other interventions (eg, debridement) in the field. Secondary and tertiary surveys are generally not possible in the field during a mass disaster. The goal at the scene is to rapidly triage the burned victims to a medical facility that can adequately evaluate and manage burns and possible associated injuries. As the patients progresses through the evacuation system to more definitive care, additional complications such as abdominal compartment syndrome should be considered, especially in the first few days after injury, primarily in patients with large percent TBSA burns [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8992503\">",
"    <span class=\"h2\">",
"     Transportation of injured",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evacuation of burned personnel has also evolved with each new conflict to which the US military has responded [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/60\">",
"     60",
"    </a>",
"    ]. Evacuation of burned patients from a combat site to a hospital occurs during the first 24 to 48 hours, while resuscitation is in progress [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/61\">",
"     61",
"    </a>",
"    ]. During the course of an evacuation from Iraq or Afghanistan, burned patients&rsquo; transition through several medical facilities before arriving at a major US medical center for definitive care was approximately 4 to 6 days after injury. Patients should be transported by personnel with expertise in burn care, if at all possible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/5\">",
"     5",
"    </a>",
"    ]. For example, transportation of severely burned patients in Spain was associated with a higher survival rate when patients were accompanied by medical personnel compared with those that were transported without medical assistants (93 versus 45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Burned personnel receive basic resuscitation and hemorrhage control, but unlike civilian burns in the US, early excision and grafting is not performed until the patients arrive at the US Army Institute of Surgical Research (USAISR, the US Army Burn Center) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/60\">",
"     60",
"    </a>",
"    ]. The military uses a level-based evacuation system based upon the severity of the burn (",
"    <a class=\"graphic graphic_table graphicRef60036 \" href=\"UTD.htm?4/49/4892\">",
"     table 3",
"    </a>",
"    ). &nbsp;In the event of a moderate or severe burn, or any burn to the face, hands, or perineum, evacuation is made to USAISR [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative to patient movement is the movement of burn intensive care units, including personnel and equipment, to intermediate locations between the burn center and the disaster site [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/63\">",
"     63",
"    </a>",
"    ]. In addition, strict infection control and screening of wounds for resistant pathogens upon arrival to the new facility are important, as outbreaks of multidrug resistant bacteria in burn units have been described after patient transfers between hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Wounds are typically wrapped with 5 percent Sulfamylon&reg; solution soaked dressing two to three times a day. The solution is easier to use than cream based therapies during movement of patients.",
"   </p>",
"   <p>",
"    In civilian mass disasters, triage may require the use of a medical facility leapfrogging process. The walking wounded and those transported by non-traditional evacuation platforms, (eg, personal vehicles) generally go to the closest hospital resulting in an overwhelmed facility, personnel, and supplies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/1\">",
"     1",
"    </a>",
"    ]. Transported burn victims may be triaged to the next closest hospital typically using standard ambulances in the US, although augmenting the ambulance with higher trained personnel for these critically ill patients should be considered.",
"   </p>",
"   <p>",
"    Overall deep venous thrombosis (DVT) rates are low in burn patients and there does not appear to be an increased risk of DVT with global evacuation of patients, with an overall low DVT rate of approximately 1 percent in patients with severe burns [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15671858\">",
"    <span class=\"h1\">",
"     LESSONS LEARNED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implementation of system-wide guidelines is effective and improves outcomes for burn patients. Standard Burn Resuscitation Guidelines (BRG) for military casualties with &gt;30 percent TBSA burns were developed to improve and standardize burn care in response to an increase in over-resuscitated burn patients (",
"    <a class=\"graphic graphic_table graphicRef78713 \" href=\"UTD.htm?19/61/20444\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68619 \" href=\"UTD.htm?19/57/20380\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/60,66\">",
"     60,66",
"    </a>",
"    ]. Fifty-six military casualties treated by the BRG protocol had significantly fewer rates of abdominal compartment syndrome compared with 62 military casualties treated two years prior to the BRG implementation (5 versus 16 percent) and a significantly higher survival rate (82 versus 64 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lessons learned from numerous fires have been summarized to improve the delivery of healthcare in the event of a mass disaster associated with burns. The lessons learned have focused on disaster plans,",
"    <span class=\"nowrap\">",
"     command/control/communication,",
"    </span>",
"    triage, transport, treatment strategies, personnel management, supplies and equipment, transfer, international response, and",
"    <span class=\"nowrap\">",
"     rehabilitation/long",
"    </span>",
"    term follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8992489\">",
"    <span class=\"h2\">",
"     Combat and mass disasters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family and burn staff psychological support is necessary, as almost 75 percent of healthcare providers appear to meet post-traumatic stress disorder criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/67-71\">",
"     67-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Burn patients are uniquely challenging in disasters due to their complicated initial management and extremely prolonged care after initial burn insult, which includes rehabilitative challenges and psychological stress. The entire system needs to be aware of this to avoid compassion fatigue of healthcare providers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If patients are unable to be evacuated to a burn unit or adequate tertiary medical center, patients with severe burns of 50 percent or greater TBSA rarely survive. Command and control is vital as illustrated by setting up a large US national burn system to report daily available burn unit beds at the onset of the wars in Iraq and Afghanistan. This enabled the entire US burn system to be ready to support a large influx of burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/73\">",
"     73",
"    </a>",
"    ]. Finally, first responders have to ensure their own safety while saving the lives of disaster victims.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8992496\">",
"    <span class=\"h2\">",
"     Application to civilian, non-mass casualty, burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experiences of war are used to improve care for civilian casualties. The major lessons led to the development of civilian disaster plans.",
"   </p>",
"   <p>",
"    Disaster plans must be developed, communicated, game planned, and improved. Table top exercises are useful to test the system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, the long term psychological issues for patients and healthcare providers must be recognized and addressed early [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/69,71\">",
"     69,71",
"    </a>",
"    ]. Alternative rehabilitation processes, such as video-gaming, are underway and appear promising [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, after action reviews of disaster events are vital and publishing those lessons learned are necessary to continue to improve disaster plans and patient care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/5,45,49\">",
"     5,45,49",
"    </a>",
"    ]. Finally, countries already have dedicated disaster expert teams that might have the ability for dual use in times of disaster, as occurred previously when earthquake teams assisted in care of patients with severe burns [",
"    <a class=\"abstract\" href=\"UTD.htm?23/26/23977/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8992510\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude and impact of burns associated with wars, bombings, and mass disasters can be devastating as they can affect large numbers of individuals simultaneously.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Burn Association (ABA) has defined a mass burn casualty disaster as any catastrophic event in which the number of burn victims exceeds the capacity of the local burn center to provide optimal burn care. (See",
"      <a class=\"local\" href=\"#H8992453\">",
"       'Management principles of the burn disaster plan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Command, control, and communication components of a disaster burn plan must be reviewed, communicated, tested, and updated regularly. There needs to be adequate and redundant personnel and processes in place to assist in delivery of adequate burn care. (See",
"      <a class=\"local\" href=\"#H8992468\">",
"       'Command, control, and communication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Key components of triage of a burn disaster preparedness plan include the primary and possibly secondary and tertiary surveys of the survivors, location of the surveys, triage officers, and the triage system. Regardless if the burn injury is civilian or combat, the severity of the burn is determined by the intensity and duration of exposure, and the percent of body area burned. (See",
"      <a class=\"local\" href=\"#H8992475\">",
"       'Triage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The current triage system guidelines for mass disasters associated with burn victims is that victims with a greater than 20 percent TBSA burn, adults and children, should be transferred to a burn center. Burns less than 20 percent can be managed at hospitals without a dedicated burn care center. (See",
"      <a class=\"local\" href=\"#H30679978\">",
"       'Triage guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial burn care in the field, as in any trauma situation, focuses on airway, breathing, and circulation. Immediate and simultaneous control of bleeding is a key strategy as exsanguination is the primary cause of reversible death during combat operations and mass disasters. (See",
"      <a class=\"local\" href=\"#H8992482\">",
"       'Treatment strategies in the field'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Burned personnel receive basic resuscitation and hemorrhage control, but unlike civilian burns in the US, early excision and grafting is not performed until the patients arrive at the US military burn center. (See",
"      <a class=\"local\" href=\"#H8992503\">",
"       'Transportation of injured'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Implementation of system-wide guidelines is effective and improves outcomes for burn patients. (See",
"      <a class=\"local\" href=\"#H15671858\">",
"       'Lessons learned'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/1\">",
"      Potin M, S&eacute;n&eacute;chaud C, Carsin H, et al. Mass casualty incidents with multiple burn victims: rationale for a Swiss burn plan. Burns 2010; 36:741.",
"     </a>",
"    </li>",
"    <li>",
"     www.nfpa.org/assets/files//PDF/firelossfacts.pdf www.nfpa.org/assets/files//PDF/firelossfacts.pdf (Accessed on November 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/3\">",
"      Barillo DJ, Wolf S. Planning for burn disasters: lessons learned from one hundred years of history. J Burn Care Res 2006; 27:622.",
"     </a>",
"    </li>",
"    <li>",
"     nfpaweb2.gvpi.net:8089/assets/files//PDF/FireOverview.pdf (Accessed on November 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/5\">",
"      Cancio, LC, Pruittt, BA. Management of mass casualty burn disasters. International Journal of Disaster Medicine 2004; 2:114.",
"     </a>",
"    </li>",
"    <li>",
"     www.nfpa.org/itemDetail.asp?categoryID=954&amp;itemID=40025&amp;URL=Research/Fire percent20statistics/Deadliest/large-loss percent20fires (Accessed on November 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/7\">",
"      ABA Board of Trustees, Committee on Organization and Delivery of Burn Care. Disaster management and the ABA Plan. J Burn Care Rehabil 2005; 26:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/8\">",
"      Jordan MH, Hollowed KA, Turner DG, et al. The Pentagon attack of September 11, 2001: a burn center's experience. J Burn Care Rehabil 2005; 26:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/9\">",
"      Mahoney EJ, Harrington DT, Biffl WL, et al. Lessons learned from a nightclub fire: institutional disaster preparedness. J Trauma 2005; 58:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Launching a National Surveillance System after an earthquake --- Haiti, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/11\">",
"      Kauvar DS, Wolf SE, Wade CE, et al. Burns sustained in combat explosions in Operations Iraqi and Enduring Freedom (OIF/OEF explosion burns). Burns 2006; 32:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/12\">",
"      Wolf SE, Kauvar DS, Wade CE, et al. Comparison between civilian burns and combat burns from Operation Iraqi Freedom and Operation Enduring Freedom. Ann Surg 2006; 243:786.",
"     </a>",
"    </li>",
"    <li>",
"     Australian Health Ministers&rsquo; Conference (AHMC) National Burns Planning and Coordinating Committee. AUSBURNPLAN Strategy Paper: Australian Mass Casualty Burn Disaster Plan 2004 www.health.gov.au/internet/main/publishing.nsf/content/DAEE022595059595CA25742F00069124/$File/ausburn.pdf (Accessed on January 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/14\">",
"      Sheffy N, Mintz Y, Rivkind AI, Shapira SC. Terror-related injuries: a comparison of gunshot wounds versus secondary-fragments-induced injuries from explosives. J Am Coll Surg 2006; 203:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/15\">",
"      Lundy JB, Swift CB, McFarland CC, et al. A descriptive analysis of patients admitted to the intensive care unit of the 10th Combat Support Hospital deployed in Ibn Sina, Baghdad, Iraq, from October 19, 2005, to October 19, 2006. J Intensive Care Med 2010; 25:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/16\">",
"      Gutierrez de Ceballos JP, Tur&eacute;gano Fuentes F, Perez Diaz D, et al. Casualties treated at the closest hospital in the Madrid, March 11, terrorist bombings. Crit Care Med 2005; 33:S107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/17\">",
"      Cancio LC, Horvath EE, Barillo DJ, et al. Burn support for Operation Iraqi Freedom and related operations, 2003 to 2004. J Burn Care Rehabil 2005; 26:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/18\">",
"      Yurt RW, Bessey PQ, Bauer GJ, et al. A regional burn center's response to a disaster: September 11, 2001, and the days beyond. J Burn Care Rehabil 2005; 26:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/19\">",
"      Cushman JG, Pachter HL, Beaton HL. Two New York City hospitals' surgical response to the September 11, 2001, terrorist attack in New York City. J Trauma 2003; 54:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/20\">",
"      Pryor, JP. The 2001 World Trade Center Disaster: Summary and Evaluation of Experiences. Eur J Trauma Emerg Surg 2009; 35:212.",
"     </a>",
"    </li>",
"    <li>",
"     The terror attack on Bali, 2002. Kamedo report 89 (Committee for Disaster Medicine Studies). www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/9209/2007-123-35_200712335.pdf (Accessed on January 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/22\">",
"      Kennedy PJ, Haertsch PA, Maitz PK. The Bali burn disaster: implications and lessons learned. J Burn Care Rehabil 2005; 26:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/23\">",
"      Tran MD, Garner AA, Morrison I, et al. The Bali bombing: civilian aeromedical evacuation. Med J Aust 2003; 179:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/24\">",
"      Southwick GJ, Pethick AJ, Thalayasingam P, et al. Australian doctors in Bali: the initial medical response to the Bali bombing. Med J Aust 2002; 177:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/25\">",
"      Hampson GV, Cook SP, Frederiksen SR. Operation Bali assist. Med J Aust 2002; 177:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/26\">",
"      Harrington DT, Biffl WL, Cioffi WG. The station nightclub fire. J Burn Care Rehabil 2005; 26:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/27\">",
"      Frykberg ER. Medical management of disasters and mass casualties from terrorist bombings: how can we cope? J Trauma 2002; 53:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/28\">",
"      Arnold JL, Halpern P, Tsai MC, Smithline H. Mass casualty terrorist bombings: a comparison of outcomes by bombing type. Ann Emerg Med 2004; 43:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/29\">",
"      Champion HR, Holcomb JB, Young LA. Injuries from explosions: physics, biophysics, pathology, and required research focus. J Trauma 2009; 66:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/30\">",
"      Wolf SJ, Bebarta VS, Bonnett CJ, et al. Blast injuries. Lancet 2009; 374:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/31\">",
"      de Ceballos JP, Tur&eacute;gano-Fuentes F, Perez-Diaz D, et al. 11 March 2004: The terrorist bomb explosions in Madrid, Spain--an analysis of the logistics, injuries sustained and clinical management of casualties treated at the closest hospital. Crit Care 2005; 9:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/32\">",
"      Crabtree J. Terrorist homicide bombings: a primer for preparation. J Burn Care Res 2006; 27:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/33\">",
"      Randic L, Carley S, Mackway-Jones K, Dunn K. Planning for major burns incidents in the UK using an accelerated Delphi technique. Burns 2002; 28:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/34\">",
"      Carley S, Mackway-Jones K, Randic L, Dunn K. Planning for major burns incidents by implementing an accelerated Delphi technique. Burns 2002; 28:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/35\">",
"      Mackie D. Mass burn casualties: a rational approach to planning. Burns 2002; 28:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/36\">",
"      Welling L, van Harten SM, Patka P, et al. The caf&eacute; fire on New Year's Eve in Volendam, the Netherlands: description of events. Burns 2005; 31:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/37\">",
"      Lynn M, Gurr D, Memon A, Kaliff J. Management of conventional mass casualty incidents: ten commandments for hospital planning. J Burn Care Res 2006; 27:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/38\">",
"      Hirshberg A, Scott BG, Granchi T, et al. How does casualty load affect trauma care in urban bombing incidents? A quantitative analysis. J Trauma 2005; 58:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/39\">",
"      Kosashvili Y, Loebenberg MI, Lin G, et al. Medical consequences of suicide bombing mass casualty incidents: the impact of explosion setting on injury patterns. Injury 2009; 40:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/40\">",
"      Kulyapin AV, Sakhautdinov VG, Temerbulatov VM, et al. Bashkiria train-gas pipeline disaster: a history of the joint USSR/USA collaboration. Burns 1990; 16:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/41\">",
"      Buerk CA, Batdorf JW, Cammack KV, Ravenholt O. The MGM Grand Hotel fire: lessons learned from a major disaster. Arch Surg 1982; 117:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/42\">",
"      Palmer DJ, Stephens D, Fisher DA, et al. The Bali bombing: the Royal Darwin Hospital response. Med J Aust 2003; 179:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/43\">",
"      Cancio LC. Airplane crash in Guam, August 6, 1997: the aeromedical evacuation response. J Burn Care Res 2006; 27:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/44\">",
"      Becker WK, Waymack JP, McManus AT, et al. Bashkirian train-gas pipeline disaster: the American military response. Burns 1990; 16:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/45\">",
"      Brevard SB, Weintraub SL, Aiken JB, et al. Analysis of disaster response plans and the aftermath of Hurricane Katrina: lessons learned from a level I trauma center. J Trauma 2008; 65:1126.",
"     </a>",
"    </li>",
"    <li>",
"     www.doctorswithoutborders.org/news/article.cfm?id=4456&amp;cat=voice-from-the-field&amp;ref=news-index (Accessed on November 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/47\">",
"      Morgan AE, Lappan CM, Fraser SL, et al. Infectious disease teleconsultative support of deployed healthcare providers. Mil Med 2009; 174:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/48\">",
"      Chung KK, Grathwohl KW, Poropatich RK, et al. Robotic telepresence: past, present, and future. J Cardiothorac Vasc Anesth 2007; 21:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/49\">",
"      Frykberg ER. Triage: principles and practice. Scand J Surg 2005; 94:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/50\">",
"      Cassuto J, Tarnow P. The discotheque fire in Gothenburg 1998. A tragedy among teenagers. Burns 2003; 29:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/51\">",
"      White CE, Renz EM. Advances in surgical care: management of severe burn injury. Crit Care Med 2008; 36:S318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/52\">",
"      Centers for Disease Control and Prevention (CDC). Deaths in World Trade Center terrorist attacks--New York City, 2001. MMWR Morb Mortal Wkly Rep 2002; 51 Spec No:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). Rapid assessment of injuries among survivors of the terrorist attack on the World Trade Center--New York City, September 2001. MMWR Morb Mortal Wkly Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/54\">",
"      Almogy G, Belzberg H, Mintz Y, et al. Suicide bombing attacks: update and modifications to the protocol. Ann Surg 2004; 239:295.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Surgeons Committee on Trauma: Advanced Trauma Life Support. Seventh Edition, 2004",
"    </li>",
"    <li>",
"     American Burn Association: Advanced Burn Life Support Manual, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/57\">",
"      Chung KK, Blackbourne LH, Wolf SE, et al. Evolution of burn resuscitation in operation Iraqi freedom. J Burn Care Res 2006; 27:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/58\">",
"      Singer AJ, Taira BR, Thode HC Jr, et al. The association between hypothermia, prehospital cooling, and mortality in burn victims. Acad Emerg Med 2010; 17:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/59\">",
"      Markell KW, Renz EM, White CE, et al. Abdominal complications after severe burns. J Am Coll Surg 2009; 208:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/60\">",
"      D'Avignon LC, Saffle JR, Chung KK, Cancio LC. Prevention and management of infections associated with burns in the combat casualty. J Trauma 2008; 64:S277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/61\">",
"      Chung KK, Blackbourne LH, Renz EM, et al. Global evacuation of burn patients does not increase the incidence of venous thromboembolic complications. J Trauma 2008; 65:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/62\">",
"      Arturson, G. The Los Alfaques disaster: a boiling-liquid expanding-vapour explosion. Burns 1981; 7:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/63\">",
"      Barillo DJ, Cancio LC, Stack RS, et al. Deployment and operation of a transportable burn intensive care unit in response to a burn multiple casualty incident. Am J Disaster Med 2010; 5:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/64\">",
"      Zanetti G, Blanc DS, Federli I, et al. Importation of Acinetobacter baumannii into a burn unit: a recurrent outbreak of infection associated with widespread environmental contamination. Infect Control Hosp Epidemiol 2007; 28:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/65\">",
"      Hospenthal DR, Crouch HK, English JF, et al. Response to infection control challenges in the deployed setting: Operations Iraqi and Enduring Freedom. J Trauma 2010; 69 Suppl 1:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/66\">",
"      Ennis JL, Chung KK, Renz EM, et al. Joint Theater Trauma System implementation of burn resuscitation guidelines improves outcomes in severely burned military casualties. J Trauma 2008; 64:S146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/67\">",
"      Serghiou M, Cowan A, Whitehead C. Rehabilitation after a burn injury. Clin Plast Surg 2009; 36:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/68\">",
"      Fung V, So K, Park E, et al. The utility of a video game system in rehabilitation of burn and nonburn patients: a survey among occupational therapy and physiotherapy practitioners. J Burn Care Res 2010; 31:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/69\">",
"      Hammond J, Brooks J. The World Trade Center attack. Helping the helpers: the role of critical incident stress management. Crit Care 2001; 5:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/70\">",
"      Hull AM, Alexander DA, Klein S. Survivors of the Piper Alpha oil platform disaster: long-term follow-up study. Br J Psychiatry 2002; 181:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/71\">",
"      Wisely JA, Wilson E, Duncan RT, Tarrier N. Pre-existing psychiatric disorders, psychological reactions to stress and the recovery of burn survivors. Burns 2010; 36:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/72\">",
"      Kenny DJ, Hull MS. Critical care nurses' experiences caring for the casualties of war evacuated from the front line: lessons learned and needs identified. Crit Care Nurs Clin North Am 2008; 20:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/73\">",
"      Barillo DJ, Jordan MH, Jocz RJ, et al. Tracking the daily availability of burn beds for national emergencies. J Burn Care Rehabil 2005; 26:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/74\">",
"      Kurenov SN, Cance WW, Noel B, Mozingo DW. Game-based mass casualty burn training. Stud Health Technol Inform 2009; 142:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/26/23977/abstract/75\">",
"      Arturson G. The tragedy of San Juanico--the most severe LPG disaster in history. Burns Incl Therm Inj 1987; 13:87.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14993 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23977=[""].join("\n");
var outline_f23_26_23977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8992510\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8992446\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8992525\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8992453\">",
"      MANAGEMENT PRINCIPLES OF THE BURN DISASTER PLAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8992468\">",
"      Command, control, and communication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3609531\">",
"      - Command",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3609538\">",
"      - Control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6524715\">",
"      - Communication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8992475\">",
"      Triage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30679900\">",
"      - Triage surveys and location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30679907\">",
"      - Triage officers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30679914\">",
"      - Over-triage or under-triage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30679978\">",
"      - Triage guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8992482\">",
"      Treatment strategies in the field",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8992503\">",
"      Transportation of injured",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15671858\">",
"      LESSONS LEARNED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8992489\">",
"      Combat and mass disasters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8992496\">",
"      Application to civilian, non-mass casualty, burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8992510\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14993\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14993|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/13/2268\" title=\"table 1\">",
"      American Burn Association grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/40/7818\" title=\"table 2\">",
"      Age TBSA survival grid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/49/4892\" title=\"table 3\">",
"      Recommendations for evacuation of burn patients from theater",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/61/20444\" title=\"table 4\">",
"      Hypotension guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/57/20380\" title=\"table 5\">",
"      Recommendations for the difficult fluid resuscitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=related_link\">",
"      Epidemiology of burn injuries globally",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=related_link\">",
"      Principles of burn reconstruction: Overview of surgical procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_26_23978="Hand-foot-and-mouth disease - lip and hand";
var content_f23_26_23978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52800%7EDERM%2F58566%7EDERM%2F53423%7EDERM%2F71314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52800%7EDERM%2F58566%7EDERM%2F53423%7EDERM%2F71314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - lip and hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Oral lesion: note the oval shape and rim of erythema. B) Oval intact vesicles are noted on the palm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - buccal mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small ulcers are present on the oral mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDsVjK8cAmpoEwD0NOMQJz+GKlRDnoQayPRFU4wAeatIu8cg4Haook6ZAq2iMOvahsSWo0JzyMVKq4YHA4FSLgcsRn0pGmzyMY9BUuSRag2O+UD7vNPQjGcZ5pq7Sp5yKkADHHGOmRUORahZWJ4eQM5PrSyKpjyAMnuKQIcYyfXNPw+3pz3pXGo2ZVEQ+8Bkk+lNZSW7465HFXRGRnsfT2pyRgr15xxgUnrsXexXht/Tknual8th3yf7uMVIEYKxMhAJ6etCkhTh2yOMkc0Jom99iAhgo3ZHPUHNKF3dOAOxOadtZlyr9fbpSx2zAnbKwb0xTHdW1FWFtxJAI6kUeUrk7wVOPu9M1ZSJ2XCyk49u9CwyYZTIwbvlQRTsRzeYqI2wpsWQY6Njinx20cmV2YIPPBzUJV8YklZV6DC1IiXCykJMRv6nHUetVbyIk3bcke3twwQ4QgZJYn9KiOwKyx27Pzw7fLx9KRWmDsUMZOeDjnPtTsTTSBT5SuB9057UegJPqyNEkLcOiKRnIHBqJ4kLEyyOyepNSuWYptdSwPKhAAKD5r5RmQjHOF5NIpadSBvIEa+XHknvtqKQcAnj69atgtt2xkbhx05qIJlskhjn+70qGUnYpkEKV2kZ5571FJFnB4HGSAKuuhU7mBwD1PeoLhlVmB2njPeoky15GfOOcKTj371RnRgAdx4rRc7gpVGPpmoJYHyDtAz1OagtbGeYznkYPaoGXkZ7mtB7ZyOTx6YpgtkUjvjv1oFcySBvOBn8KjlIYEBTn6VsTwLtOMFhVCRGByevaltoN6mTOjDnHbmsu9iLgjaMCuhlUjIA5rNuogCeMGrUrGclc5W8hwT3NcvrkAkRvQjmu3uY85DdD0rmNXgPzVtSnZmE4dTxa8iMN3JHjoSAKh7DA9q2vE9v5V7vHRu9Y2SCSep/lXrYXU45qzExjGTkUAHPWjr93FJx7106bGYDB7c9qOnHSg57DmkPbg01JbWE97isScUmD0pQBnk/U0AgHpn0FOSUviC40fL15oGefSnEckH6mk9KzlBPQaEyRzTTnPXmlK5PFIRxx1rnqRa0Q0w/nTlPXFNxikxjFZ8zj0GPBBAFBI/GmKDml4qlXvuI+5olGPftUoRVAwck02MEeg/HrViKPLfKfwNcGx3Aq4A4NBbYfY09I36ufyqKdB3zjp1qJN2LgrsgluQA3PBpqSyyjKgBQewqlMGEmGBADce9amnziFsjbk9cjiuXm5pWZ3KPLHRFiE8YcD8OKuR7MDgemKR5FlwdoGR9RUsMQPU471oo9iW12JI1XbyTtpRgNgZz+eaGUBQQfxpoO3ccc56mr8jET5ixBYAHtTowwAJIz2NNQEvgdPWpTtWQ4PPpU2HcegbBG3nrnPNQnBO3PPQ+9TKzDk7j9KRkV2DDkZ6Hr9aozuLFCgBIUcepp3lhcGNiM+h/nTfLIyVGfY08qpQjBQ98+9NCbHws5DKsmB0B29akaOQZjJRueM+tNQfuiFJx3z0xT496K+0J8ozgnP5VSM2NczgjeUOeATzimmOZeCybc/gDTJJNzAIff8AecD/AOvTFVAgZixycnb0/KlcpJrcsrKzzEKI5SRt+XK1E8cgBMsO85wFVsCpJSybQ7DY3Iz1/GhpgjkQlpCevHT2zR6slJkEv2hI8NEAhGAc9vwqVhK6hgsMWOc7iM1Bi4fjcI0PRevNLGUOFfDMDtJySAaS13NLAJgVKBQfXaKZukLAKoT0JqxkKOWA55BFMfnJRc47scCkFyJoWZeZMiqssaq2EXOOTxmrsmeCSWP5ComWRhtJwB2FTboi4spMxBHv6DpTGO7sAO4FLqluIIS6yKGJwVVutUbWcknJzis5Xi7M6FFSV0WCgOcnk+1RMoUnpjvVknOKidMnrnHNBly6lSdRjIOQaqGIZ54rQkQbOOMDrVNwM9sjt3pWKaSKM0YPIHNZ9xCTlgPzrVuCFHvjqapTYIOeDQ9CbXOdvrYkse1c/qEKsMEDpXX3pBXHtXN36Anmrg7ETjdHk/jSxzGzheVOQK4kDGQTx1PvXrviW1E0LgdcHrXks8bRzNGRgqSPrXr4Sp3OCrEibg5HB7+1N9akYAHnkDrimuefu4z+gr0OXS5ztje3WjPIHSg4H07UAEg8/U0K/QTA45x0/nQMjnPP8qNuAD+QpPXnjuaGn1ELnAzjim9RnPPoKVsnHBGegpVGM+nc1k3KT8ihvT+ppc9M/hShs9Rx2FJwDx/+qmtua4C8Z9aQqCaQdD6Uufz9KhuM/iAaQcYppztFSce/vSHGOlZVKMXsx3PupF3npipwdvemquOnQjrT0Ql8A8dq85voego3JFBJGOh602RcrkYJHFTxLlsHgn8qmWDkYxnuKhxujSLUTMa2ByQuV709LQqRtPH930rSFvnJA49BUnlgHCnnsKzdM1VbQpRo4fG78PWrSlgnUkjv6U4oeQeSevFPUccDgdM+tHLYHO5GNzMNxBX8qRpAGxg89KeSQOw9B6VGQdwGCPfNKz6CWpNG42AcNznk05tpADcL2/8Ar1CsYyCACSeo4qePkA/Ke9V6idlsPaEBBjJz6GgRjy/bvnmnMR5ZOMD2pHOM7WK/yoM7thymfKJGf7x4pCRuJkLdPTINMEyHiQ/kMg0r/MikoCCc8Hk09xpNCea4KojBz1KtwR+NN87MjCcNER1JGQKJLiNSACMHpuGMVLHPv42MQRg0JX6jtZXsMaRWBCDICjI69PftUQVieQwTOdqnp9KWSI+YoijKsfQ4z6VGEnjOJCGz0wuSMUWGtCwmxQzxNnnkH+VSXEgWRTEVMpGWVRn86jMaSRFvMBJ7AYxQnmqo2RjbznJ61V7aE2W40hiPmIKA5KDj9aU5dl2xBduMjOR7UsbszAKF34984p7I2w5OVB6DjcaQbBt2OQVy3q3anheAUPPp29qaqts3FyQR93rSqSvzM+MHHSlYlt9Bsysq7WAOOwqNynQ/K3pVlg7jknHXOOtROu08N168ZP40egRkYt3btKf3hKj+6OtJDB5IAAAzxx3rReNgSZHPtxyarTAgOdxPHJFZOHVnVCbasMwDwBg5znsaTb0PUZ4qPJzksf50x5M5ySPT3pCa6DLlxnrz71nTy7eB94j0q5JA82WThemTzmopbcRDK8j1NS2xpIz5Q8qgAcE85NV5LdyMHitN3UcHHvmopH3AbelDsTqjDmtsk7jjOcVialY/KxyQRXVSgEHHr2rMukLBsAHFJbgzzzUrOQhhkE15Z4ssjbXu7HLce31r3LUbf7xI4PpXA+LtMFxbyYGGxwcd678PUs0ctWNzy0/KPUA/rTW569T1p8yshYHgqcYPrTQBtxznq1e7TlzKx50lZjcHA/QelHG3HYdfc0A7Txwe3NLkYJ7Dt6mqWhDGgH8aFA7g4/nQCRx69aUdOv0FShiFmyc9T09qQ46joP1pWGCR+Zo9z1HQUndgHJ69f5UEA9Dj+tBHBBP1o684qPIoQggc8+1N7delPzjgdPWm54HpWc7JgHb2NAPoPmpQD0HLH9KHXblcj3NNxcdUgPvNkwvHPfmljUsvPTHWrCRBlyalbaBsxj1xXjyVz0oysFv2XjgcfWnudjfLjGKjTlsn8TSu5JwOCelC1F1HrIAAx79vWlDbjksME9KquWK7R949WFRx5jBJOc847UmyuVdDRVtvfIPc9qcApHce9VonOwD1JyBwVqdDtGWBGehqGVawrBWcBjn8OlIiRkktggdTSMysODzz1qOPaWx1yMYB/WgpKxOwUjK4/ChIwpJKqeMgA07apXOABjgf/XpnKgNhhz0oEh5Ykc8Hrwaq3UjqMMcip4xuyc545DdqdJs5H4c9KTVyk1FlG2JmV9u0D1Y1PGMImDvToFL45pn2PDZQ7D1yDUsGYmxOvGOw5HvSje2ppJp7Egji2bVUJNk7geRin2YKAeRwQcEk5U/hUMphYEtgem2ktwpOCGQ54ZMjNXfUxautSwzKGxLlZF4D84qMzIOTuMu7g84allLxtudQ7dOD8x4pqOGUfNvfJG08Y/wp3Eogzxjczxu7ZBDqMGollHmYDFQTw7CpY1lkyzqhXrt6bqaZT5heJVUYxgnOBUvUpW2JYgAGUgODyDinD5VKs4IHG096iG+LlSCmf4e30pzyIxO3JyMnjnPv6U7k2ux0TP8AMseAM8E9APpTthQl92X6AtVdChLbiQexIxTsndiMsx+uaQNFiSXcCTgHv7U3DMikr2zk/wBKiDHzQW2sRjt/Kp95AJIBXJHBoSJZVfALFge+c81WkUsh249SD0FWJJwzFNp3k8AfzpjW5c/vjhSfuKePxpNXNYvlMrLb22gs3TI6e9TrbKTukYM/YCrLBcBUVVUHIx0JqCV9pIG0+39anltuW5XEY7I8YI+gqlc3Cp97BHTbT5TJJtji+Z8dCeBSpbLFl/vsSQXIzj2AqHqVGy1ZkSKWcF1Kqex6kU/yzt3Zw3YCrjoMndktzzUM/KFjj2Hap5bDlJMzm6849M9qqzqOatSr13flVG4cYIyKa0M2tdDH1BQThhxXJarEr7hiuqvn5wT+dYF8g+Y461cJ6kyi7ankPizT/s94Z1X5Dxj0Nc4FG8hj8o5PvXqHiGyS4ikU85Fea3MRgmeN/wCHqfWvewlRTSXY82tGxW5yQB1oOBzjgdKVsjnOCfTtSKOOR9K7Fq7WOdifw8/jRnHTr2oPocfWhfvc8E0mvesLZB6e1Jk596UgKeORQeT70Ti1p1BMTOeOgFKhHPqf0pucN04pw6VmtHcq4uRkIcbQeTSYwdwBK5+WgKpOCce9ObO0c9uMVahzx5mTcYFLMcZJ6mkxgc/lT0YrwpIB6470nYk9e1QoK1h6n30GlG3A2nPAqQq/JwDnjnvRACWy6fhipzjYCBg+/avCsenzW6FdDIvBQ5749KQMeu0q3vzU5JHJKtjpSOOfm5PTIPFJaDv3RTwxViA+31FCgFRzkjnHerZcIQuMdzn9Ke2CDwBnpx0oZSY22KEhi2T3qypTHODn0qNCoGMAKOpoZ1BAwOOg7mouXa4sgBYbenTJpQqAADB7CoXCdd2Ce3emqJOik4689aVx2Lnl7UyGxnsTnNRvvGS4GT3x0oil2ocoff2pyzIwGfve/emrEajRtcZABPrnpUodQF3r8wP+eKgdImJxjg/w8YpVSWMK0bCT/ZJ5H40tUN2aJ2VX3Ekbe4U4qEnZkce2eppryJIeVKyf7R6GgIVGYjnI+YE5z9D2pgkQNHlg0ZIkXsRgGpElYgrMqhgeCDx/9anmXk712Z7sMgU5AnzhQpUjnBp2Kcr7gqbCGk3bsfKwPT/61NkVHZWZjg8FsYAPrTowMbVDPEADnuPpTTvQEMUKN1XP6UeouosjFF27vMXHUDlR70wuijPBLfdP/wBahBIxwP3f+03ekeEKuUJ3cdf88UtQskPJYxbWLKvUbeppsmAgIwrD/P40wvIyjBGVJPPB+lPWVAoMS/N3LfrRYWwjsXkHmYUn9aAwAwy7VPr0P41GWUpyWDD05/KlDF2+d9oH8Oef/rUA2TF9igAgbh65x9KYTI0S4YqhPQ8nH07VGSB8yJyOM9z+NRFtuSrMGP8AD1P5U3poRuW0wiEKAifxE9W9zQ0m4D5Rjpjpu/wqoHbcpYAse3p/jR5hXIzvOeSp5/OkaRjcfKTk7xyoHHtVNnMrMi4U9Wkx0qyHE5AjIVM/M/8AhTL/AGxRqiAKmOB6n1qJJ7mqj0YBFjjwg9ySOT9agnfIJAxnnHQGo0uFOAG3HHIqF2JUs2NpHXPX6CpbuHLYY/Q9z1z6VVZgBIMgnsaR5+wGBVeSXIYj26VINWILhtv3jjJrJuXPOM+wrSlZ2UuFOR146VnXkiLEoHXAJx0quW4Jox7vOcsOnUVlXJJU9s1ev5lTJY4POOaykcyjeoYpnAJ7n6Uox10CTMfUY8oSBmvOvE1oFm84cgdR616lq8aLLKsalVU9Cc1xmvW4eJ/cV3YebpzRx1Ypo4BgVJVsZPJ9hTcnnjBPT2FLIpDsCOQeaYWJIIPtXuxqcyuea1Zi5BxxwKRRggj7w60pxnPUDp70Imc5YDAyc0bvYALA5zg0hGPcnr7UYycr17CkHGc8f1qKk23qhpB7dqO/FJ/OhT1wcVHtU9GFhePwFBJH16AUqnABIHsKQ8nr19Kblpo9QsCjPGeO9KG24buOmaaDj8KAefr0qYySeg7H6CRnJ68+uac+OMt1Hr1qEq0Z+XvzikMgUbnI4A4NeLc9JJErgZG4DJ/T0pwjydoJC9cH/PNQxkBt2Q3+FWk5DbRnPQelG5T0RCQdwLjP170rTFTh1I9hTWk3E7Pvr1b0qKVuGHGfUVJcVfclGx2JZsY9D0pD8z43cDv3qucvlmXIxgcY/wAmnRo4CtvO7POBUmlkWUQN/I1I4EYX36/SmwKp43EH2NTuuCRtyO9Bk3rYi85DjJHPUU6Ro3HT2Ud6Y0a9ABweQetG4EgNxg4yKEO3YDFFghSeKesHBKsce/FNyWZQAw9GA7VKkpUKSpbjsff0p6EttEMlvI5wee44zxUcayLja+AOhxwatl3Y/KuAATkHtQFkBG5E29NnI5osh876lSSeVDhkyO5HGars0UiE7nXPUKMEenHerjyF9xKbTn64qvMkLZYnDeo7UmaRt1GLdTDh0Yf7QHb6VdhaMqGjfMx9RVNRLwc7kHAyP505gWGW4IPUcUrhNJludztJdgST90jpVZZXUNtYbB/E1QOzwjufTdnNNEzTcFFD9zmnoyeVotMiNkuQ8mMjnFQCSItu3E+gJpEcqNrj5B0PUrVeRgp3xtgdwD1p2EtdC7NMMquF2Ywdv8zUMzh1zvy4ORgZqv5uYjtBz1Ge1Qs2UzkZI6dKLXFoi6swydxJI449KjaX5dwY5x1JH6VVeUKu5CenODVeWYoCVwQeC2OlDBIvLKrBSCSwGevAomfKFz908AjqfYVlCXMgOMADBwOtW1bI35Z19xn8anc0TsTfbnjjKqQoHBUelZ91eSTNh+PTHWp3Jb0IPIzzUDW54Ix07Cokm9EbKS3GRyFWBPBPc0lxdhTlj070rLt55yeKqXREigAe30FS4tC5k2QTTbTjJwajEmcAsAvU1VvJwHOcAH05qlC008myBWZvQUKydipK6uaN/dLHCU5GTkjHX0rJcS3Tny+mOWYYAH1rVOm5WN7iYzFhuZB2PpVS5uHKmCIfIeMfSt+W3xGHN2MHUrGOSVGMwfjJA6D8O9RzxiNYwOCB1BzWvb2UTl3uJdpHQY4zVW9hVDtjmEo6njHNCh1JTexzt7EV3Hrk9q5rVI9wdfwrtLmLMgz0PBxXNazB5cp/unsKqGjJmro8t1qDybk7Rjdzms/pXVeKbbMBnVenNcoT6dq9ijUTjqebUjZgMdDxj+dNJIyDnNLnP40BuWHBz3NaN30uZijv3J6UuQDhgSBUeMd6d/CP1opz01Ewwc/rQ3YjpRnrnrS54Oe1VaLT1DUTHbnPXPpTMnoamC8AHHPNMOOT1HaoqUNNwTGnNKD2/Ol25yRk4GTTcD8TWPLOIz7+LglsHBHGPao3k3H5h2wMnpT5tuzewz/UmovK3ZZW2j35FeZY9FEkCBiSflIHAHNTO4UANkNnsc/T6VVZmjG1jj+tKkisRk89gB1qV1NLFl4gF3HsPzqEncnOVA4HpSNMcnLew44ApMngtznvSa7DixyfOMLye7DuPpVlF/c8ZA9ahjAQKxwR2+tSJnzsBsHt3ot3KbJEYjCFcHqfTFO8wqflOfUURqxJLKMnPU1Ec8BXAb0xRbsStxxlBA4Gcf55pC8hBPVcEfWoyMnJfco6r0xT3h6BC2709aVy9ByeYEUOCyjsOoqwkoDfJkjrzTYwdqj72OCemPwp4AHPRehPrRaxm2hWYbtqKc4xk8U3yShJdtzAcA1MgGz96vAHbpRwY/3eWxz83T8KenUhPoiAkrluvQkVGcE5VcE+vQ1O7wFATgP0OetVQ4IJDDrgAjtU27miY4SKCQCVP90U1iACWwr9sdzTYl+ZjJjA6AdvpTpCxI3H5DxnHNG5dtSjcPlBiRiW4UdKjijZx8x+YdvWpZoMOWGAD09qb905JIFCNJbaBPvSPJ+f+LkdaoNcMWHykn0Jx+OK0g+7COCoxnH+Jqlc26g7WGAasy2ZXkmPLZUjuc5INV5ZymCh59epqeS1jXBDkMARjs1Zs7BX2OcHsc8UO4tB80zl2duN2D1pplTCkSFnI5HYVVkdeQMkjB5qPAViM9f5VJasasbgjHAUnqvr7VNDdEBweo+U89azInO1dvUEde9TI2SWXIY9MDr/AIVaWhmmX2kDdtp7getG8YyGGcc+3tVTzCr5l28jrnpTllRV4GW9TSUQch8hULx344zWXdS4LDgDjpwKtP5s0qpECWP3R61t2um29lOrEfa7gLuBI+QH6d/xpcvMTz2ORtNHl1CT5j5cPVnPAA9u5Na62UVnCUgUBd3DdWb8a3TC7uZJ2255wOOKqug3NgYBGAVHSjljHbc0VRzWpz7RPLIQQVTrkZ6VH9jCqXGOTna3XFb7wY+/nC9eePpUFxGTyRweeaqw7owJICH6ALjt/Ss+4txyVXHua6Se3IBCjA6YrPuVONrjkdxUp6i5rbHK3se1RgYA9ep4rldaDOeO1d5fW+5Tn34rltUtc54qvMTkranEapAHt3UjIIIxXnMqYcqeoODXq+oQ7Qw7dK801aDyNRlToCc5ruoNPRnBVVyhgAYPelJwflPA6ZqSYru+QfLTMAcAgiu2VOMfdRzjOo+nNIcgfWnDvnqaUDBrBw6gHHIOeB+tIeenFITwQe9GcdaOZK4xS3JPPpSAgcZpueR6UAHmoVa7uFiRe2DjPWjPLE9R0pnQkjtTcnOa1lX2EkffsiIiZZio6n6/Sq8MjlvnGAOmO1SOQZQCAdvPrmh2ziNflUcZ715B6q8x80gkUCQbs84HJqF4XQZXheO/H0pyQoGGBz3GefxqyqKQTJ06cU0tNRttbFFg6AgfMR1A7f41LCWxnHtyasxpnJAAA71IbdWwT9Dk0r2YhIxhQAQT6UrKCuAct1wD2NROoQkEc9Qc8UKqibKg7Ogwe1KTEky3EoAJGSccZpGwXPylSCMgClhRdg2sSPTPeopJisvr6/8A1qBbEjAFhnAYYxnipCNi7Ryzc89MetQNICoJbnGfxpzM2DnAOOpp2KJExkdiOOv3qnZ1X5V6kcDNVPPCsM/KpP1OaesmGO0fKBz7+4NIdi2HCp84yp7g8A02YDccZU4x1psSBxnqD69qevygpkE/mcelBD0ZVJ3hSQOBke31ppYFgWwozgnHFSTIWAEQ+X34/Wq028KQSceg4x9aRcbMe+0DK4yO2OvvTBIA+dvyjk0Y4ykm44xgjgUvknd1xu9s80t2XayIp2xhk4Unoe9QplpCJRyRxVryc/KTyOmelRO2fkRAW55HajYfNoRyBWYndgjgHPWoJJHkACgZI5c1K4wFV8iMn5sCicAIPL6DnrnJq0tDNaszLmMuFVznJ5OaxNRGSQpOFOQCa2rkSysRGvTHJrMvogEbKhiepH+eKhmqiZiSgr8rHGcEVJFISenNUJf3U33vkY9xU8bsCctx09OKpaiaLyyMWGDz0x1pVdll2rjHXA5qEk+XjoDgg96ihlBk67SODmqTsKxoNJjHzZUjPXOM0kTZbK/d9TwKpySrkkEY/KtPRLbz8SuDtUgADvRe7sQ46GxpVlAsMchDtIx+Y9gO2K3Yo1ijwF2kjnBqC3yitwoQ88j1qwF35yGPYY5olK2iM1ErTDf2yAfujpVXy2Vtsa8/nitOUZwu3IXseOarYIzj5iDyPWszWOhnzRYAHTAP4+1ULtvLYbMnd3z0rVnRnDHIBPZap3IUKVRQqMATj5jn1obZcbMzTmcAsTkdcVm3IA3YOeetaZjZCdudo5wTzis+9Rdpdfutxj0PvQiZaGXdYCn7rbvRv51gaqisuR69CK2LniIsOO/4VjXx/I81pFaGUkcnq8YKnHBNec+K7crIkmB1wa9N1NQVYdMdK4jxLEJbKQbQW6g56V00n0OaojiWPJxSADp370uRzikxjjHNekl9o5QIpACRx2pck9KDgDFN01JhcRRxnvQBS4IAI70BcjrxWbjpawDMZOO9AGDTu+P1oI9O1ZOlpeI7kq2ly8UTrC/lzP5cbY4dvQH8afqEItrow+RNA8ahZI5Tlg/ft09K2kS01fTrFZbqe1ltIzCVEDSIwyTuG3oeec1Q8SXCXWop5azBIoo4VaYYdwoxuI96xdOYXR9qWUqkBeOeCfSrbybpcxH5egJPf1rlYbxhIM/Lk9PSuitJNwUYB4yPeuCLuerKLWpdSLDkKOuD161KIuOQcjjPpSwt8yg5/wDr1ZHJwCST1qhN9xYkUKMtj9alIQKAxz+FKkeABkfh2p3UgE8d6lk3RTl+WM7eeec9/aqaOYnwwwM/MK1pF4Yn1rNu4iwY7S3oOmKluxtH3kKk2M5wQOPwqOR1Vtowxx26VTjmOFGPu8Zz/MUsuCp+Zx0685qk7olxsWPMR3BB+Xtx1qXziRkt09elVUjx92TKr7UkQlMgO7jsc9KoLIuRypKSre/GKfCxYqsf3UHfkUiwgDHO7P3h2qRIyHYqdpzwBSYJluFSvLnGO2evvUu8ABU59HxzVORnX5+WxySetEU0bjG4MOSCen5UtiLXLfmZU5dc988ZpgHDbuvXp1qncXQA3g4ZeMEdf8ag8/exZXJGOmKCuUss6ljwMDqachbIOT+Pp61WQnaSOQSM5HNTIHYbwAARjPXApdR6sWUPkohBVRyR/SlhiBj6BRjOT/j3o3GN8RdcYLMM5/CnKGLqS5P8vyqm0Fn1K8+1w2OQOvGKquudqsTtznA6VfkjYjqMDnpVKTeM5Ax2yKXN0BRGtbcBV+77d6z72zKjG0ENwCeK0g5A5AB7YPSo7o7vvjjtnmpLWhxGtWjAsUXJXkgelVbbDozsd2Pfkn6V02qQbhvjbnrxXJzsY7g9geT2waqL11LeqLpchVwc98GqvmAXBx0xTWkZhgHOPWqpJNwufpgd6GJI07ZTcTqo+6epPFdxpUC29uigDIGScVzui2xJLycfL0H8q6u3OxRk+o4p/CZyV9C3GQVwc8DrVqJ9sYIGRjHpmq8KEjjH41P9zAduccEVBDViOb5B8xBHPeq+/LD5W2joMYFPcrGynGT1we9IZQoYE4OOSOfwosUtgZSV2hGyeTniq8sRQZG0r3G7pUjSkR89PUd6q3EhIDcKfu8ntVpIkoXhjVWB5U8g9x7Vg3jFRJGOmMjPetiYgGQ7Rnr75/pWNeYOXHA7UmuwamJeDC4wee1ZFwTtIPStu9+Yc9qybwg57VXNZA9Uc7fKcmuT1aIFXyOMdK7K+XIOelc3qkeUfjntWtOWpjKOh5bMmy4dcYCkimYyc5q5rEey+f35qkeAB3NetSl7hwSWpKrDZ90exqMkHgDFBOVAPIHQUg4X3raU5PToSL1BoU4GD2pc5GQRgVGecE1E5JJMaY8DIz60oHP+yKb2NS2Vw9rcRyosbsjbtsi7lP1HejnUbBudVBcXD6Npy2GuWun7IykkHnlDu3E7jgckjFc7rRn/ALRJub1L2XaP36SFwfQZPpV9vEt0DzZaYf8At0SszULt7+5MskcMbEAERRhF49hWKi3oM+pFuPMlRwed4BH9K7axIEYXjj9K830jc2tx25PG7efwr0u1HyhmxyK8ZO7uezM0YpCW69sVMXZQMd/SqcDsxGPun0q8qAsAcjHemzMsWz5QAk8/pU+zoepxTIk4GO3arKr8vHQUrXJlK2xRlLK/Q465xTJl3YOcVdkAIJ449qqOw5UkYrNo1i77GNeMFmUAYbp9ajklycM2dnIOMUa0Nu1umOhrGFy8qZXhqmPY0kram+riTAGQvr3+lXIkwrHg496zrIjYuR8vX3BrRR8AA8A9M10R2OeTuyeMMxXp6HFToVjyCo3fXOKqxsxYZJ57CrCOQdxIGPwoYdSRizR7WJwT+NZsziIkbR+XStVSGYkkn8Ko3ttuJbeSM9jWb3uaRtfUy5Zy5PzFePSoUnJwM4H1qLUB5O4ncCO/+NUvPCsDUXNeW+xuwylmUc8nHBrUhlAyDjnpWFpjl42dcBcjPvU5uGEgRGXJPUmnewKFzXVw7Zzx6VMGCqeOvSs2JpM/M3J6jpVrPTGME9aaInCxIxzk561VbDbicc9as7SfQVEU+YhSOOfpQJWK7JlQeOaqT5BIOQP0rT2jaBj5v5VQu8AkcEHpUsaMydfkO79K5LX7UkCRD93muvbpyOtZd/Cr7xkH+dC1GnZnKQvlAzdPWltVD6iuSQoGcj1qGZfss0kRJ25yPpU+gFZNQlLYIAAFdCtYL7neWSgxAvzhRzjB+tatse4AJ6gZrJsG/dAAkAjn3rWiYYHHXFTJC2LsRwoPOaSeQlclgee1QtJ8oAOMjnNRMSAQOc/xZ6VmuxFtbjo2AcndtcdcjjFLI4blSFC+p61UfIYncMkdT/ShWG4bgHJ4I6AfjVJDk+oMoZBnIHQZP9KqXA2tgNtwOATzVmcMwYbjx0C9KpqMNwAcH7wOOKfKyU0VpmmfBBwOhO3mse8hYDDFs57npW/jnA43DPPesu8OeR1B/OhxG5GFcgSnO3bjggHjNZ08SgE5H9a15lbLdB6ms2YErwMmlYVzFuY8k5H51halal1Pt6V00y9Qe1Z15ECD3yKqLaepnJHjvim2MFyGYEZ6GsMcj3Nd740sRLaM6LkxnIrgw3Xj5u1ephZrqcVWPUQkY+lKSMcZz3o74Y8D0pADnHrXZK62MbiqMqWxkCkPTBHWlK4yVBwBzTWJ655NElp7y2JTA4XGBR0OR1NHUY6AetGSDkdaydvkWW7XT7y7eFYLeVzMWEeF4cjrg+1O1RFgf7M1g1pcxYD7nLFjjk4PHPXiugsb0v4fM0dtemWG1NmZFTMUas+WcH+8QcYrF8RzrNqARIpo1t4kt1E4xIQoxlh2NZXbYH0xoMccmryTDBZE27h2Jrt7XLjjrjtXL6BaLamZs53vmumhbhTu49q8aJ7c9zVto9oBwMntVskDjjrWfC+3AwPXmrZAZflzwODV2uiOW5diYN0Jz9atCTPA6is6IMFOGH0xjFPinK85B4wTU3swlSvsXXc9CAQao3QycqKlDb2J3A++Khmw6kD7x5qWOnHlZh6z80EgznA6VyVpd7naI5DK+Ca6vU+c4HrmuGjZk17yl5D/ADflWafvHRJXR3mm58pN1aI5QkdfU1nWAYKgPQ9q1FUkccd+BXTHY45LUkt12jcRgZ61aDAgj9SKq7lKkZ4p8btuwqkdicZoYkiyx2k5IIPpUdwcpwRgdjTF+YHj8aZI4B+YM38qhopFG+jMibvlNcPqk7Wl2EZdoPau+kIKsSMjHAriPGMBNuZY1yyfNisZqyudNOV9GbmnzYt4wP7tSRjbdmTHUZFUdBbz7SF88lRgfhWzEitwRxnGTTXvIrmUdy3bKSNx5+tXoyAFGCefzqrGRGQozt21KJcEBeOetWtDGcuYvqoPbmqz7vMIRQQetLE7ljgZHTPvSkk792NxOMZrS1zFaMgJZRnr7ZrOuTwCRxn1q+74342k44x61l3jBm5IIHQjpUNGqZTcg5GelZ9zjJIPtV2RhkqD+VULoevB/nUNX2A5LxKNsfnKOnUe1HhLBDy/3j3q3q+DHIB1IPBHGaq+FFaO2iV8Furdua1hJbBbQ7W3faevHatm3kBA55xjNc7FIRtAArVtHJwBwM9qHMpxNRXB+92qOVR1P3fWomm24J+8CRx3NV3n3YGe/X1qbmbQ6R1AX5eRxnPSkWYDKEgnPTH61C/H3mPPQVXAGCcheeRjp7VaViC5IQwypAHTmqokIkwxJ6d+MelQSz4xsz6EVTluCi5JFPmtuCRoTzHYVLYycHmse7kYZ3Dr3Pr61DPeByQgLn0/xqnL9okOF4988VDnfY0jHuNuJRyAwx7ms2WfliOmeoNXZLF+srkE9uxprWyJjKjjgAdKWo7JGUxaU4VTn1xUNxbhlbd0HatWb5BgcD0FUJmOD2NJPUGkzlNdt1eJl28Yx9a8ivrc217LGRyDx9K9p1Ublfr09OleVeKYRHd+YvU8V24eVpI469PS5ikc47Dk0ICGyh5PTB6U7bgbcjnk+1MwMcde1exbqeeKQ2CABx1NNGcc9e1ObK8HqOtJycEdSaHZsNhDgHHekxzgCnKPm+fOB1IpQcZI/CsnG/oUjq9NuLO70kQNqMNoyWbWxhmJUby+7eMdcj8eKxvEl5Bd6gpt5DMkUKQ+cRgyFRgt/wDrrftJNVfRtNXQo7edEjImJjjZ1fceG3dBjGDSeJpUudPvWnFoTCYUiaFVGJcfvFUjqtc6vHoB9JWvUgHgGtqAMEUk8delYtm43MQB1zWzbPmMDkYPWvKjqe1PcvQtjAJ465/wq0ucjAJJ/CqaFQw5yTjpVyJ2Y4VR+PNNtEpWLAY8gjHc471GScnsAfSpfKOBukxz0x0qGVC2MyNg96zaNYkizEcJn8sVFcz4jLZCn0xTXiKciTJx3qjMWAOTmgq3UqXsrbTvAPpXK2QV/EJYDGEP866LUD+7y3/6q53S2H9rzN1O0Vjsy/snb25ATg44q4kmD97IrKiYkD5hkdQKswyHAGOfXtXVF6HHJGokmeMc+pp2DlAAcDg89/WqKO4c/NjtxU0O3exfdn6n+lVYlqxoLjLBmIA/nVaZuSoBJ7mm+bGw+boOnHWq7Ov8Ocd8nvRsEdxtxuUYPTNYusxCWBlI4xzzWlcT4GC3B9e1Zeot+7bPIIrKaN4GX4XnIiMf8UZKflXVxccMfxHSuE0iby9VuEzhWw2K6+CYsuf8is4O5VWNmaKyEA57DvThOwXaO/tVAyEA9/emxzoQ4AyD0z2x3rTqTGN9TSNyI+O56c5qKS6O09R+GM1Wluty7SBtwM9KpzXBLg8kA9+R9K00BRL0t+qJ8x+Y8fSqMtyGY7TgA8D1FU5mDNvxg9D/APqpsjgKNxG70z2qJDaJjNuGcmq1wwOTxmo5XbKYU9OtRytleeD29KlEuJkak+UOOoqhocgEzqDlgc/SrepcK2e9Y+iS7dQmXJ5qU7SNIx0O0icgYrTglPc55zgdqyIgTjkZFX0cgDHTGKOpV9DQDA8lj7UjFUI5G72NVbe5QOCSV7nI/lUqF5XJyoQ8cirRlKLRDLKQSD+PqKrSXBYhVZiAegrXSzi5wBnrnvUwtokI+RRgVdmZ3UTnxbzXBIUso6ZY1LFpSFS07scdiK1ZERW+UAnPJHGaTzCvKgk/UU+VdROfYpjTkjjyqqDxwTyP/r1VusdcAZ9BxVqeXOc8KOqg1mTSNtB5Abuehp+gRu9yvNJhskc+gqlJIzNxy3binzSFiNn4E+lUp2LAqMlvQdKiRqkiK5kBGB1zis6ZuD7Gp7l/p+HaqE0m0EEg+tTHcprQqXIDBiefY15v40hCksOh5xXpFw4FsMcV554zYbcZGc11J8tjkl710cYCSMD8aGJOPTsKRTwR3PWjJPP4CvZjLmgjy3uHUewoHGcDrQR2B+tICMEkE+lK9pajYpxwM9OSaVkZQCR94ZFN4PHfuaUHbz+VCad29hHZaZb2UWnWyf2VFdSy2T3ImkLHfIrHKDB7AdOtYviiKKPU0aG3S2jlgjkWFRjZlc4PvV21+y2On6dKLfULuR1MvmwzlFifJBUYBwcAZ+tZGszLc38kyxzxbgMrcSF3J9STWMXdjSPquykwBkZJNbNrPtIOc4/WubglHygdTWxbkkD+frXiLY9yW5uxSBsHpnoav27jdnPy/X+VYYlCoS3GecCpYLsmTYnQnqx6Utioxubvm4+UnOeAfSgvhfkA71RNz8m9Q249Tngn2qFZ9xy2Rn24pPQ0UC7KwIPTcRVN9xVsgY9fSpDKAPmOew7Gq7yY3Dls80iTM1Vz5Z6McVzWmzAatN64FdBqAJDbuOO9cpbuU1l8H7y4rF/EbJXidvbOdgyOOn1q0kuDle/FY1tI20DcAev1q2mQOXOCPSuqOxxyVjTaVi3+FOVyw6HPU+tZ3mLjLMTk9zUqTRY+6PWqt3IsWmdlAO4enqaWOYMSWYn1qtvXOOBn/Z609GHIAO76UMLWJHCAEgbj1GfSs6+VWiPXA5NXZXJJwOvr0rPvW3IcZJGelRI0h5nIiTy9aTHG8Fc/Q12FrL8nXHrXEa43lzQyd1krp7CUNAh4z35rnpvVo3qq6TNR5f3Z61XSRl+U5xSFxjr096a2GP3c/jWtjOLsrFyGXcCBlmPYf1pjRq/Mj4H91OtQpIdu3tntUqts64/CrT0ExPs6D7oYKRg88n8aiaNVB2qB7mrIZ3X90rYx988Cq1xhV/ePnHGBSkxK7K07jByc49T0qjPPxjIwKdPNkkjBrNnl3FiD+VZcxrGHcr6jLvQgelYOkv8A8Tps8cDmtC6kJB561i6W+3WnXHpg1F/eNFG0WejW7YUHPNXoVMvByB0z6Vm2jfIDkYFacJIB9/St5GK0LUECKuQOc9TVgHDD5iAKqh+NpJpUfHJJA7ZNNIlps0BIBjA+X1/xoklY8g59qpvLnDHg49cfjUZlYgfMMds96tMycbllzg5OfwxVO4udgxgEn1allnLIFJYZ5wBxVGaRTx94+uOgoJURZJ3b7vzY5Oxe31NULqaNumOvC53tj+QpZhheWIGe7dfwFQE4QgZHU/LxmmaKyK7MTv3A/wC4nce5qjcSOBhU2oOgNXJX2phmAB7E4xWZcSDJx8x9v60rX0KiVriQ7TuOSPTgVmTzYzgVZu2ZQBkDvjFY1y7AZJz6VFrGthl9djy/vYxxXn/iWYSSFd2RXS6lOdrHP0561x2pEu7Gm5XZjKCirmLyGNPGTkgjA7GmSjD4FPXB7dBXq4STasePUVmIRhsZ5NAPfsO1ByPcninFCBnI44ro1b0JGnPTuaCcHJ7dKXogwcu3X2FS2cxtrmOQRxyCM7tkg3KfqKT5raCvqdPbXhbR9PjtfEMenPHGVkgXeOdxO4lR1II/Kuf1p2kvi0t+NQbaP34LHPt83PFX/wDhI5G/5hmk5/69RWZf3RvbozNDBDwAUgTYvHtWaXYZ9M20hDHJxW3avyo9etcwsuLl17Bq1rSXYcnr/KvIWqPanudCHOT0561FmQlinU9+lV4LnIz/APWqwkin5Qm4+pNTJXehUJWJ1kYgLJIwzzjfn9KtxRIufl3MeeWJqvC4DDaE/AZxV2NlPXkgcelHL3LdUmVtoIxg9sCo5csCeT7UgbnB5b0HajzM9c47KOaOUz5jKu0LI+Wx3ArjdRJt9Whcn73y13VyMryR06VxPiuMiBmUEFDuHPNZVI21Oqk76G5bzlgNuPWrqSErjOPrXOaPc74Ucn7yiteGTdj5hW0HdXOWpo7F0P8AKQWGO1SQfdBGCPdsVXWQ4GDj2xVyNCw+9Ep6/Measi5Kr4IO45z60slwVcgk59/SozG68iaMHtgZzUThXH72R37nCgfrT3C49pgQeeD6VVupcjGcCleMdAG+paopFUqQACw9e1Q0xqxy/iQE27kcn2q9o90XtkIOCVHSotYjJDKPz9ayvD0+xTGx5VipzXI3yyOveB2ccilctj86Uyg5AwM85qhG2T1/KrCOi49vStzAuxOQMk49yKsI4zwCzEfxdqoRSjPBGPc1Zi3FflaMHPPzUxSLBmd1wxO3p9Ko3DDJG5QOnFSylgD82fXZzWfKVycnjuT1obKgircNgE5rMlk8tfr+taF1MijGDurNkzMxAHvn1rNx7GydkUpm8xyAKw4wE8Q7efmQNXQTwNHzgeprCuIBNq1rPkho2OCO/sfaoS5XqVe6Z3enNuVTtODjg1tRNtAweT1zWTpikovHGBzWvGvGMnpnFdEjBaj3+fouT7cU8KWAYAKPTvRjCgnGO/vTS+euMj35IpJlNDkODgZ649aY5AYDI6etIj7ie54701zgncOv4U07GUlYGXeM54HTHeq0mwAllbHp2qcMp+8Tkj5cVXuJF28A56c9TTuZ7FO4kzkCMEdS2cVRlkPfH0zxVi5YbSMdOBVFwGP949etCYFeZiWyeGI7DFVXcs3cLnNTSEZwCBnqcVFIjNkDBHsOn1qkyrmfOpfBLcf7VZF4md2Dznn3rZu2C7twGfWsmb1wOlNsfMzm76E/N8uAK529t+o2g1195GXGB+dZF1b5yMAL796cVqTKTaOHvIwjZx7VGvIHbFauuQ+WuQPxrJU4Tb6124Z2Z5VbcceRkd6CpGAvfk0qMAQSB8tBJGOTz79BXoNJq5iM6Enn0qe3kWCeN3hSZVOTG+drD0OKhOM+woDYGB3rJW1uM7WwtTd2iXa6LosMTKXUTTupKg43Y3dM9657xHAbXVnhaG1gcKu6O2YsgOM9T3rUtLsG101rqzn8qSGTT2kVgBKhPBXPcE/Ss3xK5/tQxGCaD7PEluFmxvIUYy2OMn2qUmhnu1ww+2zAZHOQatW9xjq2az9XPl34I43rnmlgcFPl6146jZWPYbuzehuTjuavLcEjluOOKwLeYoRjkitCGRcEkKBSsM3oJ1/jYn2XircUrdsg/wB0VgwzYwBkVfhlGAAcnPIHNMLmwkn98gewPApwcLg8Ht/+qqCkjI2jGf4jin7sIdzKWzkY9aLggnlyxrB1yPzImB5yK2SpLHOcnnJ5rO1BCyNjnjpUSVzeErM5PQrjy1aFwcqxX6V0cTB+AWAHvXISK1rq525w4/UV0ljL8uM5OKzpNrRk4jTU14Bzhs/iavQv027QQewzWZE4yCT+VWo2w+FZ8ewrdXOXmuaLSA8E/himk7icYGfTtUKkHqXI6dRzTlwp+XjPAycmqSC5JIuFGcntyO1VpUBGe3sMmp5Oe46+mKgc7oycj15PWokVFmXexBkYHJPTmuTtc22ryrn75Dj+tdhcjg9s1yGrARXsEvQbtp+lYTXU6aburHSxtnBHIIoeTaemR6VVsnBjGCcU6dsDOc/Whp20JjbmLcU+Tjt71bWXAGRuwOaxEnCHjAqU3C7TtJ/PrSiy5K5ptcNs44X0LYqlcXG1SQqjjGc1UkmHHH/16rzzHbjt9aOZlxiMllY5BY5PapYJRGQoBLHtVIvubqB6VagUqdx4x61UI3egq0rIknPynccetYk3yzq2fl3A1evJ8j2NY13LtI54zTqxtqZ0ZNux6FpMn7pRntWtE/GOPwNcpodwXhTBHSujt33KOtXLU05bF0qdnHbtmkaPKYVdo789KIz1GSR3pzk7Tg574x1pWIlO2hXcADhjuPoKhnPH3gAD0ps8uGOfzziqxlyTvUbQM9c0JENtj14b73J75qGVirYIz9DUEt3FGcZBfHaqr3cm0EFQOo7Gh2RA+d8yAH5CeOlVJnIYsVK/QdT7VHLeMcDIGONw6mqjzMcksfXNF0FiR2wAQ2fSoJnJTjIHYjPNNM4CnKgk98VE9zmQhuTgY7AVcWgK8iu2Qdw+npVWaI/xDCnnBNaqplSB171BLCG+Yn6Z71SjcEYssYK9B1/KqF3ANuCO3Wt6SHrhcHvVC6QeWc8Voo9zKbOA8Sx/uTxyK5lB8u73x711/icfI+RkjiuOVsV00ZqMtThrokwDgZwe+aFyT2xTRnAyOTTufvcfL1rv5k9znsJySBjgdafFG8kgWJGd24CqMk/hTNxIOOp5z7U+KVoJVkhd1dejKcEGlzLWwzo47WHVtN08XK6hbvbxeUGjtjLHIu4kEY6Hnms7xJOZdQUeVPEkMSQoJxiQqowGYeprUintdP0zT/tV9rKSzxeZ5dvMAiLuIGM+uDxSeItMtTDcXVveXk0sMcUjG6IYvG/3SD1BHoayT1uGx654lwvlS9g2PzqpaTBu+Aea0PEKrNaOjdcd+1clpt2Q5UnlTgivOqK0j0ac+ZHXRnILKGJHoOKuQBjggYUHBLetY9ndBgB2IwOa045Pn6nOaxa7G6bZrIRt+Zi+OPQCr9rI23gBQR24rJWUccAjGOeasxXBGdn5CgLs2A+MYOccU7eQeAMYrNF1kcHp2pwuRtAz16HNGhUTRMoIPPH61UvXGwgHnHBHeoTcjbjcxHX6Gq80hPXOaUnoaxRzOuLtuIpB1DVpWW4rwQPY1Q1/iMuP4Tmr9iwkgQoeqhh71jD4iqyvBFyGVs/NnJ647Vain6DB29jiqYG1CWXB9RzT1AwCCeenJrpTscbiaiTHBJxj3NSidQOowfQ1SRsLsZVJwO3WpElIU8KB/sgUmwjAt+duxkgDHHvTfN+QBTnPqetVUkXd88gAPvVe6m2MdpJ9zUyWlzdQTJZ3BXjORXL6+AYmY9vX61vGXK8nryPesHWjmB8dMGspbGkNHY0tLYPaoQeoqSdWI4Oao6C4axjA6YFacicgMP1xVJXRm9GZkxxjqPX2qNDk/LJkeoHNW54Nx6/pmqE1rICTnB6VHLZmkZEzSKGKxl2HYlcVX80BiSd59AM0qwSKfmBb+lPdXVV/1gB/2cAn0oauXzpFMysuRnZ3+apxeosXLfMOxqvPbsULFdo/3cVn3EEjZwfmHahTcNkElCa1LF1egklmAHrWRLMZpDtzsFPewlkbL529R71PFY7MEjt1rOUpzeqKjyQ2Z03hl828eD1HUGuwtmGM5GO9cV4YwsTADGGx9K623kDEA8dsj+tbLZAzUjfDcHj09/WppiFj5wfX2ptlBu5DZP8ADxUmpK8KlHIwOoxxVpaXMJ7mJeTfNsA5HYdBVKV3kGDu4OOO9X1tJruQhBhQMk9MD3q3a2xxm3i80jguB8ufr3ojBslySRhQ6beXEhCLgEZ5HarQ0eFN3nyF5D0C84rpobI5UzsAPQnApS6xxgRRqp9cVvGiupzyqS6HKz6PEkfCSHPqO1VJNJVgAcR46bhxXWzvJjpz1zjis6USMSzjP1punBApSaOTutKdRuB3L6jkVnyWrJkHP+NdhNblgQNw9MGqEtkzHliSMdRmodOHQ0jJrcxrOF5ZAE78ZrVudLMKFsZHU5HWp7GJIVLhdt0p+ZCPldf7y+hHcVqz3ImtcnkHnB9a3hBKJPM2zi5o9pwV6VjX8QAYda6a7Ta+fXjH+frXO6mSoO4AcDv1qRTPPPFBwjfzNcXwDz3rsPFr4WQep7VxwpLSRyViVjnJHA9KUkHaO3emoex6CgDOB1Jr0ea+pzChskkUuOgH1NJjBPoKMkg4PXrRzK1mB1ulXMdjpdourXcOyVTJbxPZicxITjdkkYBIPHNZ/iG5u43ltJ7hJ47gpcNMq485cfJ9AB/D2NV7bVoPskMGo6dHefZwVik81o2C5ztOOoyTTPETTvfRSXIiUyQRvHHFnbHGV+VRn0FZwnbRq4NXPZdUv1MLjjBrz8X+zUnVWxzms288STSwhckPjBB6isRbtvtIkLE88muGtdnVR909S069yBz9K6C2uxt5bnPp1rgtHuQ6riukgkYjgDgY64rPl0OtPU6WO7GcluvvzmlF4qhipJOOlc/9pwoPQD9aZBcNLIQh47kngVm29jVI6NdQKKQr9eakS/BP3uaj0vQJZ2V7p9qnGB3P4eld9pngu3+zeY0MmduVYMoyfpya0jhqktSXVhHc5CG6LEZORmtEYcDbljWtf+G5rOPerR7SoftwPXiohaPbW6veQOm7/VvnIb8RV+wcdxqqnsc1q8O6Fwe4qnpU6R7baKTesQ2hiuCe/StbVMbHxyMcVyOjysNSnUno3Fc7912Oh6x1O0TDDkDJGRjip4kQkAsQvpu/lVOB/kwzAjFPNyqfl0/rWt0zktcvrHGP+WRbjH3iMUx4kGSEI+pqul3xgZ/pTmnUqFA/XrUOw7tEUxeMnae+QeBVTMkhJbmp5ZUHPUZ7VFuzyCTg9KzaNVOw0hlA9BWXqrboyMgZGK0ZnyWIPFYuoklGwKT0HDV6ljw9cxmMJHkKpIGa6SEiRSpP4Ht9K4vw4CITySQx5rqbSU5GTirjImpGzLrRjJKltvv/AI1BLHvz7DvUnnB2GT+PrVeeRVUjrVtozTZGYVwS2c9MCkMSA8DjGeO9QtcgEdePeoJrwjpjn1boKV0PVlgxpnBH5moWij+8oGORnGKqNPu5Zl56DNN+0ggjcT24qXKxNh8ijeePwowu3gj/ABqBXLE/Nk/ypxOBwelZ8zZSWpPoBAuZ07FgcV1NuckBcZx2rjtGkH9oygdeK66BTlWHp+VHN7p2LVnV6Gm+YL1z1+lN1pwZAqhmbpt/lVPT7mRCGDYbHGKW3kBvmmc/dOBn9a1jUVrGc463NC0sY5FDagGSBcbYFGM/73qTTnBmmLZYIDhVJ4UfQcUj3YlbOPp7UJKDkA4NdCmtkc3L1JViGBuYMRS7UA6Ui8thsHjNTJGTgAYo5hWRWlXcoAXjNVJITk5FazL8vUDPXNVbkKinJB9KUmJOxkyR4OelQSRqoJYgirdwxI4XFUWhaYjg4681FwbuZd6wViy4yOmDjFSZcxIxXZlRx+FQ6m0MUbRqC8uchs8D2NRx3ZNqinAkAwwPepU2nZsPMpXnIx3rmtbDBC2eOfy/ya3r+XIJwAT+lcn4huSlvJuPAPatYSvEmR554pm3ZHviuXFa+vT+ZMQDnmskAnpTTuzjrPWxIoBxg0pwuW703FOPrjpXoLbYwG9RgVYtGgS4RryN5IQfmRG2kj2Paoeig5O49vap9OtJL/UILSIhWlbblug9Sal+6rgav2rw7jA0u/8Af/Sx/wDE1S1y9hv7pJbeJ4YkiSFEdtxwoxkmrXk+H1JQ3mouR1kWBQp9wCc4qjq9gLC6EayiaF0WWOQDG5GGQcdjSUgsNFvuZYkK+Y3Lsx+7/kVA8YG4owZFOAfX3qyHYQuMH5+CxxnHX9ackau6yPEfKReQOjn+ma3q0I1LW/r+uoozcTU8NXf7xYmzntzXoWnbZFHQ+hxXk4BAaUjErNhVHG0it/RfEkto4iu9zBOhXGAPQ1y+y9n8R0qrc9MOlC6il8hfMYDLNtPy/hViytRbmMR/KwALEAZ3fWtL4b69pstjfLLKqi7i8oSDPyuM44/Gl+zz2LbZ4iR1D4yp9wacqcUlJIdOs7uLNTSDsfdncx7k816z4X1XThbCG5ljSRlxlhxn6141bSjrnGfetSyv2jKmMjf2IHNJT6GsoKS3PR9f0mOZlktmMhcH5VQ1g39lPp+ivFd5QvJmOFhnHHP0qXR9fl0qBbm9uhErcqrnk+5HX8K5DX/E8urXklwzMYx8qbjgkdz9TSqNJak0+aUrdDK1OXasgz0rj9Ll/wCJzcgYOcVtapfDymya5Pw9dLNrF2cjAwBXlzV5o9NP3Du0lITgn6U2SZScEc1WwQoI/CoJ5QEHmDn9a1cbI5+uheFzg88AcCka6YMMED2rIaWVs+UshX1YYq9pWnXuqTJHCpYk4JPCis1GUnZIbaWpMLps/MRk9s0v2ts8bc+orpdR8CT2kSPHLbXORyUdjz+IFc5PpE0Ujb4cc9jWkqFRdAjOEtUxFkMnFVb+PKMDmtCC2jA5ZkYc8027QCM9CPWj2ehUZWZi+GgdkyjtIa3lyAT/AFrD0T5bm5UYGJM4/Ct4rkZHP4VEI3RU3qMaUqeSQahacE7XYAY4P/6qmljlVCyD5R1NMttMuL0ZA2Qr953OAD7DvVKEr2RlzIpmWJSeBJt7YPP9aq3FwZCAqpGuchEH+PNd/wCGPBsE9yGnCzHAIUvtU/Wu4vtAisdLIS1srYjp5SAlgO+6umOEk17zsYvExTslc8DM0inKpIce36VGrzOf9Vwew6/jXo2pWKszjK7jycEVz9xYBHLcbhyO9Z1MLy7s0VZPoYlnHIxJZSFPGetTXC7EIY4rQitl8tXRWRyTk54bFZepSeXuJ7dqycEkVGd2V9EkP9qzHtgV21uxO3HSvNdAvAdXmIwc16DZTblHrXOleJ0OVmblpPtfkEZOKmkZVnbywXTqMnGKzIpsnjtzg+tXElyAc1MY6lSsy7HOqn5gPertu6N94uB1zWbE6svKgg8c1YidcHywQQOf8K6YtpGXL5mnFLErkgyg+pTtS7pJCTEWK9Mk9aqRvs4DcmpDjeH3YP16Van3MpQ8yyyThcMMHPc1WuAIwPPkQDP97JFMkmg3LvRnOeWGTVS5mGGKQqiZOM4zScuyBU2+o+e6t4gdqmVvXGBWXe3rygj7qdgtQTXWeD0zWfcSY5yec1g6j2RtGklqR3TAZOAD3qi83qOvenTyAqcngmsy4lK5IPFHXQUloR311gEE8VxHiW8+RlBNb2qXIUvkhVFef6/ebty9ea0UmlYyempz96+6U1ApoblifWkHWuiCtY82bu9R+cDrn0pxbcoX0pnSlGOPU13J20Mhx9R+FWNNa4+3QGxV/tSMGj2DLE9sCqykYOafD5hljFvv87cNuz72e2Peqv16AdSTqbszyeFIHlPJf7G4yfXAOKwNae9k1BjqkbxXBAyjps2rjgBewx0rbv8AT/EF7cefIohmKgOgulVnYDGSpbgn0rnb9LmK5aO9Ei3CnawkzuFQn1YDd+JGcfdH3SakUkERn5ATlgO3vUQBUkZGAM4zkGnRriPzSTuY4XHatac5XsxNFyHcyyyb1wuEXdwT3H/16aAHQRjblzlznkAehPrVYySY8sthV5I7E1KJV8piwOegwBkev4V0+0i1Zis0WrW7ntG822keKJP4lB+c+49a7DR/Ht5FsjuZ5YVPGNxK4+n1rh1LeYIyFAHzMpHHrQ7FlMgjBLZAJB+WspUlJNxZopW3PaIPGXngFYNPYgcMFPP61eHii5ZSBPFHnH+rUD8q8Nt2lhmjS3kKysNzc9B/nmr8Ot3Cq2TuUcbsda4asKsNtTspzpyWp6rcaoGffNM8hPUs3JqlNqgYE5H0rz0a2x71XutZd+A2B9a4nUk+h1JpI6fXNb2RsqsdwzVTwFOZr+dieSw4rjLi5aZjkn863fBF15GpkE4DDvRGHVmU699Ee1Qx5jxwRjOfb1p1zbQ29rvIEk7nAHUL/n9KoWN8Nqn2454rqbIwtpF1MkCPOrAjcc4U8cfjXbGKehg6jMe2tFDA3C7z1KE/KD7Cuk0VgswVmZISfuovWsiJMKJDnAHbtVhLoRoAgAPXJ604ySG1zHd317aXFosXlO+BtVmbBBx1rmZYGYMFX5RzjHSs8agz5646mtPR2nu5iqsVi6s5xgfjWjmpuyFy+zRVsbbzbtojBHITG5w38IA689xWHqcflR4PAIrpr+7tI/N+zkPH91pBzvb0HsK4jW9R8x2JIxjp6CsKqUYlUpuTuYem3AGsXCHjODXVW8is2MkV5euqrD4iwG4cYrtbHUA4ABx3zXDSlY6ZnXada/bZ3E7eXAke75eSce1WdNs1xmMsIt5YEnIxWVpN+iSxsXClTnJ6EHsfarySlGZYZAqnpubg12wlszjkmdI2sQ2SAQh3k/vbsAViX+syTkhi2PQkms26mcfeicHP8IqjK03JSCQnvkVrKqwjGK3Lb3UkrYyR+NRh/NcQqckn5z2UdzVOQyoM3U0dsg6Bjlj7BRyay9R1eKCIxQKyxk5cufmb6+g9qxd3rI0vfSJtatqqqphhASBBhR3+p+tcF4i1QJGx3YPWo9T1lQhO/J964XWtTNzJtB4rlqvnfKjWCVNXZt+GtRxflyfvHNen6Ze5wMkk814Zpl15Eyt2FejaHqYeNTuxWfLy6FufNqem20wfDcBuwzVpJ9oKdMetctY3oKjLcGtVLkN0x7n1p8o4zOigmBXnHrg1ZEgOece4rBt7nBxn8jz+HrVuO5UYGcnOKtIrmubIkQg5Ukn3o/drgkMPx4zWRJddCPlIOD0xUX2tv+eg/Fs8/hVWEbDzKihhvwOmDms66vgVKY7k57mqE90QPvMPpxz+NZ0l0xOMNu5yAck/4UpbFxsW5ZtrMW71TuJ1JwTnPpVWa5YYGQT6D/P86oz3ORgZ65//AF+v8qxUSnInuZht9KyLu56gcDFMvbxQGO7Pv61zmpX+AQDz1GO1U0o6mTZDrmo7UYZ68Vw99OXJ3HJNXdWvTKx7isZm3E5q4Ru7nNXqW91DaWkoHPFbrc4iUZx9KCxC/WmqCwwOpo6Zz2rrU7LQkU9v1q7pF9/Z+p215s3iJw23OCR9fWqPQD3rQ0CeC11qymu8eRHICxIzj3x7HmiL0Yi/cWOjB90uo30Ib5tktn8+PrnB+tVPEN0Lu+R0imSKOFIo/N++yqMBj9a0W1MyTz6dr14t9bSNkXKHeYWI4dD6eq1W8WtF/aUCxTxzxx2sMfmRnKkhccUoybWo7GSEbGwL15JI6UHLqCw4UYU461McImwHLuMnnGznpTCVYgoNqLx9TXS6dtiLkXlnAADbu/tQTuI2gYXofWnNvySSeeBk8ilEe7ao5xyeeDWTXYoMdABln6iplO4naxCovB3Yz7fjVcEqC4zxwDnkc1LkRptTO4j5s4IOfT0q4VGroGuxJG+1WPzbpPlPI6etSCMPKkKfMqjce3OMnP09aq72wJAuUTgHGMGpUJ5Xo74yCT8w9K2jOOzFtqNaMiLzjjDnaq9D9aimhZHCkgsRnAOcfWrr+WsoyFZIlwMHv+PqaSSI7MlQZZfmyD0Hcj2PSpqYNS2Wo1Ua3MzBzgVZtJmt5kkU4INO8hfMZS4CIMlsZyaZIfMVncYc4wAMDFcMsNKKdzWM+p6DomvJJGoL/Njrmu00PxK1kVaNlIPHrkHqPpXhVvM8LgqSK27HXHQbWJxXNzygzoXLNWPd11jT7gbkt7yF8ZYR4dR9Paqs9/CH/dOzn0MZBryq01x0GY5SKvDxJKcb9sg7ZJqvbxe+hcaTWzPRP7QxyyZB/vt/QVI2tSrCUMv7nps6IPwrzZ/Ebn7m1T1z1qpca47ZLSkn60vbxWxTp33O+vdc8wYLkAcDnGK5TW9aVYnVX5Ncxc6wxUjJ/OsS6vGlY5JzWMpyqaDfLDUfd3bvdeYrfMDkGum0XX8KA7YI964vqacrlGyODTdPTQyjVs9T1y11pWAwx96uf22R/H+teSQajLGMBmFWhq8m379HNKJp7j1uenHxA6/dllA9A5AqlP4gJJOZG9MymvO31SQ/x1DJfs38Rp+0mU+RHdT68yqxVlTPp1/OsK/1nc2VclvrXNyXbN3NV5JWJ60Pmn8RLqRjsXrzUHkJGetZzMWOTTSSTRTjFR2OedRz3JI2xWzpWpNbuATxWGOaerFSOaJQuhwqcp6jperK8YII/wAa6O21BdoBrx3TtQeFwMnFdJZ6ycAFufrxWd3HRnUmpao9PivlAyensOKsC/PUHcvfkNj8+a4K11kEhWI/P+tXk1JGGSSf507p7DV0dh9uXaRlQevGKY94SnLHHbnOa5ePVCjgLIcAevSmvqm4Hc3XpnFPSxR0bXo/hOM8Yz/hVeS8IHL8egrn5NRA6N78dKqy6kOcs2KnmWw0blxe/LjOR/Ss25vuOOnoaxJ9S2g7T19ax7rUCSSXJJqHPohmtfajkEZH41zWoXzOTtPFVbq7Z+SaoSylu9VGDerMalVR0EmkLd6jNJnJorc4ZSu7id6cO38qQUvpVLVmbHqwAz0pOvHUUhycHsKF6Vu5taCAjBOOlSwRPPNHDCpeRyFVR3JqIgk57Ve0WaO11O3lmYrHkqzDqoIIz+Gc0lrqBb/sq1WTyXvpDPtLbo7ctEAOp3ZyQMdQMVm3tvLaXD284UMhzlTkEHkEHuCOa6yO2lXU7W9C3rSwRoqpEgMLhVwNsudoQ4yc+prnNemSS6jjidZBBEkJdejFRzj2zwPYUr6AMBP2dpP4mYKeO2KNoDxp/C2CaKK9WOqX9dSOo1TkyStyygYzUY+6w7HkiiisJfF940I6jPOTgcU5QMngGiisF/E+ZS2HPgIFHAz69acqA7zk5GMc0UVr9r+uzEKxPlRnJyep/HFPkk2TuAq7UX5QRkDiiitqLd/u/UmQ6GJXMSnO2QkNz6UpUedk87FGAeaKK1Xwr1Q0VyoeAyt99m5qHHOaKK8zEJcxtDYkjZsDk1NHI2MZ60UVxSWp0wbsBkY55prkhc5NFFTYpt2IHJOcmmgZooq0c0nqOVBtzznIp10irNhRwFH8qKK6Lfun8jN/ERYoCiiisDUUAc03FFFAMVVBoZRRRTEMPWlxRRSEx6jrT5EAUY9KKK6Y/ASNVRgVPA7Z69KKK45nRSZdinccg1dt7uXA570UVidhaW8l5GRxUn2mTB6UUUwGtcyMozjk1UkupCxGRiiip6jKc00hUZY1SkYtkk0UVdNIzqPQqycg1Fiiit4nn1H7woAo2iiimSG0bc0qr9aKKcdxMcygDjNCqNpNFFax3JFVB70hUAd6KKcgFLMECh2CHqueD+FNCgiiikwP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple vesicular lesions on an erythematous base are present on the foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small ulcers are present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23978=[""].join("\n");
var outline_f23_26_23978=null;
var title_f23_26_23979="Diseases associated with CPPD";
var content_f23_26_23979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Endocrine and metabolic disorders associated with calcium pyrophosphate crystal deposition disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probability of association",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemochromatosis",
"       </td>",
"       <td>",
"        Definite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperparathyroidism",
"       </td>",
"       <td>",
"        Definite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypophosphatasia",
"       </td>",
"       <td>",
"        Definite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypomagnesemia",
"       </td>",
"       <td>",
"        Definite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gitleman's syndrome",
"       </td>",
"       <td>",
"        Definite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"       <td>",
"        Probable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gout",
"       </td>",
"       <td>",
"        Possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X-linked hypophosphatemic rickets",
"       </td>",
"       <td>",
"        Possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hypocalciuric hypercalcemia",
"       </td>",
"       <td>",
"        Possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemosiderosis",
"       </td>",
"       <td>",
"        Possible",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23979=[""].join("\n");
var outline_f23_26_23979=null;
var title_f23_26_23980="CUP immunostaining";
var content_f23_26_23980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristic immunohistochemical staining patterns for undifferentiated neoplasms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Neoplasm",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cytokeratin",
"      </td>",
"      <td class=\"subtitle1\">",
"       EMA",
"      </td>",
"      <td class=\"subtitle1\">",
"       LCA",
"      </td>",
"      <td class=\"subtitle1\">",
"       S-100",
"      </td>",
"      <td class=\"subtitle1\">",
"       Desmin/ vimentin*",
"      </td>",
"      <td class=\"subtitle1\">",
"       OCT 4/ HCG/ AFP/ PLAP*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Chromogranin/ synaptophysin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carcinoma",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       S",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       S",
"      </td>",
"      <td>",
"       S",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Melanoma",
"      </td>",
"      <td>",
"       -, R",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sarcoma",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       S",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphoma",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -, R",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neuroendocrine carcinoma",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Germ cell tumor",
"      </td>",
"      <td>",
"       -, R",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EMA: Epithelial membrane antigen; LCA: Leukocyte common antigen; S-100: S-100 protein; HCG: Human chorionic gonadotrophin; AFP: Alpha-fetoprotein; PLAP: Placental leukocyte alkaline phosphatase; +: Positive; -: Negative; S: Sometimes positive; R: Rare positive cells.",
"     <br>",
"      * Positive for one or more of these markers.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Dabbs DJ. Immunohistology of metastatic carcinoma of unknown primary. In: Diagnostic Immunohistochemistry, 2nd ed, Dabbs DJ (Ed), Churchill Livingstone, Pittsburgh 2006. p.180.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23980=[""].join("\n");
var outline_f23_26_23980=null;
var title_f23_26_23981="Contents: Hospital medicine quality and safety";
var content_f23_26_23981=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?2/63/3070\">",
"       Hospital Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hospital medicine quality and safety",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital medicine quality and safety",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/51/30521\">",
"           Prevention of adverse drug events in hospitals",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-81D4F8D2EB-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f23_26_23981=[""].join("\n");
var outline_f23_26_23981=null;
var title_f23_26_23982="2010 TNM staging colorectal CA";
var content_f23_26_23982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging for colorectal cancer, 7th edition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"6\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"5\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"5\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"5\">",
"       Carcinoma in situ: intraepithelial or invasion of lamina propria*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"5\">",
"       Tumor invades submucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"5\">",
"       Tumor invades muscularis propria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"5\">",
"       Tumor invades through the muscularis propria into pericolorectal tissues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td colspan=\"5\">",
"       Tumor penetrates to the surface of the visceral peritoneum&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4b",
"      </td>",
"      <td colspan=\"5\">",
"       Tumor directly invades or is adherent to other organs or structures&bull;&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"6\">",
"       Regional lymph node (N)&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"5\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"5\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       N1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"5\">",
"       Metastasis in 1-3 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Metastasis in one regional lymph node",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Metastasis in 2-3 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N1c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional nodal metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N2",
"      </td>",
"      <td colspan=\"5\">",
"       Metastasis in four or more regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Metastasis in 4-6 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Metastasis in seven or more regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"6\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"5\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       M1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"5\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       M1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Metastasis confined to one organ or site (eg, liver, lung, ovary, nonregional node)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       M1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Metastases in more than one organ/site or the peritoneum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"6\">",
"       Anatomic stage/prognostic groups&sect;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle2\">",
"       T",
"      </td>",
"      <td class=\"subtitle2\">",
"       N",
"      </td>",
"      <td class=\"subtitle2\">",
"       M",
"      </td>",
"      <td class=\"subtitle2\">",
"       Dukes&yen;",
"      </td>",
"      <td class=\"subtitle2\">",
"       MAC&yen;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       B1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIA",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       B2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIB",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       B2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIC",
"      </td>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       B3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       IIIA",
"      </td>",
"      <td>",
"       T1-2",
"      </td>",
"      <td>",
"       N1/N1c",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       C1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N2a",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       C1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       IIIB",
"      </td>",
"      <td>",
"       T3-T4a",
"      </td>",
"      <td>",
"       N1/N1c",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       C2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2-T3",
"      </td>",
"      <td>",
"       N2a",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       C1/C2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1-T2",
"      </td>",
"      <td>",
"       N2b",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       C1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       IIIC",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N2a",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       C2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3-T4a",
"      </td>",
"      <td>",
"       N2b",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       C2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       N1-N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       C3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IVA",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1a",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IVB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1b",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Tis includes cancer cells confined within the glandular basement membrane (intraepithelial) or mucosal lamina propria (intramucosal) with no extension through the muscularis mucosae into the submucosa.",
"     <br>",
"      &bull; Direct invasion in T4 includes invasion of other organs or other segments of the colorectum as a result of direct extension through the serosa, as confirmed on microscopic examination (for example, invasion of the sigmoid colon by a carcinoma of the cecum) or, for cancers in a retroperitoneal or subperitoneal location, direct invasion of other organs or structures by virtue of extension beyond the muscularis propria (ie, respectively, a tumor on the posterior wall of the descending colon invading the left kidney or lateral abdominal wall; or a mid or distal rectal cancer with invasion of prostate, seminal vesicles, cervix, or vagina).",
"      <br>",
"       &Delta; Tumor that is adherent to other organs or structures, grossly, is classified cT4b. However, if no tumor is present in the adhesion, microscopically, the classification should be pT1-4a depending on the anatomical depth of wall invasion. The V and L classifications should be used to identify the presence or absence of vascular or lymphatic invasion whereas the PN site-specific factor should be used for perineural invasion.",
"       <br>",
"        &loz; A satellite peritumoral nodule in the pericolorectal adipose tissue of a primary carcinoma without histologic evidence of residual lymph node in the nodule may represent discontinuous spread, venous invasion with extravascular spread (V1/2), or a totally replaced lymph node (N1/2). Replaced nodes should be counted separately as positive nodes in the N category, whereas discontinuous spread or venous invasion should be classified and counted in the Site-Specific Factor category Tumor Deposits (TD).",
"        <br>",
"         &sect; cTNM is the clinical classification, pTNM is the pathologic classification. The y prefix is used for those cancers that are classified after neoadjuvant pretreatment (eg, ypTNM). Patients who have a complete pathologic response are ypT0N0cM0 that may be similar to Stage Group 0 or I. The r prefix is to be used for those cancers that have recurred after a disease-free interval (rTNM).",
"         <br>",
"          &yen; Dukes B is a composite of better (T3 N0 M0) and worse (T4 N0 M0) prognostic groups, as is Dukes C (Any TN1 M0 and Any T N2 M0). MAC is the modified Astler-Coller classification.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23982=[""].join("\n");
var outline_f23_26_23982=null;
var title_f23_26_23983="Trends in hospital stays with septicemia";
var content_f23_26_23983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 644px\">",
"   <div class=\"ttl\">",
"    Trends in hospital stays with septicemia 1993-2009",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 624px; height: 406px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the United States between 2000 and 2009, hospital stays with a principal diagnosis of septicemia increased 148 percent (10.6 percent annually), while those with secondary diagnoses of septicemia increased by only 66 percent (5.8 percent annually).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Agency for Healthcare Research and Quality Center for Delivery, Organization, and Markets. Healthcare Cost and Utilization Project, Nationwide Inpatient Sample, 1993-2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_26_23983=[""].join("\n");
var outline_f23_26_23983=null;
